1 00:00:05,960 --> 00:00:10,280 >>WISH TO EXPRESS THEIR VIEWS 2 00:00:10,280 --> 00:00:13,680 REGARDING ATTEMPT DISCUSSED 3 00:00:13,680 --> 00:00:16,400 DURING THIS MEETING CAN DO SO BY 4 00:00:16,400 --> 00:00:18,320 WRITING DR. PAULETTE GRAY, 5 00:00:18,320 --> 00:00:20,200 EXECUTIVE SECRETARY OF THE BOARD 6 00:00:20,200 --> 00:00:21,480 WITHIN TEN DAYS FOLLOWING THE 7 00:00:21,480 --> 00:00:22,800 MEETING. ANY WRITTEN STATEMENTS 8 00:00:22,800 --> 00:00:23,720 OF QUESTIONS SUBMITTED BY 9 00:00:23,720 --> 00:00:27,240 MEMBERS OF PUBLIC WILL RECEIVE 10 00:00:27,240 --> 00:00:29,120 CAREFUL CONSIDERATION. TO BOARD 11 00:00:29,120 --> 00:00:30,400 MEMBERS, I WOULD LIKE TO REMIND 12 00:00:30,400 --> 00:00:33,360 YOU THAT YOU MUST ABOUT SENT 13 00:00:33,360 --> 00:00:34,920 YOURSELVES FULLY DURING 14 00:00:34,920 --> 00:00:35,840 DISCUSSIONS WHENEVER YOUR 15 00:00:35,840 --> 00:00:37,960 PARTICIPATION AND DELIBERATIONS 16 00:00:37,960 --> 00:00:40,240 ON A PARTICULAR PRODUCT PROGRAM 17 00:00:40,240 --> 00:00:41,520 OR OTHER SPECIFIC MATTER WOULD 18 00:00:41,520 --> 00:00:43,240 CONSTITUTE A CONFLICT OF 19 00:00:43,240 --> 00:00:44,080 INTEREST OR CREATE THE 20 00:00:44,080 --> 00:00:46,480 APPEARANCE OF ONE. IT IS 21 00:00:46,480 --> 00:00:49,320 INCUMBENT UPON OURSELVES TO 22 00:00:49,320 --> 00:00:50,920 ADVISE THE EXECUTIVE SECRETARY 23 00:00:50,920 --> 00:00:51,960 AND ABSTAIN FROM ANY 24 00:00:51,960 --> 00:00:53,520 PARTICIPATION AND DISCUSSION FOR 25 00:00:53,520 --> 00:00:55,520 ACTION REGARDING THAT MATTER. 26 00:00:55,520 --> 00:00:57,360 IN LIGHT OF THE CURRENT POLICIES 27 00:00:57,360 --> 00:00:58,920 GOVERNING CONFLICT OF INTEREST 28 00:00:58,920 --> 00:01:00,840 BASED ON FINANCIAL HOLDINGS OF 29 00:01:00,840 --> 00:01:02,480 SPECIAL GOVERNMENT EMPLOYEES, 30 00:01:02,480 --> 00:01:06,240 WHICH WE ALL ARE AS BOARD 31 00:01:06,240 --> 00:01:07,640 MEMBERS, WE MUST -- WE HAVE TO 32 00:01:07,640 --> 00:01:11,840 DEPEND ON OURSELVES TO VOLUNTARY 33 00:01:11,840 --> 00:01:13,640 ABSENT DURING ANY AND ALL 34 00:01:13,640 --> 00:01:15,200 DISCUSSION OF MATTERS THAT COULD 35 00:01:15,200 --> 00:01:17,080 CONCEIVABLY IMPACT THE STATUS OF 36 00:01:17,080 --> 00:01:18,280 THOSE HOLDINGS. SO WE HAVE TO 37 00:01:18,280 --> 00:01:21,440 TRUST JUDGMENT IN THESE 38 00:01:21,440 --> 00:01:23,120 INSTANCES DURING ANY CLOSED 39 00:01:23,120 --> 00:01:25,280 SESSION ANY MATERIALS OR 40 00:01:25,280 --> 00:01:26,400 DISCUSSIONS OF THE CONFIDENTIAL 41 00:01:26,400 --> 00:01:28,480 NATURE DELIBERATED ON TODAY ARE 42 00:01:28,480 --> 00:01:29,800 PRIVILEGED INFORMATION AND ARE 43 00:01:29,800 --> 00:01:32,280 MADE AVAILABLE TO YOU ON A NEED 44 00:01:32,280 --> 00:01:34,160 TO KNOW BASIS, SUCH 45 00:01:34,160 --> 00:01:35,520 DELIBERATIONS ARE PRIVATE AND 46 00:01:35,520 --> 00:01:39,480 CONTENT SHOULDN'T BE DIVULGED. 47 00:01:39,480 --> 00:01:41,240 FUTURE MEETINGS, FUTURE MEETING 48 00:01:41,240 --> 00:01:43,040 DATES HAVE BEEN PROVIDED AND ARE 49 00:01:43,040 --> 00:01:47,800 ALSO LISTED ON THE AGENDA. NEXT 50 00:01:47,800 --> 00:01:52,520 WE NEED TO APPROVE THE JUNE 14, 51 00:01:52,520 --> 00:01:56,640 15, 2023 JOINT BSA NCAB VIRTUAL 52 00:01:56,640 --> 00:01:58,720 MEETING SUMMARY. SO CALL A 53 00:01:58,720 --> 00:01:59,880 MOTION TO APPROVE THE MEETING 54 00:01:59,880 --> 00:02:04,800 SUMMARY. 55 00:02:04,800 --> 00:02:06,640 >>APPROVAL. 56 00:02:06,640 --> 00:02:08,280 >>SECOND? 57 00:02:08,280 --> 00:02:08,560 >>SECOND. 58 00:02:08,560 --> 00:02:10,600 >>PROPERLY MOVE AND SECONDED. 59 00:02:10,600 --> 00:02:12,640 ANY FURTHER DISCUSSION? LET'S 60 00:02:12,640 --> 00:02:20,320 VOTE. I'LL ASK ARE THERE ANY 61 00:02:20,320 --> 00:02:26,840 NAYS? ANYONE ABSTAIN? IF NOT, 62 00:02:26,840 --> 00:02:27,920 PAULETTE, I BELIEVE WE HAVE A 63 00:02:27,920 --> 00:02:28,760 UNANIMOUS VOTE. 64 00:02:28,760 --> 00:02:31,120 >>CORRECT. APPROVED. 65 00:02:31,120 --> 00:02:33,800 >>SO QUORUM, BY LAW A QUORUM OF 66 00:02:33,800 --> 00:02:35,360 BOARD MEMBERS IS REQUIRED FOR 67 00:02:35,360 --> 00:02:37,280 EACH INSTANCE IN WHICH A VOTE 68 00:02:37,280 --> 00:02:39,520 MAY OCCUR WHETHER IN OPEN OR 69 00:02:39,520 --> 00:02:41,040 CLOSED SESSION. DURING THIS 70 00:02:41,040 --> 00:02:42,720 MEETING A MINIMUM OF NINE 71 00:02:42,720 --> 00:02:44,280 APPOINTED MEMBERS MUST BE 72 00:02:44,280 --> 00:02:48,360 PRESENT TO VOICE THEIR VOTES. 73 00:02:48,360 --> 00:02:50,440 CAN'T PREDICT TIME NOR 74 00:02:50,440 --> 00:02:51,880 OCCURRENCE OF ANY MOTION, OUR 75 00:02:51,880 --> 00:02:53,600 PRESENCE IN THE VIRTUAL ROOM FOR 76 00:02:53,600 --> 00:02:55,880 ALL SEGMENTS OF THE MEETING IS A 77 00:02:55,880 --> 00:02:57,880 MUST. PAULETTE, DO WE HAVE A 78 00:02:57,880 --> 00:02:58,080 QUORUM? 79 00:02:58,080 --> 00:02:59,360 >>YES, WE DO. 80 00:02:59,360 --> 00:03:03,720 >>THANK YOU. TO ENSURE THERE 81 00:03:03,720 --> 00:03:07,360 AREN'T ANY INTERRUPTIONS AT 82 00:03:07,360 --> 00:03:10,160 TODAY'S MEETINGS, REMAIN MUTED 83 00:03:10,160 --> 00:03:12,160 UNTIL RECOGNIZED BY MYSELF, THE 84 00:03:12,160 --> 00:03:14,920 EXECUTIVE SECRETARY, THE NCI 85 00:03:14,920 --> 00:03:17,800 DIRECTOR OR ONE OF THE SPEAKERS 86 00:03:17,800 --> 00:03:22,280 SO WE WILL NOW MOVE TO OUR 87 00:03:22,280 --> 00:03:24,280 DIRECTORS REPORT. FROM NCI 88 00:03:24,280 --> 00:03:27,600 DIRECTOR DR. MONICA BERTAGNOLLI. 89 00:03:27,600 --> 00:03:32,680 >>THANK YOU, DR. CARPTEN. 90 00:03:32,680 --> 00:03:35,360 LOVELY TO BE WITH Y'ALL TODAY. 91 00:03:35,360 --> 00:03:38,240 LET ME START BY SAYING THAT 92 00:03:38,240 --> 00:03:40,720 TODAY AT NCI WE ARE FACING A 93 00:03:40,720 --> 00:03:43,360 PERIOD OF SIGNIFICANT 94 00:03:43,360 --> 00:03:45,000 UNCERTAINTY ABOUT HOW MUCH 95 00:03:45,000 --> 00:03:46,360 CANCER RESEARCH THE INSTITUTE 96 00:03:46,360 --> 00:03:48,960 WILL BE ABLE TO SUPPORT OVER THE 97 00:03:48,960 --> 00:03:51,360 NEXT YEAR. CONGRESS HAS NOT YET 98 00:03:51,360 --> 00:03:54,240 FINALIZED THE BUDGET FOR FISCAL 99 00:03:54,240 --> 00:03:56,480 YEAR 2024. THAT BEGINS IN 100 00:03:56,480 --> 00:03:58,640 OCTOBER. JUST A FEW WEEKS. SO 101 00:03:58,640 --> 00:04:00,880 RIGHT NOW IT IS UNCLEAR WHAT THE 102 00:04:00,880 --> 00:04:02,880 NEXT YEAR WILL LOOK LIKE FOR OUR 103 00:04:02,880 --> 00:04:04,360 WORK TO ADVANCE PROGRESS AGAINST 104 00:04:04,360 --> 00:04:07,520 CANCER. AS A RESULT WE HAVE 105 00:04:07,520 --> 00:04:09,720 STRUCTURED TODAY'S AGENDA TO 106 00:04:09,720 --> 00:04:13,520 REALLY SPEAK TO THIS SITUATION. 107 00:04:13,520 --> 00:04:15,240 BECAUSE THERE ARE MANY STRONG 108 00:04:15,240 --> 00:04:17,480 SIGNALS THAT THE NEXT TWO YEARS 109 00:04:17,480 --> 00:04:21,680 WILL NOT BE LIKE OTHERS IN THE 110 00:04:21,680 --> 00:04:24,080 PAST AND WE LOOK TO OUR GUIDING 111 00:04:24,080 --> 00:04:29,800 BOARD FOR INPUT INTO HOW BEST TO 112 00:04:29,800 --> 00:04:31,560 MANAGE THIS SITUATION. AFTER MY 113 00:04:31,560 --> 00:04:34,040 INTRO, MK HOLOHAN, DIRECTOR OF 114 00:04:34,040 --> 00:04:35,560 OFFICE OF CONGRESSIONAL AND 115 00:04:35,560 --> 00:04:37,080 GOVERNMENT RELATIONS WILL COVER 116 00:04:37,080 --> 00:04:39,320 THE LATEST LEGISLATIVE 117 00:04:39,320 --> 00:04:41,120 DEVELOPMENTS. AS WE COME TO THIS 118 00:04:41,120 --> 00:04:45,880 FISCAL YEAR'S CLOSE. THE NEXT 119 00:04:45,880 --> 00:04:47,880 DISCUSSION DIRECTOR OF OFFICE OF 120 00:04:47,880 --> 00:04:49,160 BUDGET AND FINANCE TOGETHER WITH 121 00:04:49,160 --> 00:04:53,760 DOUG LOWY, NCI PRINCIPAL DEPUTY 122 00:04:53,760 --> 00:04:55,000 DIRECTOR WILL TALK NCI BUDGET 123 00:04:55,000 --> 00:04:57,000 OPPORTUNITIES AND CHALLENGES IN 124 00:04:57,000 --> 00:04:58,800 LIGHT OF THIS SITUATION. SOME 125 00:04:58,800 --> 00:05:00,440 RECENT HISTORY ON SIMILAR 126 00:05:00,440 --> 00:05:02,000 POLITICAL SITUATIONS AND THEIR 127 00:05:02,000 --> 00:05:04,160 EFFECTS ON NCI FUNDING AND HOW 128 00:05:04,160 --> 00:05:05,560 ARE BUDGET -- OUR BUDGET WORKS. 129 00:05:05,560 --> 00:05:09,440 IT IS A COMPLEX LARGE INSTITUTE 130 00:05:09,440 --> 00:05:11,680 AND THERE ARE INTRICACIES THAT 131 00:05:11,680 --> 00:05:15,960 WILL HELP INFORM YOUR INPUT. WE 132 00:05:15,960 --> 00:05:19,040 WILL LEAVE TIME FOR DISCUSSION 133 00:05:19,040 --> 00:05:23,960 THEN AND MYSELF AND MK, DOUG AND 134 00:05:23,960 --> 00:05:25,760 WES WILL BE AVAILABLE AT THE END 135 00:05:25,760 --> 00:05:27,360 SO TO SET THE STAGE FOR THESE 136 00:05:27,360 --> 00:05:29,040 RECESSIONS FOR THE BENEFIT OF 137 00:05:29,040 --> 00:05:31,680 NEWER BOARD MEMBERS, I THOUGHT I 138 00:05:31,680 --> 00:05:32,920 WOULD FIRST EXPLAIN WHERE WE ARE 139 00:05:32,920 --> 00:05:34,720 IN THE BUDGET PROCESS. NEXT 140 00:05:34,720 --> 00:05:40,480 SLIDE PLEASE. WELL LAST 141 00:05:40,480 --> 00:05:43,280 SEPTEMBER BECAUSE OF SPECIAL 142 00:05:43,280 --> 00:05:44,480 BUDGETARY AUTHORITY WE HAVE NCI 143 00:05:44,480 --> 00:05:47,600 SUBMITTED A FISCAL YEAR 24 144 00:05:47,600 --> 00:05:48,920 PROFESSIONAL JUDGMENT BUDGET 145 00:05:48,920 --> 00:05:50,920 PROPOSAL WHICH IS INTENDED TO 146 00:05:50,920 --> 00:05:52,160 INFORM BOTH THE PRESIDENT'S 147 00:05:52,160 --> 00:05:53,720 BUDGET DEVELOPMENT AND THE 148 00:05:53,720 --> 00:05:56,520 OVERALL APPROPRIATIONS PROCESS. 149 00:05:56,520 --> 00:05:58,960 OUR PROPOSAL PROVIDED THE 150 00:05:58,960 --> 00:06:01,440 OPTIMUM FUNDING FOR SUCCESS IN 151 00:06:01,440 --> 00:06:03,760 24 THAT WE FELT NEEDED TO MAKE 152 00:06:03,760 --> 00:06:06,080 RAPID PROGRESS BASED ON OUR 153 00:06:06,080 --> 00:06:07,840 PROFESSIONAL JUDGMENT. 154 00:06:07,840 --> 00:06:10,960 OPPORTUNITIES ARE TREMENDOUS. 155 00:06:10,960 --> 00:06:13,920 THE SIZE OF OUR OF OUR BUDGET 156 00:06:13,920 --> 00:06:15,880 WAS INCREASED TO BE ABLE TO 157 00:06:15,880 --> 00:06:19,200 ACHIEVE OUR AMBITIOUS GOALS. IN 158 00:06:19,200 --> 00:06:20,720 MARCH THE PRESIDENT SUBMITTED 159 00:06:20,720 --> 00:06:23,280 HIS FISCAL YEAR 24 BUDGET TO 160 00:06:23,280 --> 00:06:24,360 CONGRESS WHICH STARTED THE 161 00:06:24,360 --> 00:06:26,000 APPROPRIATIONS PROCESS. AND IS 162 00:06:26,000 --> 00:06:29,440 BEING CONSIDERED BY CONGRESS AS 163 00:06:29,440 --> 00:06:31,960 THEY NOW DETERMINE NEXT YEAR'S 164 00:06:31,960 --> 00:06:33,080 FISCAL APPROPRIATIONS FOR NCI 165 00:06:33,080 --> 00:06:36,000 AND OTHER AGENCIES AND PROGRAMS 166 00:06:36,000 --> 00:06:37,560 THE PRESIDENT'S BUDGET INCLUDED 167 00:06:37,560 --> 00:06:41,320 A ROBUST INCREASE TO NCI CURRENT 168 00:06:41,320 --> 00:06:43,960 BUDGET. OF COURSE WHEN WE 169 00:06:43,960 --> 00:06:45,200 CONSIDER OUR INVESTMENTS WE ALSO 170 00:06:45,200 --> 00:06:47,840 LOOK TO NEXT YEAR AND WE ARE 171 00:06:47,840 --> 00:06:50,320 OFFERED THE TIME IN AND ARE IN 172 00:06:50,320 --> 00:06:54,360 THE PROCESS WE SUBMIT THE FISCAL 173 00:06:54,360 --> 00:06:55,680 YEAR 25 PROFESSIONAL BUDGET 174 00:06:55,680 --> 00:06:58,560 PROPOSAL WHICH WILL INFORM THE 175 00:06:58,560 --> 00:07:00,560 FISCAL YEAR 25 BUDGET AND SO ON. 176 00:07:00,560 --> 00:07:03,320 THIS FISCAL YEAR 25 REQUEST IS 177 00:07:03,320 --> 00:07:06,160 ALSO IN KEEPING WITH WHAT THE 178 00:07:06,160 --> 00:07:08,760 PRESIDENT PUT FORWARD IN HIS 179 00:07:08,760 --> 00:07:10,880 FISCAL YEAR 24 BUDGET TO 180 00:07:10,880 --> 00:07:13,840 CONGRESS. WHICH AGAIN IS A 181 00:07:13,840 --> 00:07:17,680 GENEROUS INCREASE TO NCI WELL 182 00:07:17,680 --> 00:07:20,040 JUSTIFIED BY THE INCREDIBLE 183 00:07:20,040 --> 00:07:23,040 OPPORTUNITIES WE HAVE BEFORE US 184 00:07:23,040 --> 00:07:24,280 AND THE MORE SIGNIFICANT 185 00:07:24,280 --> 00:07:25,920 PROGRESS WE ARE POISED TO MAKE 186 00:07:25,920 --> 00:07:28,720 FOR THE AMERICAN PEOPLE. 187 00:07:28,720 --> 00:07:29,880 BECAUSE IT IS VERY IMPORTANT THE 188 00:07:29,880 --> 00:07:33,480 AMERICAN PEOPLE SEE THE RETURN 189 00:07:33,480 --> 00:07:34,800 THEY RECEIVE FOR THEIR TAX 190 00:07:34,800 --> 00:07:35,840 DOLLAR INVESTMENT. I WOULD LIKE 191 00:07:35,840 --> 00:07:37,720 TO FOCUS THE REST OF MY REPORT 192 00:07:37,720 --> 00:07:39,520 THIS MORNING ON WHAT OUR RECENT 193 00:07:39,520 --> 00:07:43,120 WORK HAS ACHIEVED AND HOW WE CAN 194 00:07:43,120 --> 00:07:46,120 DO MORE TO MAKE IMPORTANT 195 00:07:46,120 --> 00:07:47,320 PROGRESS AGAINST THE SECOND 196 00:07:47,320 --> 00:07:48,880 LEADING CAUSE OF DEATH IN THE 197 00:07:48,880 --> 00:07:50,520 US. AT THE END OF MY REPORT 198 00:07:50,520 --> 00:07:51,720 WE'LL HAVE TIME FOR QUESTIONS 199 00:07:51,720 --> 00:07:54,600 AND REQUEST THESE FOCUS ON NCI 200 00:07:54,600 --> 00:07:56,080 SCIENCE WHERE WE HAVE PACED OUR 201 00:07:56,080 --> 00:07:57,480 PROGRAMS TODAY, OUR PRIORITIES 202 00:07:57,480 --> 00:07:59,320 AN SAVED THE BUDGET QUESTIONS 203 00:07:59,320 --> 00:08:01,440 FOR AFTER WE HAVE GONE THROUGH 204 00:08:01,440 --> 00:08:02,800 THE THIRD PART OF OUR BUDGET 205 00:08:02,800 --> 00:08:10,160 DISCUSSION. YOU MAY ALL KNOW 206 00:08:10,160 --> 00:08:11,960 DR. WARD MS. CAUSE SKILL 207 00:08:11,960 --> 00:08:13,640 STEVENSES WHO LEADS THE ONCOLOGY 208 00:08:13,640 --> 00:08:15,840 RESEARCH PROGRAM HAS BEEN A 209 00:08:15,840 --> 00:08:18,400 POWERFUL FORCE THROUGH MANY, 210 00:08:18,400 --> 00:08:20,760 MANY YEARS LEADING OUR GOAL TO 211 00:08:20,760 --> 00:08:22,600 BRING CANCER RESEARCH TO THE 212 00:08:22,600 --> 00:08:26,440 COMMUNITIES WHERE PEOPLE LIVE 213 00:08:26,440 --> 00:08:29,760 PARTICULARLY WHO EXPERIENCE 214 00:08:29,760 --> 00:08:30,960 CANCER DISPARITIES. THROUGHOUT 215 00:08:30,960 --> 00:08:33,360 HER CAREER DR. STEVENS HAS HAD 216 00:08:33,360 --> 00:08:35,240 PASSION AND COMMITMENT TO FOLLOW 217 00:08:35,240 --> 00:08:37,040 THE ROAD LESS TRAVEL AND SHE IS 218 00:08:37,040 --> 00:08:40,800 TRULY CHANGED THE TRAJECTORY OF 219 00:08:40,800 --> 00:08:41,720 COMMUNITY CANCER RESEARCH AND 220 00:08:41,720 --> 00:08:43,600 INSPIRED OURS TO FOLLOW IN HER 221 00:08:43,600 --> 00:08:46,080 FOOTSTEPS. IF WE ARE GOING TO 222 00:08:46,080 --> 00:08:48,240 OVERCOME THE MANY CHALLENGES WE 223 00:08:48,240 --> 00:08:51,960 FACE WE NEED TO NURTURE MORE 224 00:08:51,960 --> 00:08:56,800 PEOPLE LIKE DR. 225 00:08:56,800 --> 00:08:57,880 MCCASKILL-STEVENS WHO EMBODY 226 00:08:57,880 --> 00:08:59,360 THIS COMMITMENT. WE CAN'T THINK 227 00:08:59,360 --> 00:09:01,760 OF A BETTER INSPIRATION TO THOSE 228 00:09:01,760 --> 00:09:03,480 WHO WANT TO DO THIS CRITICAL 229 00:09:03,480 --> 00:09:06,640 WORK THAN THE EXAMPLE SET BY 230 00:09:06,640 --> 00:09:09,960 WORTA. TWO WEEKS AGO WE HONORED 231 00:09:09,960 --> 00:09:11,320 HER GREAT WORK BY ANNOUNCING A 232 00:09:11,320 --> 00:09:15,240 NEW CAREER DEVELOPMENT AWARD IN 233 00:09:15,240 --> 00:09:17,760 HER NAME OPPORTUNITY WILL 234 00:09:17,760 --> 00:09:18,760 SUPPORT INSTITUTIONAL CAREER 235 00:09:18,760 --> 00:09:21,200 DEVELOPMENT PROGRAMS, DESIGNED 236 00:09:21,200 --> 00:09:26,320 TO TRAIN CLINICAL SCIENTISTS IN 237 00:09:26,320 --> 00:09:27,160 CLINICAL INTERVENTION AND 238 00:09:27,160 --> 00:09:28,880 TREATMENT RESEARCH. THIS AWARD 239 00:09:28,880 --> 00:09:32,400 WILL BE WIDELY AVAILABLE TO 240 00:09:32,400 --> 00:09:33,760 INDIVIDUALS WHO WISH TO FOLLOW 241 00:09:33,760 --> 00:09:35,640 IN HER FOOTSTEPS. SPECIAL 242 00:09:35,640 --> 00:09:37,320 EMPHASIS HAS BEEN PLACED ON 243 00:09:37,320 --> 00:09:39,680 TRAINING OF CLINICAL SCIENTISTS 244 00:09:39,680 --> 00:09:43,040 WHOSE CAREER GOAL IS TO MEET THE 245 00:09:43,040 --> 00:09:44,520 NEEDS OF UNDERSERVED OR 246 00:09:44,520 --> 00:09:45,960 MARGINALIZED COMMUNITIES FOR 247 00:09:45,960 --> 00:09:50,720 ACCESS TO CLINICAL CARE AND 248 00:09:50,720 --> 00:09:55,400 PATIENT RESEARCH. SINCE WE LAST 249 00:09:55,400 --> 00:09:56,560 MET WE CONTINUE TO BUILD 250 00:09:56,560 --> 00:09:58,880 MOMENTUM FOR THE NATIONAL CANCER 251 00:09:58,880 --> 00:10:01,200 PLAN. WE USING THE PLAN TO HELP 252 00:10:01,200 --> 00:10:06,240 US ALL, EVERYONE FOCUS OUR 253 00:10:06,240 --> 00:10:06,840 EFFORTS TOE REACH THE 254 00:10:06,840 --> 00:10:07,920 PRESIDENT'S CANCER MOON SHOT 255 00:10:07,920 --> 00:10:10,480 GOAL, TO CUT THE AGE ADJUSTED 256 00:10:10,480 --> 00:10:12,880 CANCER MORTALITY RATE IN HALF BY 257 00:10:12,880 --> 00:10:15,360 2047 AND TURN CANCER INTO OF A 258 00:10:15,360 --> 00:10:16,720 LIVABLE TREATABLE DISEASE FOR 259 00:10:16,720 --> 00:10:20,120 ALL PEOPLE. TOMORROW THE 260 00:10:20,120 --> 00:10:21,040 PRESIDENT'S CANCER PANEL WILL 261 00:10:21,040 --> 00:10:23,120 HOLD AN EVENT LED BY DRS. 262 00:10:23,120 --> 00:10:26,440 MITCHELL BURGER, CAROL BROWN AND 263 00:10:26,440 --> 00:10:29,360 LIZ JAFFE TO HOST THE LARGEST 264 00:10:29,360 --> 00:10:30,680 CANCER RELATED ORGANIZATIONS, 265 00:10:30,680 --> 00:10:32,920 EACH OF THESE ORGANIZATIONS WILL 266 00:10:32,920 --> 00:10:35,200 SHARE THE ACTIONS THEY ARE 267 00:10:35,200 --> 00:10:38,000 TAKING TO THE REST OF THE 268 00:10:38,000 --> 00:10:39,800 NATIONAL CANCER PLAN. THE 269 00:10:39,800 --> 00:10:41,680 MEETING IS OPEN TO EVERYONE AND 270 00:10:41,680 --> 00:10:43,480 SO FAR 250 PEOPLE HAVE 271 00:10:43,480 --> 00:10:45,840 REGISTERED TO ATTENDS. THIS IS 272 00:10:45,840 --> 00:10:50,520 JUST TREMENDOUS TO SEE THE 273 00:10:50,520 --> 00:10:51,840 RESPONSE TO PLAN, SO MANY 274 00:10:51,840 --> 00:10:53,640 WILLING TO JOIN IN AND WE ARE 275 00:10:53,640 --> 00:10:54,960 GRATEFUL FOR THE LEADERSHIP OF 276 00:10:54,960 --> 00:10:57,640 THE PRESIDENT'S CANCER PANEL IN 277 00:10:57,640 --> 00:10:59,840 DOING THIS REALLY CRITICAL 278 00:10:59,840 --> 00:11:03,920 ENGAGEMENT WORK. ONE GREAT 279 00:11:03,920 --> 00:11:05,280 EXAMPLE FROM GROUPS ALREADY 280 00:11:05,280 --> 00:11:07,040 SHARING THEIR NATIONAL CANCER 281 00:11:07,040 --> 00:11:08,880 PLAN ACTIONS THIS SUMMER, THE 282 00:11:08,880 --> 00:11:11,880 UNIVERSITY OF COLORADO CANCER 283 00:11:11,880 --> 00:11:14,000 CENTER GETS FIRST IN. POSTED A 284 00:11:14,000 --> 00:11:15,760 SERIES OF STORIES ON THEIR 285 00:11:15,760 --> 00:11:17,600 WEBSITE ABOUT HOW THEY ARE 286 00:11:17,600 --> 00:11:18,920 WORKING TOWARD EACH OF THE 287 00:11:18,920 --> 00:11:20,840 CANCER PLANS EIGHT GOALS. THIS 288 00:11:20,840 --> 00:11:23,320 IS A GREAT EXAMPLE OF HOW REALLY 289 00:11:23,320 --> 00:11:25,120 ANYONE, ANY PARTICIPANT CAN 290 00:11:25,120 --> 00:11:26,320 COMMUNE CASE THE KIND OF WORK 291 00:11:26,320 --> 00:11:28,440 THAT CONTRIBUTES TO THE GOALS 292 00:11:28,440 --> 00:11:29,800 THAT WE SAUL WANT TO SEE 293 00:11:29,800 --> 00:11:31,600 ACCOMPLISHED. THE MORE WE CAN 294 00:11:31,600 --> 00:11:33,480 ALL SEE WHAT OTHERS ARE DOING 295 00:11:33,480 --> 00:11:36,480 THE MORE WE CAN FIND WAYS TO 296 00:11:36,480 --> 00:11:38,240 WORK TOGETHER. ON THE CANCER 297 00:11:38,240 --> 00:11:40,040 MOON SHOT END THE WHITE HOUSE 298 00:11:40,040 --> 00:11:41,200 WILL BE LEADING ANOTHER MEETING 299 00:11:41,200 --> 00:11:43,680 AT THE CANCER CABINET THIS 300 00:11:43,680 --> 00:11:46,160 MONTH. ALL THE CABINET 301 00:11:46,160 --> 00:11:50,280 SECRETARIES PARTICIPATING IN THE 302 00:11:50,280 --> 00:11:51,440 WORK AND GOALS WE ALL SHARE. 303 00:11:51,440 --> 00:11:53,200 THIS MEETING WE WILL CONTINUE TO 304 00:11:53,200 --> 00:11:54,680 COORDINATE WITH -- ACROSS 305 00:11:54,680 --> 00:11:56,720 FEDERAL AGENCIES AS PART OF THE 306 00:11:56,720 --> 00:11:57,480 PRESIDENT'S ALL OF GOVERNMENT 307 00:11:57,480 --> 00:12:00,520 APPROACH TO ENDING CANCER AS WE 308 00:12:00,520 --> 00:12:03,360 KNOW IT AND THERE WILL BE A FACT 309 00:12:03,360 --> 00:12:04,800 SHEET WITH HIGHLIGHTS OF THE 310 00:12:04,800 --> 00:12:08,000 MEETING AFTERWARD. A VERY 311 00:12:08,000 --> 00:12:10,880 EXCITING NEW DATA INITIATIVE IS 312 00:12:10,880 --> 00:12:12,880 PA MOON SHOT COLLABORATION THAT 313 00:12:12,880 --> 00:12:14,440 IS DIRECTLY ALIGNED WITH THE 314 00:12:14,440 --> 00:12:17,560 NATIONAL CANCER PLANS GOALS TO 315 00:12:17,560 --> 00:12:20,120 MAXIMIZE DATA UTILITY, LED BY 316 00:12:20,120 --> 00:12:21,680 MULTIPLE HEALTH FOCUSED 317 00:12:21,680 --> 00:12:24,800 AGENCYINGS, COORDINATED -- 318 00:12:24,800 --> 00:12:26,880 AGENCIES COORDINATED THROUGH THE 319 00:12:26,880 --> 00:12:28,200 OFFICE OF SECRETARY OF HEALTH 320 00:12:28,200 --> 00:12:29,440 AND HUMAN SERVICES AN INCLUDES 321 00:12:29,440 --> 00:12:33,400 NCI, CDC FDA, CDC OFFICE OF 322 00:12:33,400 --> 00:12:36,080 NATIONAL COORDINATOR ARPA-H AND 323 00:12:36,080 --> 00:12:38,200 OTHERS. RIGHT NOW WE ARE IN THE 324 00:12:38,200 --> 00:12:39,960 VERY ACTIVE PLANNING STAGES THAT 325 00:12:39,960 --> 00:12:44,840 WILL COORDINATE ACROSS HHS 326 00:12:44,840 --> 00:12:47,600 ACTIVITIES AND THE INITIATIVE 327 00:12:47,600 --> 00:12:50,400 INCLUDES STANDARD DATA FOR 328 00:12:50,400 --> 00:12:51,920 LINKAGES, CROSS HHS ALIGNMENT 329 00:12:51,920 --> 00:12:53,840 FOR STANDARDS AND 330 00:12:53,840 --> 00:12:54,840 INTEROPERABILITY AND BILLING 331 00:12:54,840 --> 00:12:56,520 PARTNERSHIPS BETWEEN THE PUBLIC 332 00:12:56,520 --> 00:12:58,400 -- BUILDING PARTNERSHIPS BETWEEN 333 00:12:58,400 --> 00:13:01,520 PUBLIC AND SECTOR TO POWER 334 00:13:01,520 --> 00:13:03,120 ADOPTION AND DATA SHARING. 335 00:13:03,120 --> 00:13:04,880 ACROSS HEALTH SYSTEMS AND 336 00:13:04,880 --> 00:13:06,520 AGENCIES WE HAVE VALUABLE DATA 337 00:13:06,520 --> 00:13:08,920 RESOURCES. BUT THESE ARE STILL 338 00:13:08,920 --> 00:13:10,880 NOT OPTIMIZED SO THAT WE CAN 339 00:13:10,880 --> 00:13:12,360 TAKE FULL ADVANTAGE OF THE 340 00:13:12,360 --> 00:13:14,440 POTENTIAL TO REVEAL INSIGHTS 341 00:13:14,440 --> 00:13:16,160 THAT WILL PREVENT CANCER AND 342 00:13:16,160 --> 00:13:17,720 MAKE IT LIVABLE AND TREATABLE 343 00:13:17,720 --> 00:13:20,480 FOR ALL PEOPLE. WE NEED 344 00:13:20,480 --> 00:13:22,360 COLLABORATION AT A MASSIVE SCALE 345 00:13:22,360 --> 00:13:24,560 TO LEVERAGE AND CONNECT OUR 346 00:13:24,560 --> 00:13:25,800 RESPECTIVE STRENGTHS AND 347 00:13:25,800 --> 00:13:29,240 RESOURCES. AND THIS INITIATIVE 348 00:13:29,240 --> 00:13:32,760 TRULY HHS WIDE, IS A BIG STEP IN 349 00:13:32,760 --> 00:13:34,520 THAT DIRECTION. LEVERAGING THE 350 00:13:34,520 --> 00:13:37,560 RESOURCES ACROSS THESE AGENCIES 351 00:13:37,560 --> 00:13:39,240 AND IT ALSO PROVIDES A ROADMAP 352 00:13:39,240 --> 00:13:42,840 TO IMPROVE ALL OF HEALTH BEYOND 353 00:13:42,840 --> 00:13:49,640 CANCER. SHIFTING GEARS. WE ARE 354 00:13:49,640 --> 00:13:50,800 DOING EVERYTHING WE CAN TO 355 00:13:50,800 --> 00:13:52,400 ENSURE NCI'S WORK IS ALIGNED 356 00:13:52,400 --> 00:13:53,880 WITH THE NATIONAL CANCER PLAN 357 00:13:53,880 --> 00:13:55,680 GOALS. FOR THE NEXT FEW SLIDES 358 00:13:55,680 --> 00:13:58,240 YOU WILL SEE ON THE RIGHT OUR 359 00:13:58,240 --> 00:13:59,160 ACTIVITIES WORK TOWARD THESE 360 00:13:59,160 --> 00:14:01,240 GOALS. THESE TOKENS IN THE 361 00:14:01,240 --> 00:14:02,840 CORNER INDICATE HOW MANY OF THE 362 00:14:02,840 --> 00:14:04,240 EIGHT GOALS ARE ADDRESSED BY THE 363 00:14:04,240 --> 00:14:07,560 WORK LISTED ON THE SLIDE. THAT 364 00:14:07,560 --> 00:14:08,880 SYNTHESIZES SO MUCH OF WHAT WE 365 00:14:08,880 --> 00:14:11,760 DO CUTS ACROSS THE DIFFERENT 366 00:14:11,760 --> 00:14:13,240 NATIONAL CANCER PLAN GOALS AND 367 00:14:13,240 --> 00:14:15,560 HOW SO THEY ARE NOT SILOED. NONE 368 00:14:15,560 --> 00:14:18,160 OF THESE GOALS ARE SILOED. THEY 369 00:14:18,160 --> 00:14:19,600 DEMAND COLLABORATION FOR 370 00:14:19,600 --> 00:14:22,240 SUCCESS. IN TERMS OF PREVENTION 371 00:14:22,240 --> 00:14:23,680 SCREENING AND EARLY DETECTION IT 372 00:14:23,680 --> 00:14:26,040 IS CRITICAL WE FIND WAYS TO STOP 373 00:14:26,040 --> 00:14:29,360 CANCER BEFORE THEY DEVELOP OR 374 00:14:29,360 --> 00:14:30,480 ALTERNATIVELY WE CAN DETECT 375 00:14:30,480 --> 00:14:32,400 CANCER EARLY ENOUGH TO 376 00:14:32,400 --> 00:14:33,240 SUCCESSFULLY TREAT IT. THIS 377 00:14:33,240 --> 00:14:34,680 YEAR WE LAUNCHED A MAJOR 378 00:14:34,680 --> 00:14:37,880 NATIONAL STUDY WITH CLINICAL 379 00:14:37,880 --> 00:14:41,200 TRIALS TO START IN 2024 TO SEE 380 00:14:41,200 --> 00:14:43,000 WHETHER MULTI-CANCER DETECTION 381 00:14:43,000 --> 00:14:44,920 TESTS IDENTIFY CANCER EARLY 382 00:14:44,920 --> 00:14:47,120 ENOUGH TO REDUCE DEATHS. AND 383 00:14:47,120 --> 00:14:48,520 UNDERSTAND WHETHER THE BENEFITS 384 00:14:48,520 --> 00:14:49,840 OF THESE TESTS CAN OUTWEIGH THE 385 00:14:49,840 --> 00:14:54,280 HARMS. ABILITY TO SCREEN FOR 386 00:14:54,280 --> 00:14:56,040 MANY CANCERS AT ONCE THROUGH A 387 00:14:56,040 --> 00:14:58,440 BLOOD DRAW CAN HAVE PROFOUND 388 00:14:58,440 --> 00:15:00,240 IMPACT ON OUTCOME AND THESE 389 00:15:00,240 --> 00:15:02,440 TESTS CAN POTENTIALLY BOOST 390 00:15:02,440 --> 00:15:04,760 UPTAKE IN SCREENING IF PEOPLE 391 00:15:04,760 --> 00:15:05,680 RECEIVE TEST AS PART OF THE 392 00:15:05,680 --> 00:15:07,840 USUAL VISIT TO THEIR PRIMARY 393 00:15:07,840 --> 00:15:09,040 CARE PHYSICIAN AND YET THERE ARE 394 00:15:09,040 --> 00:15:11,160 TO DATE NO TRIALS THAT SHOW 395 00:15:11,160 --> 00:15:14,280 THESE TESTS TRULY DO REDUCE 396 00:15:14,280 --> 00:15:16,120 CANCER DEATH, AND THAT THE 397 00:15:16,120 --> 00:15:19,040 DOWNSTREAM EFFECT ON HEALTHCARE 398 00:15:19,040 --> 00:15:21,120 SERVICES, AND POTENTIAL FOR 399 00:15:21,120 --> 00:15:22,520 OVERTREATMENT ARE ADDRESSED. 400 00:15:22,520 --> 00:15:25,000 THESE ARE REAL CONCERNS THAT 401 00:15:25,000 --> 00:15:27,360 THIS NEW STUDY WE ARE LAUNCHING 402 00:15:27,360 --> 00:15:29,920 WILL ADDRESS THESE CRITICAL 403 00:15:29,920 --> 00:15:31,240 QUESTIONS ABOUT CANCER SCREENING 404 00:15:31,240 --> 00:15:33,440 INCLUDING EFFICACY, 405 00:15:33,440 --> 00:15:34,600 EFFECTIVENESS, ADOPTION AND 406 00:15:34,600 --> 00:15:39,360 IMPLEMENTATION. YOU SEE OTHER 407 00:15:39,360 --> 00:15:40,920 PROGRAMS LISTED HERE I WON'T 408 00:15:40,920 --> 00:15:44,000 PROVIDE MORE DETAIL ON, 409 00:15:44,000 --> 00:15:45,000 UNDERSTANDING THAT WE HAVE A 410 00:15:45,000 --> 00:15:46,360 ROBUST PORTFOLIO OF WORK MOVING 411 00:15:46,360 --> 00:15:47,680 AHEAD IN PREVENTION SCREENING 412 00:15:47,680 --> 00:15:49,320 AND EARLY DETECTION. NEXT 413 00:15:49,320 --> 00:15:54,400 SLIDE. CLINICAL TRIALS KEY 414 00:15:54,400 --> 00:15:55,760 PRIORITY AREA. WE ARE MAKING A 415 00:15:55,760 --> 00:15:57,840 BIG PUSH TO TRANSFORM OUR 416 00:15:57,840 --> 00:15:59,360 CLINICAL TRIALS SO THEY ACHIEVE 417 00:15:59,360 --> 00:16:02,480 RESULTS FASTER AN BETTER SERVE 418 00:16:02,480 --> 00:16:04,840 EVERYONE, ALL POPULATIONS. TWO 419 00:16:04,840 --> 00:16:06,040 KEY CHALLENGES WE ARE FOCUSING 420 00:16:06,040 --> 00:16:08,880 ON IS HOW TO GET MORE PEOPLE 421 00:16:08,880 --> 00:16:10,480 ACCRUED TO TRIALS PARTICULARLY 422 00:16:10,480 --> 00:16:11,440 THOSE FROM UNDER-REPRESENTED 423 00:16:11,440 --> 00:16:14,520 POPULATIONS. TO STREAMLINE 424 00:16:14,520 --> 00:16:18,080 TRIALS SO THEY ARE MORE COST 425 00:16:18,080 --> 00:16:18,680 EFFECTIVE AND DELIVER RESULTS 426 00:16:18,680 --> 00:16:20,280 FOR EFFICIENTLY. WE NEED TO 427 00:16:20,280 --> 00:16:22,400 BREAK AWAY FROM ROUTINE 428 00:16:22,400 --> 00:16:23,480 PRACTICES THAT NO LONGER SERVE 429 00:16:23,480 --> 00:16:25,440 OUR NEEDS. AND SO WE NEED TO 430 00:16:25,440 --> 00:16:27,280 TEST NEW MODELS THAT CAN 431 00:16:27,280 --> 00:16:30,120 TRANSFORM CLINICAL TRIALS. OUR 432 00:16:30,120 --> 00:16:31,240 NEW CLINICAL TRIALS INNOVATION 433 00:16:31,240 --> 00:16:33,360 UNIT IS HELPING EXPLORE THROUGH 434 00:16:33,360 --> 00:16:34,760 DEVELOPING NEW TRIALS THAT TEST 435 00:16:34,760 --> 00:16:36,360 MODELS AND PUSH US TO WORK 436 00:16:36,360 --> 00:16:38,080 DIFFERENTLY. WE HAVE ALSO 437 00:16:38,080 --> 00:16:40,560 LAUNCHED THE PRAGMATIC LUNG 438 00:16:40,560 --> 00:16:41,640 TRIAL EARLIER THIS YEAR, AN 439 00:16:41,640 --> 00:16:44,640 EARLY EXAMPLE OF APPROACHES THAT 440 00:16:44,640 --> 00:16:47,720 HELP US GET RESULTS FASTER BY 441 00:16:47,720 --> 00:16:49,120 FOCUSING ON OBTAINING ONLY DATA 442 00:16:49,120 --> 00:16:51,640 NEEDED TO DETERMINE IMPACT OF A 443 00:16:51,640 --> 00:16:53,200 COMBINATION OF TREATMENTS ON 444 00:16:53,200 --> 00:16:55,400 SURVIVAL FOR PATIENTS WITH 445 00:16:55,400 --> 00:16:56,920 ADVANCE NON-SMALL CELL LUNG 446 00:16:56,920 --> 00:16:59,280 CANCER AND USING EXTREMELY BROAD 447 00:16:59,280 --> 00:17:03,760 ELIGIBILITY CRITERIA TO HELP 448 00:17:03,760 --> 00:17:04,960 ENGAGE PATIENTS PARTICULARLY 449 00:17:04,960 --> 00:17:07,280 THOSE FROM POPULATIONS TOO OFTEN 450 00:17:07,280 --> 00:17:08,960 LEFT OUT OF TRIALS. THIS WILL 451 00:17:08,960 --> 00:17:10,840 ALSO HELP US COMPLETE ACCRUAL 452 00:17:10,840 --> 00:17:12,960 QUICKLY. WE ARE ALSO BUILDING 453 00:17:12,960 --> 00:17:16,200 WHAT WE HAVE LEARNED THROUGH 454 00:17:16,200 --> 00:17:18,480 SUCCESSFUL NCI PRECISION 455 00:17:18,480 --> 00:17:20,160 MEDICINE TRIAL NCI MATCH BY 456 00:17:20,160 --> 00:17:21,440 LAUNCHING COMBO MATCH, THE 457 00:17:21,440 --> 00:17:23,040 LARGEST INITIATIVE OF ITS KIND 458 00:17:23,040 --> 00:17:24,960 TO TEST COMBINATIONS OF CANCER 459 00:17:24,960 --> 00:17:30,400 DRUGS THAT ARE CHOSEN BASED ON 460 00:17:30,400 --> 00:17:32,480 TUMOR GENOMICS AND OTHER 461 00:17:32,480 --> 00:17:34,000 MOLECULAR CHARACTERISTICS. 462 00:17:34,000 --> 00:17:35,920 UNLIKE NCI MATCH, COMBO MATCH 463 00:17:35,920 --> 00:17:37,440 TRIALS INCLUDE CHILDREN IN THIS 464 00:17:37,440 --> 00:17:39,680 CANCER. MORE INCLUSIVE. SO 465 00:17:39,680 --> 00:17:41,560 IMPORTANT WE CONTINUE TO 466 00:17:41,560 --> 00:17:42,680 STRENGTHEN OUR CLINICAL TRIALS 467 00:17:42,680 --> 00:17:43,840 WORK THROUGH INNOVATION AND 468 00:17:43,840 --> 00:17:47,400 LEARNING AND ENSURE ALL WHO FACE 469 00:17:47,400 --> 00:17:49,760 CANCER HAVE THE OPPORTUNITY TO 470 00:17:49,760 --> 00:17:52,280 PARTICIPATE. AND THAT ALL 471 00:17:52,280 --> 00:17:54,160 POPULATIONS ARE ADEQUATELY 472 00:17:54,160 --> 00:17:56,800 REPRESENTED TO PRODUCE SCIENCE 473 00:17:56,800 --> 00:17:59,680 THAT HELPS EVERYONE. THIS IS A 474 00:17:59,680 --> 00:18:01,360 CRITICAL PRIORITY FOR NCI. NEXT 475 00:18:01,360 --> 00:18:09,400 SLIDE. ANOTHER PRIORITY FOR NCI 476 00:18:09,400 --> 00:18:10,840 IS CLOSING THE GAPS THAT LEAD TO 477 00:18:10,840 --> 00:18:12,200 HIGHER INCIDENCE IN MORTALITY 478 00:18:12,200 --> 00:18:13,680 FOR SOME POPULATIONS 479 00:18:13,680 --> 00:18:15,440 PARTICULARLY THOSE WHO LONG 480 00:18:15,440 --> 00:18:16,680 FACED SYSTEMIC BARRIERS TO 481 00:18:16,680 --> 00:18:18,560 RESEARCH AND CARE. WE HAVE 482 00:18:18,560 --> 00:18:20,040 LAUNCHED A NUMBER OF NEW 483 00:18:20,040 --> 00:18:21,360 PROGRAMS OVER THE LAST FEW YEARS 484 00:18:21,360 --> 00:18:25,000 TO PUSH OUR DISPARITIES RESEARCH 485 00:18:25,000 --> 00:18:26,560 INTO NEW AREAS AS WE HAVE COME 486 00:18:26,560 --> 00:18:27,640 TO BETTER UNDERSTAND THE GAPS 487 00:18:27,640 --> 00:18:31,120 THAT EXIST. THIS YEAR WE 488 00:18:31,120 --> 00:18:32,680 LAUNCHED THE FIRST INITIATIVE TO 489 00:18:32,680 --> 00:18:35,360 STUDY HOW PERSISTENT POVERTY 490 00:18:35,360 --> 00:18:36,480 LEAD TO WORSE CANCER OUTCOME 491 00:18:36,480 --> 00:18:37,640 CONSIST AND HOW TO OVERCOME 492 00:18:37,640 --> 00:18:39,640 THESE BARRIERS. RESEARCH HAS 493 00:18:39,640 --> 00:18:40,760 SHOWN CANCER DEATH RATES ARE 494 00:18:40,760 --> 00:18:44,720 HIGHER IN AREAS WITH PERSISTENT 495 00:18:44,720 --> 00:18:47,480 POVERTY IN THE U.S. WE KNOW OUT 496 00:18:47,480 --> 00:18:50,560 EFFECTIVE INTERVENTIONS, 497 00:18:50,560 --> 00:18:51,800 PERSISTENT POVERTY WILL LIKELY 498 00:18:51,800 --> 00:18:54,120 CONTINUE TO EXACERBATE HEALTH 499 00:18:54,120 --> 00:18:56,680 DISPARITIES IN CARIS AND IN 500 00:18:56,680 --> 00:18:57,400 OTHER DISEASE -- CANCER AND 501 00:18:57,400 --> 00:18:58,880 OTHER DISEASES. WE ARE STUDYING 502 00:18:58,880 --> 00:19:00,440 HOW TO IMPROVE REPRESENTATION IN 503 00:19:00,440 --> 00:19:02,080 CLINICAL TRIALS, HOW TELEHEALTH 504 00:19:02,080 --> 00:19:06,040 CAN MAKE IT EASIER FOR PEOPLE TO 505 00:19:06,040 --> 00:19:07,720 ACCESS CANCER CARE AND 506 00:19:07,720 --> 00:19:09,880 PARTICIPATE IN TRIALS AND HOW IT 507 00:19:09,880 --> 00:19:12,840 CAN OVERCOME OR PERHAPS IF NOT 508 00:19:12,840 --> 00:19:15,320 USE WELL EVEN EXACERBATE CANCER 509 00:19:15,320 --> 00:19:20,800 HEALTH INEQUITIES. SOMETHING 510 00:19:20,800 --> 00:19:22,200 THAT SETS NCI APART IS HOW TO 511 00:19:22,200 --> 00:19:23,840 BUILD THE FUTURE OF CANCER 512 00:19:23,840 --> 00:19:26,960 RESEARCH THROUGH OUR INVESTMENTS 513 00:19:26,960 --> 00:19:28,960 IN PEOPLE AN ESSENTIAL 514 00:19:28,960 --> 00:19:29,600 INFRASTRUCTURE THAT MAKE IT 515 00:19:29,600 --> 00:19:30,640 POSSIBLE FOR MUCH OF THE 516 00:19:30,640 --> 00:19:34,240 PROGRESS THAT OUR PATIENTS NEED 517 00:19:34,240 --> 00:19:36,040 WE PROVIDE CRITICAL 518 00:19:36,040 --> 00:19:36,960 OPPORTUNITIES TO STRENGTHEN THE 519 00:19:36,960 --> 00:19:38,880 WORK FORCE TO BRING THE WIDEST 520 00:19:38,880 --> 00:19:40,840 POSSIBLE VARIETY OF IDEAS AND 521 00:19:40,840 --> 00:19:42,440 PERSPECTIVES TO DELIVER THE BEST 522 00:19:42,440 --> 00:19:48,320 CANCER SCIENCE. THAT INCLUDES 523 00:19:48,320 --> 00:19:50,160 NEWER PROGRAMS TO FUNDS AND 524 00:19:50,160 --> 00:19:51,480 MENTOR SCIENTIST BACKGROUND TO 525 00:19:51,480 --> 00:19:52,960 BUILD A PIPELINE OF TALENTED 526 00:19:52,960 --> 00:19:55,480 CANCER RESEARCHERS WE NEED 527 00:19:55,480 --> 00:19:57,080 DESPERATELY TO MEET TODAY'S 528 00:19:57,080 --> 00:19:58,280 OPPORTUNITIES. DIVERSITY AMONG 529 00:19:58,280 --> 00:19:59,720 OUR SCIENTISTS IS VITAL TO 530 00:19:59,720 --> 00:20:01,120 ASKING THE RIGHT RESEARCH 531 00:20:01,120 --> 00:20:05,440 QUESTIOQUESTIONS. AND UNDERSTANE 532 00:20:05,440 --> 00:20:07,720 CHALLENGES FACED BY ALL 533 00:20:07,720 --> 00:20:10,160 POPULATIONS. IN PARTICULAR I 534 00:20:10,160 --> 00:20:11,960 WILL SPOTLIGHT ONE OF THESE NEW 535 00:20:11,960 --> 00:20:13,440 PROGRAMS THE CANCER MOON SHOT 536 00:20:13,440 --> 00:20:15,320 SCHOLAR, DESIGNED WITH GOAL TO 537 00:20:15,320 --> 00:20:16,760 ADVANCE OUR SCIENCE THROUGH 538 00:20:16,760 --> 00:20:19,720 GREATER DIVERSITY IN OUR RO1 539 00:20:19,720 --> 00:20:21,160 APPLICANT POOL. THIS IS 540 00:20:21,160 --> 00:20:23,160 IMPORTANT BECAUSE RO1s ARE THE 541 00:20:23,160 --> 00:20:24,960 SOURCE OF SO MANY OF THE 542 00:20:24,960 --> 00:20:26,520 INNOVATIVE IDEAS AND SOME OF THE 543 00:20:26,520 --> 00:20:28,560 MOST SIGNIFICANT DISCOVERIES IN 544 00:20:28,560 --> 00:20:30,040 CANCER RESEARCH WHO JUST 545 00:20:30,040 --> 00:20:32,200 ANNOUNCED OUR FIRST COHORT OF 546 00:20:32,200 --> 00:20:34,080 SCHOLARS. HERE THEY ARE. AS YOU 547 00:20:34,080 --> 00:20:36,080 CAN SEE, FROM THIS LIST OF 548 00:20:36,080 --> 00:20:38,760 RECENT PROJECTS, THE PROGRAM 549 00:20:38,760 --> 00:20:42,280 ALREADY COVERS QUITE A RANGE OF 550 00:20:42,280 --> 00:20:44,520 CANCER TYPES, SPANS IMPORTANT 551 00:20:44,520 --> 00:20:46,640 DISCIPLINES IN SCIENCE FROM 552 00:20:46,640 --> 00:20:48,000 BASIC TO TREATMENT TO 553 00:20:48,000 --> 00:20:56,640 IMPLEMENTATION SCIENCE RESEARCH 554 00:20:56,640 --> 00:20:58,360 ANOTHER INVESTMENT WE MADE IS IN 555 00:20:58,360 --> 00:20:59,720 CANCER DATA AND TECHNOLOGY. 556 00:20:59,720 --> 00:21:02,640 THESE ARE TRANSFORMING WHAT IS 557 00:21:02,640 --> 00:21:05,680 POSSIBLE FOR CANCER RESEARCH AND 558 00:21:05,680 --> 00:21:07,000 INCLUDES BUILDING INFRASTRUCTURE 559 00:21:07,000 --> 00:21:08,200 THAT CONNECTS VAST COLLECTIONS 560 00:21:08,200 --> 00:21:10,760 OF DATA TO POWER MORE ROBUST 561 00:21:10,760 --> 00:21:13,440 ANALYSIS AND CREATE 3-D TUMOR 562 00:21:13,440 --> 00:21:18,040 ATLASES MAKING IT POSSIBLE TO 563 00:21:18,040 --> 00:21:21,680 DETECT HOW CANCER EVOLVE 564 00:21:21,680 --> 00:21:23,160 PRE-CANCEROUS LESIONS TO ADVANCE 565 00:21:23,160 --> 00:21:25,120 DISEASE. THESE RESOURCES ARE 566 00:21:25,120 --> 00:21:26,320 VALUABLE AS THE QUANTITY AND 567 00:21:26,320 --> 00:21:28,680 QUALITY OF THE DATA THAT IS WHY 568 00:21:28,680 --> 00:21:32,720 WE NEED TO INVEST IN COLLECT 569 00:21:32,720 --> 00:21:34,760 COLLECTING ENOUGH DATA FROM ALL 570 00:21:34,760 --> 00:21:36,200 POPULATIONS TO WORK FOR EACH. TO 571 00:21:36,200 --> 00:21:37,200 DO SO IT IS ESSENTIAL THAT 572 00:21:37,200 --> 00:21:40,400 PEOPLE WITH CANCER OR LISTK RISK 573 00:21:40,400 --> 00:21:41,880 OF DISEASE HAVE THE CHANCE TO 574 00:21:41,880 --> 00:21:43,200 CONTRIBUTE. SO THIS IS A FOCUS 575 00:21:43,200 --> 00:21:44,840 OF ALL OF OUR DATA COLLECTION 576 00:21:44,840 --> 00:21:48,360 ACTIVITIES. THIS GIVES US THE 577 00:21:48,360 --> 00:21:49,800 POTENTIAL TO LEARN FROM EVERY 578 00:21:49,800 --> 00:21:50,880 PATIENT AND IMPROVE RESULTS FOR 579 00:21:50,880 --> 00:21:56,000 EVERYONE. THE CHILDHOOD CANCER 580 00:21:56,000 --> 00:21:57,480 DATA INITIATIVE IN PARTICULAR 581 00:21:57,480 --> 00:21:58,920 HAS MADE TREMENDOUS PROGRESS IN 582 00:21:58,920 --> 00:22:03,320 A FEW YEARS, TO MAKE ACCESSIBLE 583 00:22:03,320 --> 00:22:04,600 DATA HISTORICALLY CHALLENGING 584 00:22:04,600 --> 00:22:06,280 FOR RESEARCHERS TO ACCESS 585 00:22:06,280 --> 00:22:07,800 BECAUSE OF HOW RARE CHILDHOOD 586 00:22:07,800 --> 00:22:09,160 CANCER CAN BE AND BECAUSE THIS 587 00:22:09,160 --> 00:22:10,440 DATA ARE OFTEN STORED IN 588 00:22:10,440 --> 00:22:11,400 HOSPITALS WHERE IT CAN BE HARD 589 00:22:11,400 --> 00:22:15,960 TO REACH. NOT ONLY DOES CCDI 590 00:22:15,960 --> 00:22:19,360 HELP RESEARCHERS STUDY THESE 591 00:22:19,360 --> 00:22:21,960 RARE CANCER, ITS USE WILL HELP 592 00:22:21,960 --> 00:22:23,880 ONCOLOGISTS AND PATIENTS MAKE 593 00:22:23,880 --> 00:22:24,840 THE BEST POSSIBLE TREATMENT 594 00:22:24,840 --> 00:22:29,520 DECISIONS. AMONG CCDIs RECENT 595 00:22:29,520 --> 00:22:31,000 DEVELOPMENTS IS IT FACILITATED 596 00:22:31,000 --> 00:22:35,280 THE RELEASE OF A SIGNIFICANT NEW 597 00:22:35,280 --> 00:22:38,000 SOURCE OF PEDIATRIC BRAIN TUMOR 598 00:22:38,000 --> 00:22:38,720 CHARACTERIZATION AND CLINICAL 599 00:22:38,720 --> 00:22:40,360 DATA FROM THE CHILDREN'S BRAIN 600 00:22:40,360 --> 00:22:43,800 TUMOR NETWORK. THE PACIFIC 601 00:22:43,800 --> 00:22:45,480 PEDIATRIC NEURAL ONCOLOGY 602 00:22:45,480 --> 00:22:47,960 CONSORTIUM AND THE CHILDREN'S 603 00:22:47,960 --> 00:22:50,040 HOSPITAL OF PHILADELPHIA. I CALL 604 00:22:50,040 --> 00:22:51,280 YOUR ATTENTION TO THIS 605 00:22:51,280 --> 00:22:52,800 PARTICULAR INITIATIVE LAUNCHED 606 00:22:52,800 --> 00:22:55,240 AS A DATA SHARING INITIATIVE 607 00:22:55,240 --> 00:22:59,640 WHICH IS NOW BECOME A COMMUNITY 608 00:22:59,640 --> 00:23:02,720 FOCUS FOR RESEARCH DIRECTED AT 609 00:23:02,720 --> 00:23:09,720 OVERCOMING PEDIATRIC CANCERS. 610 00:23:09,720 --> 00:23:11,480 OF COURSE WHAT ULTIMATELY 611 00:23:11,480 --> 00:23:13,360 MATTERS IS WHETHER WE DELIVER 612 00:23:13,360 --> 00:23:15,280 SCIENTIFIC RESULTS THAT MOVE US 613 00:23:15,280 --> 00:23:17,000 TOWARD REAL PROGRESS. THIS IS 614 00:23:17,000 --> 00:23:20,760 JUST A LIST OF SO MANY EXAMPLES 615 00:23:20,760 --> 00:23:22,080 OVER THE PAST YEAR THAT HAVE 616 00:23:22,080 --> 00:23:25,000 BEEN SELECTED TO SHOW NCI 617 00:23:25,000 --> 00:23:26,640 SUPPORT HOW NCI SUPPORT OF 618 00:23:26,640 --> 00:23:29,040 SCIENCE HAS PAID OFF WITH MANY 619 00:23:29,040 --> 00:23:31,720 SIGNIFICANT ADVANCES. WE WON'T 620 00:23:31,720 --> 00:23:32,880 ACHIEVE SCIENTIFIC PROGRESS THAT 621 00:23:32,880 --> 00:23:35,440 TRULY ADDRESSES THE NEEDS OF ALL 622 00:23:35,440 --> 00:23:39,160 WHO HAVE CANCER OR AT RISK OF 623 00:23:39,160 --> 00:23:41,640 DISEASE WITHOUT THE FOUNDATIONAL 624 00:23:41,640 --> 00:23:42,560 UNDERSTANDING THAT COMES FROM 625 00:23:42,560 --> 00:23:46,760 BASIC SCIENCE. BECAUSE OF SOME 626 00:23:46,760 --> 00:23:48,520 OF OUR BASIC SCIENCE ADVANCES 627 00:23:48,520 --> 00:23:50,880 THIS YEAR, WE BETTER UNDERSTAND 628 00:23:50,880 --> 00:23:56,120 WHAT FUELS THE GROWTH OF 629 00:23:56,120 --> 00:23:57,880 PANCREATIC CANCER HOW COLON 630 00:23:57,880 --> 00:24:00,640 CANCER METASTASIZES AND WHAT 631 00:24:00,640 --> 00:24:02,280 TRIGGERS THE FORMATION AND 632 00:24:02,280 --> 00:24:03,280 PROGRESSION OF ESOPHAGEAL 633 00:24:03,280 --> 00:24:05,800 CANCECANCER. A NUMBER OF STUDIEU 634 00:24:05,800 --> 00:24:07,960 SEE HERE BRING BENEFIT TO THOSE 635 00:24:07,960 --> 00:24:10,880 WHO ARE WORKING TO PREVENT AND 636 00:24:10,880 --> 00:24:13,200 TREAT CANCER. AN EXAMPLE OF THE 637 00:24:13,200 --> 00:24:14,880 IMPLEMENTATION SCIENCE END WE 638 00:24:14,880 --> 00:24:16,360 FOUND THROUGH ONE OF OUR CANCER 639 00:24:16,360 --> 00:24:19,280 MOON SHOT FUNDED PROGRAMS THAT 640 00:24:19,280 --> 00:24:21,120 CLINICIAN FOCUSED NUDGES USING 641 00:24:21,120 --> 00:24:21,920 ELECTRONIC HEALTH RECORDS CAN 642 00:24:21,920 --> 00:24:24,120 RESULT IN MORE CANCER PATIENTS 643 00:24:24,120 --> 00:24:25,080 ENGAGING IN TOBACCO USE 644 00:24:25,080 --> 00:24:28,520 TREATMENT. FROM RESEARCH ON 645 00:24:28,520 --> 00:24:31,600 CANCER SURVIVORS WE HAVE A 646 00:24:31,600 --> 00:24:32,720 BETTER UNDERSTANDING OF 647 00:24:32,720 --> 00:24:34,280 ASSOCIATION OF METABOLIC 648 00:24:34,280 --> 00:24:36,440 SYNDROME IN CANCER SURVIVORS BY 649 00:24:36,440 --> 00:24:42,360 GENDER. THE STUDY ALSO FOUND MEN 650 00:24:42,360 --> 00:24:45,040 WITH HISTORY OF HEMATOLOGIC 651 00:24:45,040 --> 00:24:47,360 MALIGNANCIES AND WOMEN WITH 652 00:24:47,360 --> 00:24:48,520 CERVICAL CANCER WERE GREATEST 653 00:24:48,520 --> 00:24:49,880 RISK OF DEVELOPING METABOLIC 654 00:24:49,880 --> 00:24:56,560 SYNDROME. WHILE NCI SCIENCE LED 655 00:24:56,560 --> 00:24:57,560 TO TREATMENT POSSIBILITIES THIS 656 00:24:57,560 --> 00:24:59,160 YEAR I ALSO LIKE TO JUST 657 00:24:59,160 --> 00:25:01,800 SPOTLIGHT THIS ADVANCE IN 658 00:25:01,800 --> 00:25:05,360 PARTICULAR. NCI CLINICAL TRIAL 659 00:25:05,360 --> 00:25:09,240 CONDUCTED AT THE CLINICAL CENTER 660 00:25:09,240 --> 00:25:11,160 ON THE NIH CAMPUS LED TO 661 00:25:11,160 --> 00:25:12,840 APPROVAL TO TREAT ADULTS AN 662 00:25:12,840 --> 00:25:15,280 CHILDREN TWO YEARS AND OLDER FOR 663 00:25:15,280 --> 00:25:18,120 THE RARE CANCER ADVANCED 664 00:25:18,120 --> 00:25:19,840 ALVEOLAR SARCOMA. I HIGHLIGHT 665 00:25:19,840 --> 00:25:21,280 THIS BECAUSE OUR GOAL IS TO ENDS 666 00:25:21,280 --> 00:25:22,440 CANCER AS WE KNOW IT FOR ALL 667 00:25:22,440 --> 00:25:24,560 PEOPLE. AND THIS EXAMPLE SHOWS 668 00:25:24,560 --> 00:25:29,680 WHAT I THINK ARE REALLY 669 00:25:29,680 --> 00:25:33,000 IMPORTANT UNIQUE CONTRIBUTIONS 670 00:25:33,000 --> 00:25:34,360 OF NCI RESEARCH. RESEARCH FUNDED 671 00:25:34,360 --> 00:25:36,480 BY THE AMERICAN PEOPLE CAN FOCUS 672 00:25:36,480 --> 00:25:41,640 ON RARE CANCER. UNDERSTUDIED 673 00:25:41,640 --> 00:25:42,640 WITHIN THE CANCER RESEARCH 674 00:25:42,640 --> 00:25:43,840 COMMUNITY OVERALL FOR A VARIETY 675 00:25:43,840 --> 00:25:45,720 OF REASONS. A BIG REASON WE CAN 676 00:25:45,720 --> 00:25:48,000 AS THE QUOTE FROM DR. DOROSHOW 677 00:25:48,000 --> 00:25:49,240 IN THE BOTTOM RIGHT NOTES ABOUT 678 00:25:49,240 --> 00:25:50,880 THIS TRIAL, THAT THE NCI 679 00:25:50,880 --> 00:25:54,080 CLINICAL CENTER MAKES IT 680 00:25:54,080 --> 00:25:55,200 POSSIBLE -- NIH CLINICAL CENTER 681 00:25:55,200 --> 00:25:56,920 MAKES IT POSSIBLE TO BRING IN 682 00:25:56,920 --> 00:25:58,520 PATIENTS FROM ALL OVER THE WORLD 683 00:25:58,520 --> 00:26:00,360 FOR DEDICATE STUDIES ON RARE 684 00:26:00,360 --> 00:26:05,400 CANCER, THE ONLY WAY TO MAKE 685 00:26:05,400 --> 00:26:06,800 PROGRESS QUICKLY. YOU WILL HEAR 686 00:26:06,800 --> 00:26:09,040 MORE ABOUT THE WORK TO CONQUER 687 00:26:09,040 --> 00:26:10,520 RAREST OF CANCERS IN TODAY'S 688 00:26:10,520 --> 00:26:11,040 MEETING IN OUR SCIENTIFIC 689 00:26:11,040 --> 00:26:16,880 PRESENTATION. SO LOOKING 690 00:26:16,880 --> 00:26:18,040 FORWARD, WHEN YOU LOOK ACROSS 691 00:26:18,040 --> 00:26:21,680 THE AREAS I FOCUSED ON TODAY YOU 692 00:26:21,680 --> 00:26:26,840 WILL SEE NCI PUT KEY PLACES INTO 693 00:26:26,840 --> 00:26:29,840 PLACE PIECES INTO PLACE TO 694 00:26:29,840 --> 00:26:31,120 ADDRESS SCIENTIFIC CHALLENGES WE 695 00:26:31,120 --> 00:26:33,040 FACE. WE CAN'T LAUNCH THIS 696 00:26:33,040 --> 00:26:33,720 PROGRAM, BUILD THE 697 00:26:33,720 --> 00:26:34,840 INFRASTRUCTURE NEEDED FOR ALL, 698 00:26:34,840 --> 00:26:38,600 AND THEN JUST WALK AWAY. CCBI 699 00:26:38,600 --> 00:26:40,960 FOR EXAMPLE STARTED MODESTLY. 700 00:26:40,960 --> 00:26:43,720 AND NOW LOOK WHAT IT IS DOING TO 701 00:26:43,720 --> 00:26:46,360 TRULY GALVANIZE THE ENTIRE 702 00:26:46,360 --> 00:26:48,480 PEDIATRIC CANCER COMMUNITY. IT 703 00:26:48,480 --> 00:26:50,680 IS GROWN SO MUCH AND IS TRULY 704 00:26:50,680 --> 00:26:53,880 CHANGING WHAT IS POSSIBLE FOR 705 00:26:53,880 --> 00:26:55,480 (INAUDIBLE). WE CAN DO MUCH MORE 706 00:26:55,480 --> 00:26:58,600 OF THIS. FOR EVERYONE. SOME OF 707 00:26:58,600 --> 00:26:59,880 OUR PROGRAMS ARE STILL GETTING 708 00:26:59,880 --> 00:27:03,000 OFF THE GROUND BUT WILL PAY BIG 709 00:27:03,000 --> 00:27:04,200 DIVIDENDS DOWN THE ROAD. WE 710 00:27:04,200 --> 00:27:06,560 NEED TO SUSTAIN THEM. WE ALSO 711 00:27:06,560 --> 00:27:09,480 NEED TO PUSH INTO OTHER AREAS, 712 00:27:09,480 --> 00:27:10,480 CONSISTENT WITH MEETING THE 713 00:27:10,480 --> 00:27:11,600 GOALS OF THE NATIONAL CANCER 714 00:27:11,600 --> 00:27:14,040 PLAN. WE WOULD LOVE TO BE ABLE 715 00:27:14,040 --> 00:27:16,040 TO LAUNCH MORE COMPREHENSIVE 716 00:27:16,040 --> 00:27:18,440 SYSTEMS BIOLOGY WORK FOR 717 00:27:18,440 --> 00:27:20,640 INSTANCE. THROUGH SUCCESS IN 718 00:27:20,640 --> 00:27:21,880 COMMUNITY OUTREACH AND 719 00:27:21,880 --> 00:27:23,920 ENGAGEMENT WORK THROUGH CANCER 720 00:27:23,920 --> 00:27:25,840 CENTERS WE CAN DO SO MUCH MORE 721 00:27:25,840 --> 00:27:27,880 FOR THE UNDERSERVED. WE WOULD 722 00:27:27,880 --> 00:27:30,640 LIKE TO EXPAND SUCCESSFUL 723 00:27:30,640 --> 00:27:32,640 APPROACHES, CONSIDERABLY, WITH A 724 00:27:32,640 --> 00:27:34,480 FOCUS ON PARTICULAR CANCER 725 00:27:34,480 --> 00:27:35,960 CENTERS THAT EXCEL IN CARING FOR 726 00:27:35,960 --> 00:27:38,120 UNDERSERVED POPULATIONS. WE 727 00:27:38,120 --> 00:27:39,800 HAVE A NEW SCREENING NETWORK AND 728 00:27:39,800 --> 00:27:42,160 WOULD LIKE TO ROLL OUT THE 729 00:27:42,160 --> 00:27:43,720 MOLECULAR -- MULTI-CANCER 730 00:27:43,720 --> 00:27:45,520 DETECTION PROGRAM IN A BIG WAY. 731 00:27:45,520 --> 00:27:48,040 SO DEMONSTRATE A BENEFIT TO 732 00:27:48,040 --> 00:27:50,200 CANCER SURVIVAL. WE NEED TO 733 00:27:50,200 --> 00:27:52,200 SIGNIFICANTLY INCREASE ACCRUAL 734 00:27:52,200 --> 00:27:54,640 TO CLINICAL TRIALS AND BEYOND, 735 00:27:54,640 --> 00:27:56,280 INNOVATING IN HOW WE CONDUCT 736 00:27:56,280 --> 00:28:00,840 THEM. WE ALSO REALLY NEED MORE 737 00:28:00,840 --> 00:28:03,640 TRIALS. THE PRIVATE INDUSTRY 738 00:28:03,640 --> 00:28:07,120 COMMUNITY WILL NOT ADDRESS EVERY 739 00:28:07,120 --> 00:28:08,520 QUESTION OUR CANCER PATIENTS 740 00:28:08,520 --> 00:28:10,920 NEED. THERE'S STILL SO MUCH MORE 741 00:28:10,920 --> 00:28:12,480 WE NEED TO DO TO UNDERSTAND 742 00:28:12,480 --> 00:28:14,760 ABOUT CANCER BIOLOGY TO IDENTIFY 743 00:28:14,760 --> 00:28:16,560 POTENTIAL APPROACH AGAINST 744 00:28:16,560 --> 00:28:19,560 CANCER, FOR EXAMPLE WHICH WE 745 00:28:19,560 --> 00:28:21,440 STILL DON'T HAVE SUFFICIENT 746 00:28:21,440 --> 00:28:22,760 UNDERSTANDING OR SOLUTIONS. 747 00:28:22,760 --> 00:28:28,640 ANOTHER CRITICAL FOCUS IS TO 748 00:28:28,640 --> 00:28:29,200 SUPPORTS RESEARCH PROJECT 749 00:28:29,200 --> 00:28:30,760 GRANTS. WE MUST CONTINUE TO 750 00:28:30,760 --> 00:28:31,920 RAISE OUR PAY LINES AS WE DID 751 00:28:31,920 --> 00:28:34,440 THIS YEAR, SO THAT WE AREN'T 752 00:28:34,440 --> 00:28:38,360 FORCED TO LEAVE GREAT IDEAS FROM 753 00:28:38,360 --> 00:28:39,840 OUR NATION OF SCIENTIFIC TALENT 754 00:28:39,840 --> 00:28:43,240 ON THE TABLE. TO DO ALL OF THIS 755 00:28:43,240 --> 00:28:45,600 WILL TAKE SIGNIFICANTLY MORE 756 00:28:45,600 --> 00:28:50,560 FUNDING: AS I SAID AT THE TOP 757 00:28:50,560 --> 00:28:51,680 DISCUSSION THIS MONTH WE WILL 758 00:28:51,680 --> 00:28:54,200 RELEASE OUR FISCAL YEAR 25 759 00:28:54,200 --> 00:29:04,720 PROFESSIONAL JUDGMENT BUDGET. 760 00:29:11,520 --> 00:29:17,480 >>NEXT SLIDE. WHEN YOU LOOK AT 761 00:29:17,480 --> 00:29:18,400 ALL I HAVE HIGHLIGHTED TODAY YOU 762 00:29:18,400 --> 00:29:19,840 CAN SEE THAT NCI IS FULLY 763 00:29:19,840 --> 00:29:22,400 COMMITTED TO DOING EVERYTHING WE 764 00:29:22,400 --> 00:29:24,240 CAN TO POWER CANCER RESEARCH 765 00:29:24,240 --> 00:29:26,880 ACROSS THE FULL SPECTRUM FROM 766 00:29:26,880 --> 00:29:29,320 BASIC DISCOVERY OF CANCER 767 00:29:29,320 --> 00:29:31,320 BIOLOGY TO UNDERSTANDING HOW TO 768 00:29:31,320 --> 00:29:32,680 DELIVER THE VERY BEST HEALTHCARE 769 00:29:32,680 --> 00:29:34,800 FOR ALL WHO NEED IT. WE ALL 770 00:29:34,800 --> 00:29:37,120 KNOW THERE IS STILL SO MUCH TO 771 00:29:37,120 --> 00:29:39,080 DO TO ACCOMPLISH OUR ULTIMATE 772 00:29:39,080 --> 00:29:42,240 GOAL AGAINST THIS AWFUL DISEASE. 773 00:29:42,240 --> 00:29:44,240 I KNOW WE CAN SUCCEED, WE CAN 774 00:29:44,240 --> 00:29:46,320 EXPAND ON SO MANY SUCCESSES IN 775 00:29:46,320 --> 00:29:50,440 THE RECENT PAST BUT THAT WILL 776 00:29:50,440 --> 00:29:51,680 TAKE ACTION AT ALL LEVELS OF 777 00:29:51,680 --> 00:29:52,680 SOCIETY AND THAT ACTION STARTS 778 00:29:52,680 --> 00:29:54,160 WITH RESEARCH TO SHOW THE WAY 779 00:29:54,160 --> 00:29:56,160 FORWARD WHICH IS THE PRIMARY 780 00:29:56,160 --> 00:29:58,280 ROLE OF NCI. SO ON THAT NOTE I 781 00:29:58,280 --> 00:30:00,560 WOULD LIKE TO STOP HERE. I HOPE 782 00:30:00,560 --> 00:30:02,280 WE HAVE A FEW MINUTES TO OPEN UP 783 00:30:02,280 --> 00:30:05,640 TO YOUR QUESTIONS. THANK YOU. 784 00:30:05,640 --> 00:30:06,040 DR. CARPTEN. 785 00:30:06,040 --> 00:30:11,720 >>THANKS, MONICA. BOARD MEMBERS 786 00:30:11,720 --> 00:30:15,320 PLEASE FEEL FREE TO DONE YOUR -- 787 00:30:15,320 --> 00:30:17,720 TURN YOUR CAMERAS ON. WOULD LOVE 788 00:30:17,720 --> 00:30:19,160 TO HEAR MORE ABOUT ADVANCES ON 789 00:30:19,160 --> 00:30:22,480 THE MOON SHOT PARTICULARLY THE 790 00:30:22,480 --> 00:30:26,000 CONCEPT OF THE CANCER CABINET. 791 00:30:26,000 --> 00:30:28,680 WHICH WAS THIS CONCEPT OF 792 00:30:28,680 --> 00:30:31,720 BRINGING TO BEAR THE BROADER 793 00:30:31,720 --> 00:30:32,840 ARMAMENTARIUM OF THE GOVERNMENT 794 00:30:32,840 --> 00:30:34,240 TOWARDS OTHER CANCER MOON SHOT. 795 00:30:34,240 --> 00:30:36,600 CAN YOU GIVE SOME EXAMPLES OR 796 00:30:36,600 --> 00:30:39,200 GIVE LATE INSIGHT SOMEHOW THE 797 00:30:39,200 --> 00:30:40,240 CANCER CABINET IS WORKING WITH 798 00:30:40,240 --> 00:30:42,320 NCI AND NIH AND HOW THAT IS 799 00:30:42,320 --> 00:30:45,480 ADVANCING? 800 00:30:45,480 --> 00:30:47,840 >>THE FIRST I WILL JUST SAY THE 801 00:30:47,840 --> 00:30:53,360 FIRST BIG SUCCESS I'M THRILLED 802 00:30:53,360 --> 00:30:54,920 ACROSS HHS DATA DATA 803 00:30:54,920 --> 00:30:56,400 INTEGRATION. IF YOU CAN IMAGINE 804 00:30:56,400 --> 00:30:58,680 FOR THE FIRST TIME WE ARE GOING 805 00:30:58,680 --> 00:31:02,400 TO BE ABLE TO BRING TO BARE DATA 806 00:31:02,400 --> 00:31:08,440 COLLECTED BY CDC, CMS, FDA, 807 00:31:08,440 --> 00:31:10,200 ACROSS NIH, WE HAVE MANY 808 00:31:10,200 --> 00:31:13,680 PARTNERS AT NIH ALSO THAT ALSO 809 00:31:13,680 --> 00:31:14,920 CAN DELIVER DATA ESSENTIAL FOR 810 00:31:14,920 --> 00:31:15,960 THE CANCER SPACE COORDINATED 811 00:31:15,960 --> 00:31:17,480 THROUGH THE OFFICE OF NATIONAL 812 00:31:17,480 --> 00:31:19,840 COORDINATORS SO THAT WE HAVE 813 00:31:19,840 --> 00:31:21,080 EVERYTHING WE CAN COMPARE APPLES 814 00:31:21,080 --> 00:31:22,880 TO APPLES AND ACHIEVE THE SCALE 815 00:31:22,880 --> 00:31:25,600 WE WANT TO SEE. SO FIRST OF ALL 816 00:31:25,600 --> 00:31:29,520 WITHIN OUR OWN AGENCY OF THE 817 00:31:29,520 --> 00:31:30,840 FEDERAL GOVERNMENT THIS IS A 818 00:31:30,840 --> 00:31:31,720 BIG, BIG PROGRESS. THAT IS GOING 819 00:31:31,720 --> 00:31:33,200 TO BE PRESENTED TO THE CANCER 820 00:31:33,200 --> 00:31:34,760 CABINET TODAY AS AN EXAMPLE OF 821 00:31:34,760 --> 00:31:37,960 WHAT ONE AGENCY CAN DO. THERE 822 00:31:37,960 --> 00:31:39,400 ARE MANY OTHER CROSS AGENCIES 823 00:31:39,400 --> 00:31:41,160 COLLABORATIONS. I KNOW YOU ARE 824 00:31:41,160 --> 00:31:44,560 AWARE, DEPARTMENT OF DEFENSE, 825 00:31:44,560 --> 00:31:48,560 ENVIRONMENTAL PROTECTION AGENCY. 826 00:31:48,560 --> 00:31:50,320 EVEN FEMA BELIEVE IT OR NOT. WE 827 00:31:50,320 --> 00:31:51,360 KNOW THESE EXAMPLES THAT P 828 00:31:51,360 --> 00:31:53,360 HAPPENED IN THE PAST. AND THE 829 00:31:53,360 --> 00:31:55,480 CABINET IS JUST AN OPPORTUNITY 830 00:31:55,480 --> 00:31:58,720 TO GET THE SECRETARIES TOGETHER 831 00:31:58,720 --> 00:32:01,920 TO FINALIZE PLANS GOING FORWARD 832 00:32:01,920 --> 00:32:03,480 I'M REALLY LOOKING FORWARD TO 833 00:32:03,480 --> 00:32:05,400 SEEING WHAT THE LATEST CABINET 834 00:32:05,400 --> 00:32:07,080 MEETING PRESENTS. THIS IS ONLY 835 00:32:07,080 --> 00:32:08,080 THE SECOND WE HAVE HAD THIS 836 00:32:08,080 --> 00:32:09,680 YEAR. AND YOU WILL SEE THAT IN 837 00:32:09,680 --> 00:32:10,800 THE FACT SHEET. 838 00:32:10,800 --> 00:32:13,920 >>GREAT. THANKS, MONICA. ANNA, 839 00:32:13,920 --> 00:32:14,520 I SEE YOUR HAND UP. 840 00:32:14,520 --> 00:32:18,040 >>YES. THANK YOU SO MUCH. MY 841 00:32:18,040 --> 00:32:23,080 QUESTION WAS RELATED TO THE HHS 842 00:32:23,080 --> 00:32:26,240 CANCER MOON SHOT. I WAS THINKING 843 00:32:26,240 --> 00:32:28,960 ABOUT ALL THE DATA OUTSIDE OF 844 00:32:28,960 --> 00:32:30,640 HHS THAT YOU MENTIONED. I WAS 845 00:32:30,640 --> 00:32:37,040 THINKING THE EPA DAT DATA. USDS, 846 00:32:37,040 --> 00:32:38,960 OTHER AGENCIES THAT HAVE 847 00:32:38,960 --> 00:32:40,080 IMPORTANT ENVIRONMENTAL DATA 848 00:32:40,080 --> 00:32:41,600 IMPORTANT FOR CANCER. SO I DON'T 849 00:32:41,600 --> 00:32:44,560 KNOW IF YOU MENTIONED, I BELIEVE 850 00:32:44,560 --> 00:32:45,680 I UNDERSTAND THOSE WERE EFFORTS 851 00:32:45,680 --> 00:32:47,240 FROM THE PAST. I DON'T KNOW IF 852 00:32:47,240 --> 00:32:50,120 YOU ARE THINKING ALSO IN 853 00:32:50,120 --> 00:32:53,360 BRINGING THESE EFFORTS TOGETHER 854 00:32:53,360 --> 00:32:55,120 HHS IS TOO AMBITIOUS BUT BE 855 00:32:55,120 --> 00:32:57,320 CURIOUS TO KNOW IF THERE IS ANY 856 00:32:57,320 --> 00:32:59,680 CONVERSATION ALREADY GOING ON. 857 00:32:59,680 --> 00:33:03,680 >>THANK YOU FOR THAT QUESTION. 858 00:33:03,680 --> 00:33:05,120 SO IN ANYTHING THAT IS BIG YOU 859 00:33:05,120 --> 00:33:10,400 HAVE TO HAVE PRIORITIES. OUR 860 00:33:10,400 --> 00:33:11,840 FIRST PRIORITY WHICH IS 861 00:33:11,840 --> 00:33:13,560 INCREDIBLY AMBITIOUS IN ITSELF 862 00:33:13,560 --> 00:33:17,320 IS DATA FROM THE CLINICAL CARE 863 00:33:17,320 --> 00:33:18,640 ENVIRONMENT. WE ARE LOOKING THIS 864 00:33:18,640 --> 00:33:28,840 IS WHY CMS, CDC, OF HHS, VA. WE 865 00:33:28,840 --> 00:33:30,800 WANT VA PARTNER PARTNERS. WE WO 866 00:33:30,800 --> 00:33:31,560 BRING WHAT IS HAPPENING TO 867 00:33:31,560 --> 00:33:34,120 PEOPLE OUT THERE IN TO OUR DATA 868 00:33:34,120 --> 00:33:35,880 STREAMS AND WE FEEL HHS IS THE 869 00:33:35,880 --> 00:33:38,720 BEST PLACE TO START WITH THAT. 870 00:33:38,720 --> 00:33:40,800 SO THAT IS ONE OF THE BIG 871 00:33:40,800 --> 00:33:42,600 INITIATIVES. THEN SECONDARILY, 872 00:33:42,600 --> 00:33:44,400 LOT OF THESE OTHER DATA SETS, 873 00:33:44,400 --> 00:33:49,640 THERE IS A WHOLE ARM WHICH IS IN 874 00:33:49,640 --> 00:33:53,520 COLLABORATION WITH THE ARPA-H 875 00:33:53,520 --> 00:33:54,320 ANNOUNCEMENT IS TO BRING 876 00:33:54,320 --> 00:33:55,440 TOGETHER A FEDERATED ENVIRONMENT 877 00:33:55,440 --> 00:33:57,480 TO ALLOW US TO PULL IN DATA FROM 878 00:33:57,480 --> 00:33:59,440 EPA AND OTHER RESOURCES YOU ARE 879 00:33:59,440 --> 00:34:01,800 LOOKING AT. WITH THE FEDERATED 880 00:34:01,800 --> 00:34:02,840 GOVERNANCE SYSTEM. THE LAST 881 00:34:02,840 --> 00:34:04,360 THING I WILL SAY, WE DONE HAVE 882 00:34:04,360 --> 00:34:05,720 TIME BUT ONE FEATURE I WANT 883 00:34:05,720 --> 00:34:09,360 EVERYONE TO KNOW ABOUT IS THIS 884 00:34:09,360 --> 00:34:16,280 DATA CLINICAL CARE ENVIRONMENT 885 00:34:16,280 --> 00:34:19,760 HAS THE MANDATE WE DEVELOP A WAY 886 00:34:19,760 --> 00:34:21,000 EVERY INDIVIDUAL PATIENT KNOWS 887 00:34:21,000 --> 00:34:22,920 -- HAS GIVEN PERMISSION FOR 888 00:34:22,920 --> 00:34:24,560 THEIR DATA TO BE USED AND KNOWS 889 00:34:24,560 --> 00:34:25,600 WHAT WE ARE DOING WITH THEIR 890 00:34:25,600 --> 00:34:33,080 DATA. WE ARE COMMITTED TO THAT, 891 00:34:33,080 --> 00:34:35,280 THAT IS THE REALLY HEAVY LIFT WE 892 00:34:35,280 --> 00:34:38,160 CHOSE, TO MAKE IT DOWN TO THE 893 00:34:38,160 --> 00:34:40,840 INDIVIDUAL PERSON TOE GIVE 894 00:34:40,840 --> 00:34:42,200 PERMISSION AND KNOW WHAT THEIR 895 00:34:42,200 --> 00:34:43,920 PARTICIPATION IS. 896 00:34:43,920 --> 00:34:45,520 >>THANKS. IF YOU HAVE A 897 00:34:45,520 --> 00:34:47,200 QUESTION PLEASE USE THE RAISE 898 00:34:47,200 --> 00:34:55,280 YOUR HAND TOOL. 899 00:34:55,280 --> 00:34:56,600 >>HOW ARE WE ON TIME? 900 00:34:56,600 --> 00:34:57,920 >>WE HAVE AT LEAST FIVE 901 00:34:57,920 --> 00:35:00,480 MINUTES. SO WE HAVE TIME FOR 902 00:35:00,480 --> 00:35:01,200 ADDITIONAL QUESTIONS. 903 00:35:01,200 --> 00:35:02,960 >>THIS IS AN OPEN SESSION SO 904 00:35:02,960 --> 00:35:06,160 YOU CAN ALSO USE THE CHAT. 905 00:35:06,160 --> 00:35:11,000 >>THANKS, PAW LEGAL. YOU CAN 906 00:35:11,000 --> 00:35:15,520 USE THE CHAT. T ANN BARKER. YOU 907 00:35:15,520 --> 00:35:21,360 ARE MUTED, ANN. 908 00:35:21,360 --> 00:35:22,600 >>SO THANK YOU, MONICA. THAT 909 00:35:22,600 --> 00:35:26,800 WAS REALLY INSPIRING. I WANTED 910 00:35:26,800 --> 00:35:27,960 TO ADDRESS SOMETHING YOU JUST 911 00:35:27,960 --> 00:35:30,960 MENTIONED THAT I THINK IS A 912 00:35:30,960 --> 00:35:32,200 REMARKABLE SET OF NEW 913 00:35:32,200 --> 00:35:34,200 INITIATIVES WITH ARPA-H. I THINK 914 00:35:34,200 --> 00:35:36,000 WE ARE ALL WONDERING ABOUT THIS 915 00:35:36,000 --> 00:35:39,320 BEING PART OF THIS OVERALL PLAN 916 00:35:39,320 --> 00:35:40,720 TO LEARN MORE ABOUT CANCER BUT 917 00:35:40,720 --> 00:35:44,480 IT IS REALLY COMING INTO FOCUS 918 00:35:44,480 --> 00:35:46,320 NOW. THE DATA INITIATIVE IT IS 919 00:35:46,320 --> 00:35:48,280 REMARKABLE. I JUST ATTENDED A 920 00:35:48,280 --> 00:35:51,520 MEETING WEEK BEFORE LAST, AN 921 00:35:51,520 --> 00:35:54,720 ARPA-NCI COORDINATED EFFORT OVER 922 00:35:54,720 --> 00:35:56,400 TIME TO CREATE NEW CLINICAL 923 00:35:56,400 --> 00:35:59,440 TRIAL DESIGNS SO I THINK THIS IS 924 00:35:59,440 --> 00:36:01,040 -- I WONDER IF YOU CAN SAY MORE 925 00:36:01,040 --> 00:36:02,120 ABOUT THE COLLABORATION THERE 926 00:36:02,120 --> 00:36:04,320 AND HOW YOU SEE THAT PAYING OFF 927 00:36:04,320 --> 00:36:05,600 IN TERMS OF BEING ABLE TO SCALE 928 00:36:05,600 --> 00:36:06,360 SOME OF THE THINGS WE DO AS 929 00:36:06,360 --> 00:36:08,360 WELL. 930 00:36:08,360 --> 00:36:09,760 >>IT IS BEEN A GREAT 931 00:36:09,760 --> 00:36:14,080 PARTNERSHIP. THAT IS THE WAY TO 932 00:36:14,080 --> 00:36:16,440 VIEW IT. THEY HAVE A DIFFERENT 933 00:36:16,440 --> 00:36:18,560 MODEL FOR HOW THEY VIEW 934 00:36:18,560 --> 00:36:20,080 RESEARCH. I THINK Y'ALL HEARD ME 935 00:36:20,080 --> 00:36:22,080 SAY THIS BEFORE, NCI TAKE IT IS 936 00:36:22,080 --> 00:36:23,440 LONG VIEW. WE WANT TO GO ALL THE 937 00:36:23,440 --> 00:36:25,120 WAY FROM THE MOLECULAR DISCOVERY 938 00:36:25,120 --> 00:36:27,200 TO WHAT HAPPENED IN A PATIENT. 939 00:36:27,200 --> 00:36:29,520 AND WE OWN EVERY BIT OF THAT 940 00:36:29,520 --> 00:36:32,120 PATHWAY. WHEREAS ARPA H TAKES 941 00:36:32,120 --> 00:36:34,920 THE, WE WANT TO RUN IN AND SOLVE 942 00:36:34,920 --> 00:36:38,880 CRITICAL PROBLEMS FOCUS, BE 943 00:36:38,880 --> 00:36:40,120 NIMBLE SOLVE CRITICAL PROBLEMS 944 00:36:40,120 --> 00:36:43,600 AND MOVE TO THE NEXT. SO IT IS 945 00:36:43,600 --> 00:36:44,880 INCREDIBLY COMPLIMENTARY WHAT WE 946 00:36:44,880 --> 00:36:48,120 ARE DOING AND I THINK YOU ARE 947 00:36:48,120 --> 00:36:49,440 GOING TO SEE THAT PLAYED OUT IN 948 00:36:49,440 --> 00:36:51,480 THE DATA SPACE BECAUSE WE HAVE A 949 00:36:51,480 --> 00:36:53,640 LOT OF CRITICAL PROBLEMS THAT IF 950 00:36:53,640 --> 00:36:57,560 WE CAN JUST GET ONE PIECE OF THE 951 00:36:57,560 --> 00:36:59,600 PUZZLE INTENSELY FOCUSED ON THAT 952 00:36:59,600 --> 00:37:02,320 WILL HELP US WITH OUR 953 00:37:02,320 --> 00:37:04,000 LONGITUDINAL PLANS IN A GREAT 954 00:37:04,000 --> 00:37:07,280 WAY. SO YOU ARE SEEING SOME OF 955 00:37:07,280 --> 00:37:09,160 THAT AND THEY WILL HAVE AN 956 00:37:09,160 --> 00:37:12,040 ANNOUNCEMENT SOON ABOUT OUR BIG 957 00:37:12,040 --> 00:37:13,280 COLLABORATION IN THE DATA SPACE 958 00:37:13,280 --> 00:37:16,960 OR ONE. THERE'S MORE THAN ONE. 959 00:37:16,960 --> 00:37:20,560 >>SORT OF SPEAKS TO LEVERAGE. 960 00:37:20,560 --> 00:37:22,120 IN THESE TIMES IT IS ALWAYS 961 00:37:22,120 --> 00:37:24,560 GREAT TO PARTNER AND LEVERAGE 962 00:37:24,560 --> 00:37:27,360 ACROSS. I GUESS THAT SORT OF 963 00:37:27,360 --> 00:37:28,600 BRINGS UP THE OLD CONVERSATIONS 964 00:37:28,600 --> 00:37:30,960 ABOUT PUBLIC PRIVATE 965 00:37:30,960 --> 00:37:32,920 PARTNERSHIPS. WHAT IS NCI DOING 966 00:37:32,920 --> 00:37:37,000 TO SORT OF REACH OUT TO THE 967 00:37:37,000 --> 00:37:38,440 INDUSTRY BIOTECH COMMUNITY, ARE 968 00:37:38,440 --> 00:37:39,360 THERE OPPORTUNITIES THERE YOU 969 00:37:39,360 --> 00:37:40,840 WOULD LIKE TO PROVIDE SOME 970 00:37:40,840 --> 00:37:41,920 INSIGHTS AROUND? 971 00:37:41,920 --> 00:37:44,360 >>THERE IS MANY DIFFERENT WAYS 972 00:37:44,360 --> 00:37:47,680 THAT WE INTERSECT WITH THE 973 00:37:47,680 --> 00:37:48,840 PRIVATE FOR PROFIT COMMUNITY. 974 00:37:48,840 --> 00:37:50,800 FIRST WE HAVE OUR SBIR PROGRAM 975 00:37:50,800 --> 00:37:52,720 WHICH WE JUST HAD A DEEP DIVE 976 00:37:52,720 --> 00:37:54,840 INTO YESTERDAY. I JUST HAVE TO 977 00:37:54,840 --> 00:37:55,800 TELL YOU ANYONE WHO IS 978 00:37:55,800 --> 00:37:57,240 INTERESTED TAKE A LOOK. OR GO TO 979 00:37:57,240 --> 00:38:02,080 THE WEBSITE. IT IS REALLY 980 00:38:02,080 --> 00:38:03,280 INCREDIBLY HEALTHY ACTIVE 981 00:38:03,280 --> 00:38:07,560 PROGRAM BRIDGING THE GAP, 982 00:38:07,560 --> 00:38:10,680 BRINGING NEW TECHNOLOGIES NEW 983 00:38:10,680 --> 00:38:12,000 THERAPEUTICS TO 984 00:38:12,000 --> 00:38:12,560 COMMERCIALIZATION WHICH IS 985 00:38:12,560 --> 00:38:14,720 EXCITING. I THINK THERE ARE MANY 986 00:38:14,720 --> 00:38:17,840 OTHER PLACES NATIONAL CLINICAL 987 00:38:17,840 --> 00:38:19,600 TRIALS NETWORK, ALL OUR CLINICAL 988 00:38:19,600 --> 00:38:20,880 TRIALS WORK IS AN EXAMPLE 989 00:38:20,880 --> 00:38:23,480 THROUGH THE CREDA SYSTEM TO 990 00:38:23,480 --> 00:38:27,240 OBTAIN DRUGS DESIZES AND OTHER 991 00:38:27,240 --> 00:38:29,280 ABSOLUTELY NEEDED RESOURCES IN 992 00:38:29,280 --> 00:38:32,560 ORDER TO CONDUCT RESEARCH. THEN 993 00:38:32,560 --> 00:38:34,160 I THINK WE ARE STARTING TO SEE 994 00:38:34,160 --> 00:38:37,120 IT CLEARLY IN THE DATA SYSTEMS 995 00:38:37,120 --> 00:38:38,320 AND DATA SCIENCE WORK AS WELL, 996 00:38:38,320 --> 00:38:42,000 THIS IS A LITTLE NEWER BUT THE 997 00:38:42,000 --> 00:38:44,680 ROAD MAP IS QUITE THERE FOR 998 00:38:44,680 --> 00:38:46,240 INTERACTION WITH INDUSTRY IN 999 00:38:46,240 --> 00:38:47,960 ALMOST ANYTHING WE DO AND WE ARE 1000 00:38:47,960 --> 00:38:51,160 STARTING TO SEE IT BRING TO BARE 1001 00:38:51,160 --> 00:38:52,200 IN THE DATA SCIENCE WORLD AS 1002 00:38:52,200 --> 00:38:52,400 WELL. 1003 00:38:52,400 --> 00:38:54,480 >>GREAT. THANKS, MONICA. ARE 1004 00:38:54,480 --> 00:38:56,600 THERE ANY ADDITIONAL QUESTIONS 1005 00:38:56,600 --> 00:38:58,400 FOR DR. BERTAGNOLLI BEFORE WE 1006 00:38:58,400 --> 00:39:06,480 MOVE ON? YOU ARE MUTED. 1007 00:39:06,480 --> 00:39:10,080 >>SO SORRY. DR. BERTAGNOLLI, 1008 00:39:10,080 --> 00:39:12,000 ONE OF THE THINGS THAT HAS COME 1009 00:39:12,000 --> 00:39:14,560 OUT IN A VERY PUBLIC WAY IS THE 1010 00:39:14,560 --> 00:39:16,840 WHOLE ISSUE AROUND AI. IN WHAT 1011 00:39:16,840 --> 00:39:19,600 WAY -- I KNOW IT IS A HUGE 1012 00:39:19,600 --> 00:39:22,120 SUBJECT BUT WHAT WAY WILL YOU 1013 00:39:22,120 --> 00:39:24,400 TRY TO CREATE SOME EDUCATIONAL 1014 00:39:24,400 --> 00:39:29,600 MATERIALS FOR THE PUBLIC TO 1015 00:39:29,600 --> 00:39:32,120 UNDERSTAND THE CONVERGENCE OF AI 1016 00:39:32,120 --> 00:39:34,800 WITH SCIENCE AND NOT FEAR IT, 1017 00:39:34,800 --> 00:39:36,560 NOT MISUNDERSTAND IT, BECAUSE 1018 00:39:36,560 --> 00:39:38,800 THIS IS A HUGE ISSUE THAT I 1019 00:39:38,800 --> 00:39:42,320 ALREADY SEE IN THE PUBLIC ARENA 1020 00:39:42,320 --> 00:39:44,120 WHICH I'M WORKING ON SIDEWAY 1021 00:39:44,120 --> 00:39:46,480 PROJECTS. LIKE TO KNOW WHERE NCI 1022 00:39:46,480 --> 00:39:49,920 IS GOING TO ENTER INTEGRATE AND 1023 00:39:49,920 --> 00:39:51,600 INTERVENE TO MAKE SURE ONCE 1024 00:39:51,600 --> 00:39:52,760 AGAIN THE PUBLIC UNDERSTANDS IT 1025 00:39:52,760 --> 00:39:56,760 AND DOESN'T FEAR IT? 1026 00:39:56,760 --> 00:39:58,920 >>OH, YEAH, THIS FITS TO THE 1027 00:39:58,920 --> 00:40:01,160 CATEGORY OF SO MANY THINGS IN 1028 00:40:01,160 --> 00:40:04,520 SCIENCE THAT ARE NEW. SO MACHINE 1029 00:40:04,520 --> 00:40:06,480 LEARNING IS A NEW WAY OF 1030 00:40:06,480 --> 00:40:08,160 ANALYZING DATA THAT CAN PRODUCE 1031 00:40:08,160 --> 00:40:10,160 INSIGHTS THAT AREN'T IMMEDIATELY 1032 00:40:10,160 --> 00:40:12,360 OBVIOUS AND CAN TAKE LARGE DATA 1033 00:40:12,360 --> 00:40:15,360 COLLECTIONS TO DO SO. THERE ARE 1034 00:40:15,360 --> 00:40:18,960 MANY OTHER USES BUT THAT IS THE 1035 00:40:18,960 --> 00:40:21,200 USE WE PRIMARILY DO IN THE 1036 00:40:21,200 --> 00:40:24,600 RESEARCH COMMUNITY. I THINK THAT 1037 00:40:24,600 --> 00:40:28,960 US BEING VERY EFFECTIVE 1038 00:40:28,960 --> 00:40:33,080 COMMUNICATORS WITH PEOPLE IS ONE 1039 00:40:33,080 --> 00:40:35,400 OF OUR CRITICAL JOBS. AI IS AN 1040 00:40:35,400 --> 00:40:36,840 EXAMPLE WE CAN DO, I THINK THE 1041 00:40:36,840 --> 00:40:41,040 BEST WE CAN DO IS EXPLAIN 1042 00:40:41,040 --> 00:40:43,240 EXACTLY WHY WE USE THESE NEW 1043 00:40:43,240 --> 00:40:44,240 TECHNIQUES WHAT THE NEW 1044 00:40:44,240 --> 00:40:45,880 TECHNIQUES PRODUCE FOR THEM. 1045 00:40:45,880 --> 00:40:47,880 WHAT THE IMPACT OF NEW 1046 00:40:47,880 --> 00:40:49,400 TECHNIQUES MIGHT BE ON THE NEW 1047 00:40:49,400 --> 00:40:52,080 TREATMENT OR NEW APPROACHES THEY 1048 00:40:52,080 --> 00:40:53,560 MAY SEE FROM THEIR PHYSICIANS IN 1049 00:40:53,560 --> 00:40:55,600 CLINIC. SO COMMUNICATING THOSE 1050 00:40:55,600 --> 00:40:57,920 THAT THE TOPIC OF AI IS TOO BIG, 1051 00:40:57,920 --> 00:40:59,360 WE NEED TO GET DOWN TO SPECIFICS 1052 00:40:59,360 --> 00:41:01,560 FOR PEOPLE, ONE BY ONE AND 1053 00:41:01,560 --> 00:41:03,520 EXPLAIN HOW THESE NEW DISCOVERY 1054 00:41:03,520 --> 00:41:06,720 TOOLS ARE BEING USED. LAST OF 1055 00:41:06,720 --> 00:41:08,680 ALL, I ALSO THINK IT IS 1056 00:41:08,680 --> 00:41:11,840 ABSOLUTELY CRITICAL. I REINFORCE 1057 00:41:11,840 --> 00:41:13,640 AGAIN THAT PEOPLE UNDERSTAND IF 1058 00:41:13,640 --> 00:41:15,480 WE DO RESEARCH WITH PEOPLE WE 1059 00:41:15,480 --> 00:41:17,400 ENGAGE PEOPLE. YOU HAVE TO DO 1060 00:41:17,400 --> 00:41:22,280 THAT IN A MANNER OF TRUST AND 1061 00:41:22,280 --> 00:41:22,880 BIDIRECTIONAL COMMUNICATION 1062 00:41:22,880 --> 00:41:23,760 WHICH IS WHAT YOU ARE TALKING 1063 00:41:23,760 --> 00:41:25,880 ABOUT HERE. I THINK WE ARE GOING 1064 00:41:25,880 --> 00:41:29,360 TO SEE MORE AND MORE FOCUS ON 1065 00:41:29,360 --> 00:41:31,440 THAT BECAUSE IT IS CERTAINLY ONE 1066 00:41:31,440 --> 00:41:34,280 OF MY PERSONAL HIGH PRIORITIES I 1067 00:41:34,280 --> 00:41:36,960 KNOW FOR NCI. NOT JUST AI BUT 1068 00:41:36,960 --> 00:41:40,520 REALLY EVERYTHING WE DO. WE 1069 00:41:40,520 --> 00:41:42,520 SHOULD HAVE BLACK BOXES FOR 1070 00:41:42,520 --> 00:41:44,400 PATIENTS AND OUR PEOPLE. THEY 1071 00:41:44,400 --> 00:41:55,000 NEED TO KNOW WHAT WE ARE DOING. 1072 00:41:55,920 --> 00:41:58,400 LOOK AT WHAT WE ARE EVEN 1073 00:41:58,400 --> 00:41:59,640 OFFERING TODAY. THERE IS QUITE A 1074 00:41:59,640 --> 00:42:02,040 BIT THERE, THERE'S OPPORTUNITIES 1075 00:42:02,040 --> 00:42:04,160 FOR INTERACTION. CHECK OUT ALL 1076 00:42:04,160 --> 00:42:05,760 THE WEB SITES AVAILABLE, YOU 1077 00:42:05,760 --> 00:42:07,720 WILL BE SURPRISED HOW MUCH IS 1078 00:42:07,720 --> 00:42:09,800 ALREADY THERE. 1079 00:42:09,800 --> 00:42:11,320 >>IN THE INTEREST OF TIME WE 1080 00:42:11,320 --> 00:42:13,560 WILL MOVE ON TO OUR NEXT 1081 00:42:13,560 --> 00:42:15,080 PRESENTATION. IF YOU HAVE A 1082 00:42:15,080 --> 00:42:16,200 QUESTION OR COMMENT PLEASE TYPE 1083 00:42:16,200 --> 00:42:18,680 INTO THE CHAT, I THINK EVERYONE 1084 00:42:18,680 --> 00:42:22,640 WOULD LOVE TO HEAR FROM YOU. 1085 00:42:22,640 --> 00:42:24,440 NEXT WE HAVE MK HOLOHAN WHO WILL 1086 00:42:24,440 --> 00:42:26,960 GIVE US THE LEGISLATIVE REPORT. 1087 00:42:26,960 --> 00:42:29,280 >>THANK YOU, DR. CARPTEN. THANK 1088 00:42:29,280 --> 00:42:30,760 YOU FOR THE OPPORTUNITY TO SPEAK 1089 00:42:30,760 --> 00:42:32,760 WITH THE BOARD TODAY. AS ALWAYS 1090 00:42:32,760 --> 00:42:34,240 I'M GOING TO REMIND YOU THERE IS 1091 00:42:34,240 --> 00:42:35,880 A DETAILED LEGISLATIVE UPDATE IN 1092 00:42:35,880 --> 00:42:37,280 YOU ARE YOU MATERIALS AND THAT 1093 00:42:37,280 --> 00:42:39,960 MY TEAM ARE PAP PI TO TALK WITH 1094 00:42:39,960 --> 00:42:41,520 YOU AND/OR YOUR STAFF ANY TIME 1095 00:42:41,520 --> 00:42:43,160 SO REACH OUT IF THERE'S ISSUES 1096 00:42:43,160 --> 00:42:44,400 YOU WOULD LIKE TO LEARN MORE 1097 00:42:44,400 --> 00:42:46,200 ABOUT THAT I CAN'T COVER TODAY. 1098 00:42:46,200 --> 00:42:48,840 IN THE TIME WE HAVE I'M GOING TO 1099 00:42:48,840 --> 00:42:51,360 FOCUS ON FY 24 APPROPRIATION AND 1100 00:42:51,360 --> 00:42:53,480 PROVIDE SOME CONTEXT TO WHAT I'M 1101 00:42:53,480 --> 00:42:54,560 SURE YOU ARE READING IN THE NEW 1102 00:42:54,560 --> 00:42:57,120 YORK TIMES AND THE "WALL STREET 1103 00:42:57,120 --> 00:42:57,880 JOURNAL" AND WHATEVER OTHER 1104 00:42:57,880 --> 00:43:00,880 SOURCES YOU LIKE TO USE. NEXT 1105 00:43:00,880 --> 00:43:02,640 SLIDE PLEASE. SO THE TOPICS I 1106 00:43:02,640 --> 00:43:04,440 WILL COVER ARE THE DEBT LIMIT 1107 00:43:04,440 --> 00:43:06,400 BUDGET DEAL WHICH SORT OF SETS 1108 00:43:06,400 --> 00:43:09,600 THE STAGE FOR FY 24. THE FY 24 1109 00:43:09,600 --> 00:43:11,200 APPROPRIATIONS HAS SUBMITTED 1110 00:43:11,200 --> 00:43:12,560 VERSUS THE SENATE AND THE 1111 00:43:12,560 --> 00:43:13,920 CONGRESSIONAL WORK AHEAD AND THE 1112 00:43:13,920 --> 00:43:16,240 SHORT TIME THAT IS LEFT BEFORE 1113 00:43:16,240 --> 00:43:17,840 FY 24 BEGINS. NEXT SLIDE 1114 00:43:17,840 --> 00:43:22,160 PLEASE. SO THE DEBT LIMIT 1115 00:43:22,160 --> 00:43:24,600 BUDGET DEAL THAT SET CAPS ON 1116 00:43:24,600 --> 00:43:28,360 SPENDING WHICH IS GOING TO MAKE 1117 00:43:28,360 --> 00:43:30,240 FY 24 A LEAN BUDGET YEAR NOT AS 1118 00:43:30,240 --> 00:43:33,240 LEAN AS SOME WOULD LIKE, THESE 1119 00:43:33,240 --> 00:43:35,520 PROCESSES ARE PROCEEDING 1120 00:43:35,520 --> 00:43:36,480 DIFFERENTLY IN THE HOUSE AND 1121 00:43:36,480 --> 00:43:38,000 SENATE BUT WHEN THE BILL IS 1122 00:43:38,000 --> 00:43:39,320 PASSED AND WE AVOID DEFAULTING 1123 00:43:39,320 --> 00:43:41,480 ON DEBT IN THE VERY END OF MAY, 1124 00:43:41,480 --> 00:43:45,120 BEGINNING OF JUNE, THERE WAS A 1125 00:43:45,120 --> 00:43:46,960 CELEBRATORY AIR THAT SPEAKER 1126 00:43:46,960 --> 00:43:48,240 MCCARTHY HAD A PRESS CONFERENCE 1127 00:43:48,240 --> 00:43:49,680 WITH HIS LEADERSHIP TEAM, 1128 00:43:49,680 --> 00:43:52,120 PRESIDENT BIDEN SIGNED THE BILL. 1129 00:43:52,120 --> 00:43:53,920 THE HOUSE BUDGET COMMITTEE 1130 00:43:53,920 --> 00:44:00,840 CHAIRED BY REPRESENTATIVE JODY 1131 00:44:00,840 --> 00:44:01,840 HARRINGTON (PHONETIC) OF TEXAS 1132 00:44:01,840 --> 00:44:04,280 PUT OUT A STATEMENT, TOUTING THE 1133 00:44:04,280 --> 00:44:08,240 AGREEMENT AS THE LARGEST EVER 1134 00:44:08,240 --> 00:44:09,680 DEBT REDUCTION BILL SAYING THIS 1135 00:44:09,680 --> 00:44:12,480 IS A CONSTRUCTIVE PATH, AND THIS 1136 00:44:12,480 --> 00:44:13,920 WOULD ELIMINATE THE POSSIBILITY 1137 00:44:13,920 --> 00:44:16,480 OF A CONTINUING RESOLUTION THAT 1138 00:44:16,480 --> 00:44:20,320 WOULD FOR THE ENTIRE YEAR STICK 1139 00:44:20,320 --> 00:44:24,560 AT FY 23 FUNDING LEVELS THEY 1140 00:44:24,560 --> 00:44:26,400 WERE HAPPY WITH. IT WAS A SHORT 1141 00:44:26,400 --> 00:44:28,600 LIVED CELEBRAT CELEBRATION. SPER 1142 00:44:28,600 --> 00:44:33,360 MCCARTHY HAD A DAY BEFORE THE 1143 00:44:33,360 --> 00:44:34,680 SORT OF VERY FRACTIOUS PART OF 1144 00:44:34,680 --> 00:44:40,280 HIS CAUCUS, THE HOUSE 1145 00:44:40,280 --> 00:44:41,680 (INAUDIBLE) CAUCUS REVOLUNTEERED 1146 00:44:41,680 --> 00:44:44,320 AT THE THOUGHT OF CONTINUING 1147 00:44:44,320 --> 00:44:45,880 (INAUDIBLE) FY 24 SO THIS 1148 00:44:45,880 --> 00:44:47,200 JOURNAL SUMMARIZE IT IS MAJOR 1149 00:44:47,200 --> 00:44:50,840 PARTS OF THE DEBT LIMIT DEAL. 1150 00:44:50,840 --> 00:44:53,120 SUSPENSION OF THE DEBT LIMIT IS 1151 00:44:53,120 --> 00:44:54,560 ALWAYS AN OPPORTUNITY FOR A 1152 00:44:54,560 --> 00:44:56,800 BUDGET DIAL. THERE'S LEVERAGE IN 1153 00:44:56,800 --> 00:44:59,200 THE URGENCY OF THE DEBT LIMIT, A 1154 00:44:59,200 --> 00:45:00,480 SITS INTENTION THAT IS NEEDED. 1155 00:45:00,480 --> 00:45:02,200 BUT TYPICALLY WHEN THERE IS A 1156 00:45:02,200 --> 00:45:03,600 BUDGET DEAL REACHED THE PARTIES 1157 00:45:03,600 --> 00:45:06,560 STICK WITH THE TERMS AGREED TO 1158 00:45:06,560 --> 00:45:08,360 AND MEMORIALIZEIZED IN THE 1159 00:45:08,360 --> 00:45:11,080 LEGISLATION. THAT IS NOT WHAT 1160 00:45:11,080 --> 00:45:13,560 HAS HAPPENED HERE. THE HOUSE 1161 00:45:13,560 --> 00:45:16,320 FREEDOM CAUCUS WERE VERY UPSET 1162 00:45:16,320 --> 00:45:18,800 ABOUT THE LEVEL OF CUTS THEY HAD 1163 00:45:18,800 --> 00:45:20,920 -- THE HOUSE PASSED A BILL THAT 1164 00:45:20,920 --> 00:45:22,960 WOULD TAKE FUNDING BACK TO THE 1165 00:45:22,960 --> 00:45:24,800 FY 22 LEVELS THAT IS ESSENTIALLY 1166 00:45:24,800 --> 00:45:26,160 WHAT THEY ARE EXISTING ON NOW. 1167 00:45:26,160 --> 00:45:28,280 THE PART THAT I HIGHLIGHTED IS 1168 00:45:28,280 --> 00:45:29,600 SPENDING WHICH IS THEY ARE 1169 00:45:29,600 --> 00:45:31,160 INSISTING A DIFFERENT LEVEL OF 1170 00:45:31,160 --> 00:45:32,560 SPENDING AT THIS POINT AND THESE 1171 00:45:32,560 --> 00:45:34,680 MAJOR PROVISIONS ARE VERY 1172 00:45:34,680 --> 00:45:37,560 DIFFERENT. THE HOUSE GOP IS NOW 1173 00:45:37,560 --> 00:45:40,840 SORT OF PIVOTED TO SAYING THE 1174 00:45:40,840 --> 00:45:42,600 CAPS DISCUSSED AND AGREED TO IN 1175 00:45:42,600 --> 00:45:45,960 THE FISCAL RESPONSIBILITY ACT 1176 00:45:45,960 --> 00:45:48,080 FRA ARE A FLOOR, NOT A CEILING. 1177 00:45:48,080 --> 00:45:49,480 SO THEY CAN FUND AT LOWER 1178 00:45:49,480 --> 00:45:50,840 LEVELS. THAT IS THE MAXIMUM 1179 00:45:50,840 --> 00:45:54,640 THEY CAN FUND AT. SO THEY CHANGE 1180 00:45:54,640 --> 00:45:56,720 RESCISSIONS AS WELL, THEY 1181 00:45:56,720 --> 00:45:58,480 TARGETED SOME OF THE PROGRAMS 1182 00:45:58,480 --> 00:46:00,160 THAT DEMOCRATS WOULD HAVE NEVER 1183 00:46:00,160 --> 00:46:01,800 AGREED TO IN THIS DEAL AND I 1184 00:46:01,800 --> 00:46:03,640 HIGHLIGHTED THIS RESCIND 20 1185 00:46:03,640 --> 00:46:05,280 BILLION IRS FUNDING ALLOCATED 1186 00:46:05,280 --> 00:46:07,240 THROUGH THE IRA OF THE THAT WAS 1187 00:46:07,240 --> 00:46:10,880 AGREED TO ACTUALLY THE SPENDING 1188 00:46:10,880 --> 00:46:13,440 BILLS THAT HOUSE REPUBLICANS 1189 00:46:13,440 --> 00:46:16,360 ADVANCED ARE TARGETING ABOUT 67 1190 00:46:16,360 --> 00:46:18,800 BILLION A BIT MORE THAN THAT 1191 00:46:18,800 --> 00:46:20,680 GIVEN IRS FUNDING SPREAD ACROSS 1192 00:46:20,680 --> 00:46:22,880 FOUR BILLS SO IT IS REALLY 1193 00:46:22,880 --> 00:46:24,280 DIFFERENT THAN WHAT WAS AGREED 1194 00:46:24,280 --> 00:46:27,520 TO HERE. I WANT -- I HIGHLIGHTED 1195 00:46:27,520 --> 00:46:31,360 THIS SORT OF SKIT THAT YOU CAN 1196 00:46:31,360 --> 00:46:33,360 TAKE CONGRESS IS NOT THE MOST 1197 00:46:33,360 --> 00:46:34,960 SELF-AWARE ORGANIZATION BUT THEY 1198 00:46:34,960 --> 00:46:35,960 DO KNOW HOW DIFFICULT IT IS FOR 1199 00:46:35,960 --> 00:46:37,960 THEM TO GET THESE SPENDING BILLS 1200 00:46:37,960 --> 00:46:39,800 DONE ON TIME. SO WHAT THEY DID 1201 00:46:39,800 --> 00:46:42,880 IS INSERTED A DEADLINE AND A 1202 00:46:42,880 --> 00:46:44,840 PENALTY THAT IF ALL 12 1203 00:46:44,840 --> 00:46:46,200 APPROPRIATIONS BILLS ARE NOT 1204 00:46:46,200 --> 00:46:49,360 DONE BY JANUARY 1 THERE IS A 1% 1205 00:46:49,360 --> 00:46:51,280 CUT MANDATORY. THAT WOULD APPLY 1206 00:46:51,280 --> 00:46:54,160 NOT ONLY TO DEFENSE BUT ALSO TO 1207 00:46:54,160 --> 00:46:56,320 NON-DEFENSE. SO THAT -- THE FACT 1208 00:46:56,320 --> 00:46:57,960 IT WOULD APPLY TO DEFENSE IS 1209 00:46:57,960 --> 00:46:59,080 SOMETHING THAT WILL GET 1210 00:46:59,080 --> 00:47:01,600 ATTENTION OF A LOT OF MEMBERS 1211 00:47:01,600 --> 00:47:03,160 WHO MAY NOT SUPPORT 1212 00:47:03,160 --> 00:47:04,760 NON-DISCRETIONARY FUNDING WHICH 1213 00:47:04,760 --> 00:47:06,240 IS NEAR AND DEAR TO OUR ARTS 1214 00:47:06,240 --> 00:47:08,160 BECAUSE THAT IS WHERE NIH GETS 1215 00:47:08,160 --> 00:47:13,240 ITS FUNDING. WHERE DOES THIS 1216 00:47:13,240 --> 00:47:16,040 LEAVE US? THIS ROLL CALL ARTICLE 1217 00:47:16,040 --> 00:47:17,720 THAT TALKED HOUSE AND SENATE ON 1218 00:47:17,720 --> 00:47:19,000 A COLLISION COURSE IS NOT AN 1219 00:47:19,000 --> 00:47:21,040 OVERSTATEMENT. THE SENATE IS 1220 00:47:21,040 --> 00:47:22,840 WRITING TO THE LEVELS THAT WERE 1221 00:47:22,840 --> 00:47:24,240 AGREED UPON. THEY HAVE ALSO HAD 1222 00:47:24,240 --> 00:47:27,080 A BIPARTISAN AGREEMENT TO ADD 1223 00:47:27,080 --> 00:47:29,000 EMERGENCY FUNDING. 2 BILLION 1224 00:47:29,000 --> 00:47:31,080 WOULD GO TO THE LABOR HHS BILL 1225 00:47:31,080 --> 00:47:32,920 AND EMERGENCY FUNDING ALSO FOR 1226 00:47:32,920 --> 00:47:34,320 SUPPLEMENTAL APPROPRIATIONS FOR 1227 00:47:34,320 --> 00:47:37,280 SOME OF THE DISASTER AID 1228 00:47:37,280 --> 00:47:39,840 REQUIRED NOW. THE HOUSE ENDED UP 1229 00:47:39,840 --> 00:47:42,600 WRITING TO 142 BILLION LESS THAN 1230 00:47:42,600 --> 00:47:44,720 TOTAL IN THE SENATE AND THAT IS 1231 00:47:44,720 --> 00:47:47,440 SIGNIFICANT. THERE IS DEADLINES 1232 00:47:47,440 --> 00:47:49,400 NOT ONLY JANUARY 1 DEADLINE I 1233 00:47:49,400 --> 00:47:51,040 DESCRIBED BUT OBVIOUSLY OCTOBER 1234 00:47:51,040 --> 00:47:54,120 1ST IS WHEN THE FISCAL YEAR 1235 00:47:54,120 --> 00:47:57,080 BEGINS IN 24 DAYS FROM NOW. 1236 00:47:57,080 --> 00:47:59,440 JANUARY 1ST. NOW THAT ONE 1237 00:47:59,440 --> 00:48:01,880 PERCENT REDUCTION IS REQUIRED IF 1238 00:48:01,880 --> 00:48:03,480 ALL 12 BILLS AREN'T DONE, IF ALL 1239 00:48:03,480 --> 00:48:06,560 12 ARE NOT COMPLETED BY APRIL 1240 00:48:06,560 --> 00:48:09,320 30TH THAT CUT BECOMES PERMANENT. 1241 00:48:09,320 --> 00:48:10,960 SO WE WILL SEE WHERE THAT GOES 1242 00:48:10,960 --> 00:48:15,360 BUT THIS IS REALLY UNUSUAL. IT 1243 00:48:15,360 --> 00:48:18,360 ALSO MAKES IT TO ME IT SUGGESTS 1244 00:48:18,360 --> 00:48:20,360 THAT WE OFTEN DON'T HAVE FINAL 1245 00:48:20,360 --> 00:48:21,480 APPROPRIATIONS UNTIL WELL INTO 1246 00:48:21,480 --> 00:48:26,520 THE FISCAL YEAR. THIS APRIL 30TH 1247 00:48:26,520 --> 00:48:28,640 DEADLINE COULD POTENTIALLY MEAN 1248 00:48:28,640 --> 00:48:30,240 IT WILL BE THAT LONG INTO FISCAL 1249 00:48:30,240 --> 00:48:31,920 YEAR BEFORE WE HAVE FINAL 1250 00:48:31,920 --> 00:48:33,440 APPROPRIATION. I HOPE THAT IS T 1251 00:48:33,440 --> 00:48:35,320 NOT WHAT HAPPENS. BUT THAT IS 1252 00:48:35,320 --> 00:48:36,800 VERY DIFFICULT FOR PLANNING 1253 00:48:36,800 --> 00:48:38,520 PURPOSES, IT IS VERY DIFFICULT 1254 00:48:38,520 --> 00:48:40,440 FOR SETTING TARGETS FOR WHAT WE 1255 00:48:40,440 --> 00:48:41,920 ARE ABLE TO INVEST BECAUSE WE 1256 00:48:41,920 --> 00:48:43,000 REALLY DON'T KNOW. NEXT SLIDE 1257 00:48:43,000 --> 00:48:48,160 PLEASE. I WANTED TO REMINDER 1258 00:48:48,160 --> 00:48:49,600 ABOUT PROCESS AND HOW NCI 1259 00:48:49,600 --> 00:48:52,560 RECEIVES ITS FUNDING, AS DR. 1260 00:48:52,560 --> 00:48:57,000 BERTAGNOLLI REMINDED THE BOARD, 1261 00:48:57,000 --> 00:48:59,000 NCI HAS A -- WHAT IS COMMONLY 1262 00:48:59,000 --> 00:49:00,920 REFERRED TO AS A BYPASS BUDGET, 1263 00:49:00,920 --> 00:49:02,120 A PROFESSIONAL JUDGMENT BUDGET 1264 00:49:02,120 --> 00:49:03,280 REQUIRED BY THE NATIONAL CANCER 1265 00:49:03,280 --> 00:49:05,760 ACT. AND WE ARE THE ONLY 1266 00:49:05,760 --> 00:49:08,080 INSTITUTE THAT IS ABLE TO DO 1267 00:49:08,080 --> 00:49:11,080 THIS WITHIN NIH. THERE IS AN 1268 00:49:11,080 --> 00:49:12,440 ALZHEIMER'S DISEASE PROFESSIONAL 1269 00:49:12,440 --> 00:49:13,920 JUDGMENT BUDGET AS WELL REQUIRED 1270 00:49:13,920 --> 00:49:15,720 BY APPROPRIATIONS LANGUAGE THAT 1271 00:49:15,720 --> 00:49:17,720 IS ABOUT MAYBE THE PAST 7 OR 8 1272 00:49:17,720 --> 00:49:19,560 YEARS, THAT'S BEEN SOMETHING 1273 00:49:19,560 --> 00:49:21,960 THAT NIH PRODUCES AND NIA 1274 00:49:21,960 --> 00:49:25,040 OFFERS. BUT FOR US THIS IS 1275 00:49:25,040 --> 00:49:27,640 REALLY SETTING THE IDEAL LEVELS 1276 00:49:27,640 --> 00:49:29,560 TO PURSUE ALL RESEARCH 1277 00:49:29,560 --> 00:49:31,000 OPPORTUNITIES AS DR. BERTAGNOLLI 1278 00:49:31,000 --> 00:49:32,480 EXPLAINED. WE WANTED TO TALK 1279 00:49:32,480 --> 00:49:34,360 ABOUT THAT BRIEFLY JUST TO SAY 1280 00:49:34,360 --> 00:49:36,560 THE FY 24 PROFESSIONAL JUDGMENT 1281 00:49:36,560 --> 00:49:37,640 BUDGET WAS RELEASED LAST 1282 00:49:37,640 --> 00:49:38,960 SEPTEMBER. THE ONE THAT IS 1283 00:49:38,960 --> 00:49:41,800 COMING OUT THIS MONTH IS FY 25 1284 00:49:41,800 --> 00:49:43,280 THOUGH WE ARE OBVIOUSLY STILL IN 1285 00:49:43,280 --> 00:49:45,600 THE THICK OF FY 24 AND NOT 1286 00:49:45,600 --> 00:49:48,720 HAVING BEEN COMPLETED. WE ARE 1287 00:49:48,720 --> 00:49:49,840 STILL BETWEEN STEPS TWO AND 1288 00:49:49,840 --> 00:49:52,800 THREE BECAUSE THE APPROPRIATIONS 1289 00:49:52,800 --> 00:49:54,800 COMMITTEES HAVE NOT -- THEY ARE 1290 00:49:54,800 --> 00:49:56,480 FAR APART. THEY ARE DIFFERENT -- 1291 00:49:56,480 --> 00:49:57,640 THEY ARE LOOKING AT DIFFERENT 1292 00:49:57,640 --> 00:50:00,200 TOP LINES AND THEY CERTAINLY 1293 00:50:00,200 --> 00:50:01,360 HAVE HAVEN'T CONFERENCED 1294 00:50:01,360 --> 00:50:02,200 ANYTHING WHICH IS WHERE THEY 1295 00:50:02,200 --> 00:50:05,680 COME TOGETHER AND COME UP WITH A 1296 00:50:05,680 --> 00:50:08,920 UNIFIED BILL. SO WHAT I WANT TO 1297 00:50:08,920 --> 00:50:13,080 POINT OUT HERE IS SORT OF THE 1298 00:50:13,080 --> 00:50:14,640 DISCONNECT BETWEEN HOUSE AND 1299 00:50:14,640 --> 00:50:18,080 SENATE REPUBLICANS. WHAT WE ARE 1300 00:50:18,080 --> 00:50:22,160 SEEING HERE IS SENATOR CORNIN 1301 00:50:22,160 --> 00:50:23,560 TWEETED YESTERDAY THAT THE HOUSE 1302 00:50:23,560 --> 00:50:25,360 AND SENATE AND HIS WORDS WERE 1303 00:50:25,360 --> 00:50:26,480 COMPLETELY DIFFERENT UNIVERSES 1304 00:50:26,480 --> 00:50:29,240 WHEN IT COMES TO HOW LAW MAKERS 1305 00:50:29,240 --> 00:50:31,080 FUND FEDERAL AGENCIES IN SHORT 1306 00:50:31,080 --> 00:50:34,000 APPROXIMATE LONG TERM. SENATE 1307 00:50:34,000 --> 00:50:36,600 MINORITY LEADER MITCH MCCONNELL 1308 00:50:36,600 --> 00:50:40,000 ALSO SAID YET HE SUPPORTS 1309 00:50:40,000 --> 00:50:42,240 SUPPLEMENTAL FUNDING MEASURES 1310 00:50:42,240 --> 00:50:44,240 AND TO KEEP THE GOVERNMENT 1311 00:50:44,240 --> 00:50:45,560 WORKING AFTER OCTOBER 1ST. THE 1312 00:50:45,560 --> 00:50:49,000 LEFT IS A PICTURE OF HOUSE 1313 00:50:49,000 --> 00:50:51,040 FREEDOM CAUCUS MEMBERS LED IN 1314 00:50:51,040 --> 00:50:54,520 THIS SLIDE BY THIS PHOTO BY CHIP 1315 00:50:54,520 --> 00:50:57,600 ROY A FELLOW TEXASN AND SENATOR 1316 00:50:57,600 --> 00:50:58,840 CORNIN WHO HAS A DIFFERENT 1317 00:50:58,840 --> 00:51:01,040 PERSPECTIVE. THE FREE COME 1318 00:51:01,040 --> 00:51:03,840 CAUCUS COMMITTED IN WRITING TO 1319 00:51:03,840 --> 00:51:06,400 THEIR REFUSAL TO SUPPORT A 1320 00:51:06,400 --> 00:51:08,080 CONTINUING RESOLUTION WITHOUT A 1321 00:51:08,080 --> 00:51:09,200 BORDER SECURITY BILL PASSED BY 1322 00:51:09,200 --> 00:51:11,360 THE HOUSE, IF IT DOESN'T INCLUDE 1323 00:51:11,360 --> 00:51:14,240 POLICY RIDERS THAT WOULD 1324 00:51:14,240 --> 00:51:15,720 SOMEWHAT NEGATIVELY EFFECT WITH 1325 00:51:15,720 --> 00:51:19,880 DOJ AND FBI. SO WE WILL SEE 1326 00:51:19,880 --> 00:51:21,280 WHERE THIS GOES. THEY ARE ALSO 1327 00:51:21,280 --> 00:51:24,840 SAYING THAT THEY ARE GOING TO 1328 00:51:24,840 --> 00:51:25,960 REFUSE OFTEN TIME THERE'S 1329 00:51:25,960 --> 00:51:28,520 CONTINUING RESOLUTIONS THAT SORT 1330 00:51:28,520 --> 00:51:31,240 OF RAMP UP THE PROCESS IN TERMS 1331 00:51:31,240 --> 00:51:33,480 OF PRESSURE AS IT GETS CLOSE TO 1332 00:51:33,480 --> 00:51:34,920 HOLIDAYS USUALLY SOMETIME IN 1333 00:51:34,920 --> 00:51:36,760 DECEMBER. SO I DON'T KNOW WHAT 1334 00:51:36,760 --> 00:51:38,240 TIME THAT MIGHT EFFECT THE TIME 1335 00:51:38,240 --> 00:51:41,160 FRAME OF A CR, WE WILL SEE 1336 00:51:41,160 --> 00:51:43,280 INTRODUCED HOPEFULLY SOON. BUT 1337 00:51:43,280 --> 00:51:45,280 IT MIGHT BE ONE THAT GOES A 1338 00:51:45,280 --> 00:51:46,640 SHORTER TIME FRAME AND NOT 1339 00:51:46,640 --> 00:51:48,880 SETTING A DATE FAR OUT, WE WILL 1340 00:51:48,880 --> 00:51:50,680 SEE WHAT HAPPENS THERE. IT IS 1341 00:51:50,680 --> 00:51:54,240 REALLY REMARKABLE HOW OUT OF 1342 00:51:54,240 --> 00:51:55,560 SYNC THE HOUSE AND SENATE 1343 00:51:55,560 --> 00:51:58,240 REPUBLICAN PARTIES ARE AND THERE 1344 00:51:58,240 --> 00:52:01,120 IS EVEN MORE TURMOIL WITHIN THE 1345 00:52:01,120 --> 00:52:02,560 HOUSE GOP BECAUSE THERE'S LOTS 1346 00:52:02,560 --> 00:52:04,160 OF VIEW POINTS NOT REFLECTED IN 1347 00:52:04,160 --> 00:52:06,160 THIS DEMAND. BY THE HOUSE 1348 00:52:06,160 --> 00:52:08,200 FREEDOM CAUCUS. ONE THING TOO, 1349 00:52:08,200 --> 00:52:10,240 A CR IS A STOP GAP FUNDING 1350 00:52:10,240 --> 00:52:12,680 MEASURE. IT IS SUPPOSED TO 1351 00:52:12,680 --> 00:52:14,880 CONTINUE GOVERNMENT FUNDING 1352 00:52:14,880 --> 00:52:17,280 WHILE THE TWO PARTIES NEGOTIATE 1353 00:52:17,280 --> 00:52:21,320 DIFFERENCES. IT IS NECESSARY 1354 00:52:21,320 --> 00:52:22,800 WHEN THERE ISN'T AGREEMENT ON 1355 00:52:22,800 --> 00:52:24,360 FUNDING LEVELS OR POTENTIALLY 1356 00:52:24,360 --> 00:52:25,920 POLICY ISSUES ASSOCIATED WITH 1357 00:52:25,920 --> 00:52:30,040 FUNDING LEVELS FOR AGENCIES. TO 1358 00:52:30,040 --> 00:52:31,920 INSIST ON CR THAT INCLUDES 1359 00:52:31,920 --> 00:52:33,280 POLICY PROVISIONS IS A LITTLE 1360 00:52:33,280 --> 00:52:35,280 DEFEATING THE PURPOSE OF WHAT CR 1361 00:52:35,280 --> 00:52:37,080 IS SUPPOSED TO DO. IT WILL BE 1362 00:52:37,080 --> 00:52:39,360 VERY DIFFICULT. NEXT SLIDE 1363 00:52:39,360 --> 00:52:42,840 PLEASE. WHAT I WANT TO POINT 1364 00:52:42,840 --> 00:52:44,080 OUT NOT ONLY BECAUSE I LOVE THIS 1365 00:52:44,080 --> 00:52:47,600 PICTURE ON THE FAR LEFT, WHICH 1366 00:52:47,600 --> 00:52:49,280 IS THE THEN SITTING FEMALE 1367 00:52:49,280 --> 00:52:52,920 SENATORS IN 1997, THEY ARE 1368 00:52:52,920 --> 00:52:55,480 CELEBRATING HERE BECAUSE THEY 1369 00:52:55,480 --> 00:52:58,040 JUST GOT A SOMEWHAT DECENT SIZE 1370 00:52:58,040 --> 00:52:59,680 RESTROOM FOR WOMEN THAT IS NEAR 1371 00:52:59,680 --> 00:53:02,440 THE FLOOR OF THE SENATE. SO WHAT 1372 00:53:02,440 --> 00:53:04,640 I WANT TO POINT OUT HERE IS THAT 1373 00:53:04,640 --> 00:53:07,080 YOU SEE SENATOR SUSAN COLLINS 1374 00:53:07,080 --> 00:53:09,120 AND SENATOR PATTY MURRAY ON THE 1375 00:53:09,120 --> 00:53:11,960 LEFT AS COLLEAGUES. WHO BOTH 1376 00:53:11,960 --> 00:53:13,960 HAVE ALWAYS EARNED THE 1377 00:53:13,960 --> 00:53:15,320 REPUTATION OF VALUING THE 1378 00:53:15,320 --> 00:53:16,480 BIPARTISAN PROCESS AND 1379 00:53:16,480 --> 00:53:18,560 ENGAGEMENT IN NEGOTIATION. YOU 1380 00:53:18,560 --> 00:53:20,680 SEE ON THE RIGHT TODAY AS THE 1381 00:53:20,680 --> 00:53:22,880 CHAIR AND RANKING MEMBER OF THE 1382 00:53:22,880 --> 00:53:25,440 SENATE APPROPRIATIONS COMMITTEE. 1383 00:53:25,440 --> 00:53:29,440 I EXCERPTED A STATEMENT THAT 1384 00:53:29,440 --> 00:53:32,240 THEY MADE AFTER THE FIRST FULL 1385 00:53:32,240 --> 00:53:33,880 COMMITTEE MARK UP AND PRIOR 1386 00:53:33,880 --> 00:53:36,800 RECENT YEARS THE SENATE HAS HAD 1387 00:53:36,800 --> 00:53:40,120 ENOUGH PARTISAN DISPUTE ABOUT 1388 00:53:40,120 --> 00:53:42,480 SPENDING BILLS THEY HAVEN'T 1389 00:53:42,480 --> 00:53:44,360 ADVANCED BILLS OUT SUBCOMMITTEES 1390 00:53:44,360 --> 00:53:45,720 VERY REGULARLY. OUR BILL 1391 00:53:45,720 --> 00:53:47,280 SPECIFICALLY POSTED BY MAJORITY 1392 00:53:47,280 --> 00:53:48,440 AND THEN THE CONFERENCE IS THAT 1393 00:53:48,440 --> 00:53:50,560 MUCH HARDER TO TRY TO NEGOTIATE 1394 00:53:50,560 --> 00:53:53,200 FUNDING LEVELS. BUT YES SEEING A 1395 00:53:53,200 --> 00:53:54,200 -- WE ARE SEEING A DIFFERENT 1396 00:53:54,200 --> 00:53:56,600 APPROACH THIS YEAR BECAUSE THESE 1397 00:53:56,600 --> 00:53:58,160 TWO LEADERS ARE DETERMINED THERE 1398 00:53:58,160 --> 00:54:00,400 IS GOING TO BE BIPARTISAN 1399 00:54:00,400 --> 00:54:02,040 PROCESS IN THE SENATE 1400 00:54:02,040 --> 00:54:03,640 APPROPRIATIONS COMMITTEE AND THE 1401 00:54:03,640 --> 00:54:05,520 SENATE HAS REALLY SOME BILLS 1402 00:54:05,520 --> 00:54:07,280 HAVE PASSED UNANIMOUSLY, THERE 1403 00:54:07,280 --> 00:54:08,880 -- THEY HAVE PASSED ALL THEIR 1404 00:54:08,880 --> 00:54:10,680 BILLS OUT OF THE APPROPRIATIONS 1405 00:54:10,680 --> 00:54:13,480 COMMITTEE. SO YOU SEE A VERY 1406 00:54:13,480 --> 00:54:14,480 DIFFERENT LEVEL OF COOPERATION 1407 00:54:14,480 --> 00:54:17,480 AND COLLABORATION IN THE SENATE 1408 00:54:17,480 --> 00:54:18,920 AND THE LEADERS OF THESE 1409 00:54:18,920 --> 00:54:19,760 APPROPRIATE -- OF THE 1410 00:54:19,760 --> 00:54:20,680 APPROPRIATIONS COMMITTEE ON BOTH 1411 00:54:20,680 --> 00:54:21,920 SIDES ARE REALLY COMMITTED TO 1412 00:54:21,920 --> 00:54:26,440 THAT. AND HAVE BEEN VERY CLOSE 1413 00:54:26,440 --> 00:54:29,240 COLLEAGUES FOR DECADES. NEXT 1414 00:54:29,240 --> 00:54:33,040 SLIDE PLEASE. SO THIS SLIDE I'M 1415 00:54:33,040 --> 00:54:35,480 TRYING TO SHOW THE DISASTER AID, 1416 00:54:35,480 --> 00:54:39,360 THIS IS A REALLY BIG DEAL AND IT 1417 00:54:39,360 --> 00:54:42,280 MAY HOPEFULLY PROVIDE A LITTLE 1418 00:54:42,280 --> 00:54:43,840 MORE MOMENTUM FOR A STOP GAP, 1419 00:54:43,840 --> 00:54:45,880 FOR A CLEAN STOP GAP TO GET 1420 00:54:45,880 --> 00:54:47,680 THROUGH AND KEEP THE GOVERNMENT 1421 00:54:47,680 --> 00:54:49,000 FUNDED AFTER OCTOBER 1ST. THE 1422 00:54:49,000 --> 00:54:52,160 WHITE HOUSE HAS REQUESTED AN 1423 00:54:52,160 --> 00:54:52,840 ADDITIONAL $4 BILLION BECAUSE OF 1424 00:54:52,840 --> 00:54:55,240 THE RECENT HURRICANES AND WILD 1425 00:54:55,240 --> 00:54:56,880 FIRES SO YOU KNOW CALIFORNIA, 1426 00:54:56,880 --> 00:54:59,080 HAWAII, FLORIDA, VERMONT, 1427 00:54:59,080 --> 00:55:01,880 THERE'S BEEN REALLY SIGNIFICANT 1428 00:55:01,880 --> 00:55:03,680 FLOODING IN SOME NEW ENGLAND 1429 00:55:03,680 --> 00:55:06,000 AREAS, THIS IS ON TOP OF $12 1430 00:55:06,000 --> 00:55:07,680 MILLION SUPPLEMENT REQUESTED 1431 00:55:07,680 --> 00:55:11,880 EARLIER IN AUGUST, FOR FEMA. THE 1432 00:55:11,880 --> 00:55:13,920 OTHER ISSUE THAT IS SOMEWHAT 1433 00:55:13,920 --> 00:55:15,280 PARTISAN THAT WILL BE INCLUDED 1434 00:55:15,280 --> 00:55:18,080 IN SUPPLEMENTAL EMERGENCY AID 1435 00:55:18,080 --> 00:55:20,320 WOULD BE MONEY FOR UKRAINE. 1436 00:55:20,320 --> 00:55:22,320 THERE IS CONTINGENT OF MEMBERS 1437 00:55:22,320 --> 00:55:23,320 AND CERTAINLY OFFICIAL POSITION 1438 00:55:23,320 --> 00:55:25,120 OF THE HOUSE FREEDOM CAUCUS THEY 1439 00:55:25,120 --> 00:55:27,240 DON'T WANT WHAT THEY DESCRIBE A 1440 00:55:27,240 --> 00:55:28,960 BLANK CHECK TO THE UKRAINE. SO 1441 00:55:28,960 --> 00:55:33,360 THERE IS AN URGENCY HERE THAT IS 1442 00:55:33,360 --> 00:55:35,160 SIGNIFICANT. ONE SIGNAL I 1443 00:55:35,160 --> 00:55:37,800 THOUGHT WAS INTERESTING OVER THE 1444 00:55:37,800 --> 00:55:39,760 WEEKEND SPEAKER MCCARTHY MADE A 1445 00:55:39,760 --> 00:55:44,400 TRIP TO HAWAII WITH A BIPARTISAN 1446 00:55:44,400 --> 00:55:47,240 HOUSE DELEGATION. HE PLEDGED 1447 00:55:47,240 --> 00:55:48,560 THERE WAS GOING TO BE SUPPORT 1448 00:55:48,560 --> 00:55:50,840 FROM THE GOVERNMENT TO REBUILD, 1449 00:55:50,840 --> 00:55:52,320 HE ALSO PLEDGED INVESTIGATION TO 1450 00:55:52,320 --> 00:55:54,760 FIGURE OUT WHY THINGS WENT AS -- 1451 00:55:54,760 --> 00:55:59,080 PROCESS WAS AS IT WAS IN HAWAII 1452 00:55:59,080 --> 00:56:00,360 SENATOR MCCONNELL YESTERDAY ALSO 1453 00:56:00,360 --> 00:56:01,960 COMMENTED WE ABSOLUTELY HAVE TO 1454 00:56:01,960 --> 00:56:04,760 FUNDING THESE DISASTER RELIEF 1455 00:56:04,760 --> 00:56:06,680 PRIORITIES. NOT SURE WHAT THAT 1456 00:56:06,680 --> 00:56:08,400 MEANS IN TERMS OF THE CR BUT THE 1457 00:56:08,400 --> 00:56:11,800 FACT THE SPEAKER TRAVELED TO 1458 00:56:11,800 --> 00:56:13,280 HAWAII IS I THINK ENCOURAGING 1459 00:56:13,280 --> 00:56:15,240 THAT THIS IS A PRIORITY HE WILL 1460 00:56:15,240 --> 00:56:16,520 BE BRINGING BACK TO HOUSE AND 1461 00:56:16,520 --> 00:56:21,640 HIS LEADERSHIP TEAM. SO THESE 1462 00:56:21,640 --> 00:56:22,960 ARE THE NUMBERS WE ARE LOOKING 1463 00:56:22,960 --> 00:56:26,600 AT HERE FOR WHAT THE HOUSE HAS 1464 00:56:26,600 --> 00:56:29,400 PASSED, WHAT THE SENATE HAS 1465 00:56:29,400 --> 00:56:30,960 PASSED, THESE ARE JUST OUT OF 1466 00:56:30,960 --> 00:56:33,640 COMMITTEE, THESE AREN'T PASSAGE. 1467 00:56:33,640 --> 00:56:36,960 FOR NIH, NCI AND ARPA H. SO WHAT 1468 00:56:36,960 --> 00:56:40,880 WE ARE SEEING IN THE HOUSE THEY 1469 00:56:40,880 --> 00:56:45,000 DECLINED TO FILL IN THE 1470 00:56:45,000 --> 00:56:46,320 $2,616,000,000 AS PART OF 1471 00:56:46,320 --> 00:56:48,800 APPROPRIATION FY 23 FOR THE MOON 1472 00:56:48,800 --> 00:56:53,880 SHOT. THAT WAS OF COURSE VIA THE 1473 00:56:53,880 --> 00:56:55,680 21ST CENTURY CURE ACT THERE WAS 1474 00:56:55,680 --> 00:56:57,000 A MANDATORY FUNDING STREAM IN 1475 00:56:57,000 --> 00:56:59,360 YEARS PAST WHERE WE HAD DECREASE 1476 00:56:59,360 --> 00:57:02,280 IN MOON SHOT FUNDING LEVELS, THE 1477 00:57:02,280 --> 00:57:03,960 APPROPRIATORS HAD TO BACK FILL 1478 00:57:03,960 --> 00:57:06,320 THOSE NUMBERS AND THIS REFLECTS 1479 00:57:06,320 --> 00:57:08,440 AN ABSENCE OF MOON SHOT BEING ON 1480 00:57:08,440 --> 00:57:11,120 A FLAT BUDGET. THE SENATE WOULD 1481 00:57:11,120 --> 00:57:13,280 CONTINUE THAT FUNDING BUT WOULD 1482 00:57:13,280 --> 00:57:16,360 ALSO PROVIDE INCREASE OF $60 1483 00:57:16,360 --> 00:57:17,560 MILLION. OBVIOUSLY THESE ARE 1484 00:57:17,560 --> 00:57:19,680 NOT LARGE INCREASES BUT IT IS A 1485 00:57:19,680 --> 00:57:20,840 TIGHT BUDGET YEAR, THIS IS WHAT 1486 00:57:20,840 --> 00:57:23,680 WE ARE LOOKING AT, AT THIS POINT 1487 00:57:23,680 --> 00:57:25,280 IN TIME. WE DON'T KNOW WHERE 1488 00:57:25,280 --> 00:57:28,760 THIS IS GOING TO LAND. IT IS 1489 00:57:28,760 --> 00:57:30,640 CERTAINLY GOING TO BE A 1490 00:57:30,640 --> 00:57:31,760 DIFFICULT NEGOTIATION PROCESS 1491 00:57:31,760 --> 00:57:37,720 FOR THE CHAMBERS. I WANTED TO 1492 00:57:37,720 --> 00:57:39,040 POINT OUT HERE CONTINUING 1493 00:57:39,040 --> 00:57:41,600 RESOLUTIONS ARE VERY, VERY 1494 00:57:41,600 --> 00:57:43,240 COMMON SO WHEN YOU SEE THE -- ON 1495 00:57:43,240 --> 00:57:46,120 THE LEFT THE COLUMN THAT GOES 1496 00:57:46,120 --> 00:57:48,680 OUT TO 365 DAY THOSE ARE WHEN 1497 00:57:48,680 --> 00:57:54,640 SOME IF NOT ALL APPROPRIATIONS 1498 00:57:54,640 --> 00:57:56,680 BILLS WERE GIVEN A FULL YEAR CR. 1499 00:57:56,680 --> 00:58:00,120 THEY SHOW 365 IT WAS TEN OUT OF 1500 00:58:00,120 --> 00:58:02,480 TWELVE, FOR EXAMPLE DEFENSE -- 1501 00:58:02,480 --> 00:58:04,480 THE DEFENSE BILL HAS NOT HAD 1502 00:58:04,480 --> 00:58:08,280 THAT SITUATION BUT OTHER BILLS 1503 00:58:08,280 --> 00:58:11,080 HAVE. THIS SLIDES GOES UP TO FY 1504 00:58:11,080 --> 00:58:13,320 22, IN FQ 23 WE HAD THREE 1505 00:58:13,320 --> 00:58:14,480 CONTINUING RESOLUTIONS WHICH 1506 00:58:14,480 --> 00:58:16,400 TOOK US THROUGH THE FIRST 90 1507 00:58:16,400 --> 00:58:18,560 DAYS OF THE FISCAL YEAR. 90 DAYS 1508 00:58:18,560 --> 00:58:21,000 IS BETTER THAN 180 OR 365. SO WE 1509 00:58:21,000 --> 00:58:22,720 ARE CAUTIOUSLY OPTIMISTIC THAT 1510 00:58:22,720 --> 00:58:24,720 WE WILL END UP WITH SOMETHING 1511 00:58:24,720 --> 00:58:30,240 LESS THAN A FULL YEAR CR. LOT OF 1512 00:58:30,240 --> 00:58:32,480 WORK AHEAD, THE SENATE RETURNED 1513 00:58:32,480 --> 00:58:33,720 FROM THEIR LONG AUGUST RECESS 1514 00:58:33,720 --> 00:58:35,200 YESTERDAY, THE HOUSE IS NOT BACK 1515 00:58:35,200 --> 00:58:37,000 UNTIL NEXT TUESDAY. THEY ARE 1516 00:58:37,000 --> 00:58:39,720 ONLY 11 LEGISLATIVE DAYS IN 1517 00:58:39,720 --> 00:58:42,040 SEPTEMBER WHERE BOTH CHAMBERS OF 1518 00:58:42,040 --> 00:58:44,720 -- ARE IN SESSION. THE STOP GAP 1519 00:58:44,720 --> 00:58:46,480 FUNDING MEASURE IS GOING TO BE 1520 00:58:46,480 --> 00:58:49,480 PROBLEMATIC AS WE DISCUSSED. 1521 00:58:49,480 --> 00:58:52,200 THERE IS ALSO OTHER MUST HAVE 1522 00:58:52,200 --> 00:58:53,000 LEGISLATION, NOT JUST 1523 00:58:53,000 --> 00:58:55,760 APPROPRIATIONS THERE IS EXPIRING 1524 00:58:55,760 --> 00:58:59,760 FDA USER FEE AUTHORIZATION. 1525 00:58:59,760 --> 00:59:00,440 PANDEMIC AUTHORIZATION. FARM 1526 00:59:00,440 --> 00:59:02,920 BILL, P IFAA BILL AND NATIONAL 1527 00:59:02,920 --> 00:59:04,680 DEFENSE AUTHORIZATION THAT IS A 1528 00:59:04,680 --> 00:59:08,600 LOT OF WORK. THESE PRESENT 1529 00:59:08,600 --> 00:59:10,520 OPPORTUNITIES. ANY LEGISLATIVE 1530 00:59:10,520 --> 00:59:11,960 VEHICLE MOVING PRESENTS AN 1531 00:59:11,960 --> 00:59:13,520 OPPORTUNITY. OR SOMETHING TO BE 1532 00:59:13,520 --> 00:59:14,560 ATTACHED, MAYBE THERE IS A WAY 1533 00:59:14,560 --> 00:59:16,720 THAT LEADERSHIP CAN PEEL 1534 00:59:16,720 --> 00:59:18,000 SOMETHING OFF THAT IS A DEMAND 1535 00:59:18,000 --> 00:59:20,360 OF THE HOUSE FREEDOM CAUCUS AND 1536 00:59:20,360 --> 00:59:22,760 FIND A WAY APPROPRIATE TO 1537 00:59:22,760 --> 00:59:24,720 ADDRESS IT SEPARATE FROM 1538 00:59:24,720 --> 00:59:25,640 APPROPRIATIONS, BUT THERE IS 1539 00:59:25,640 --> 00:59:27,080 OPPORTUNITY IN THE FACT THAT 1540 00:59:27,080 --> 00:59:28,120 THINGS ARE MOVING. WHAT WE 1541 00:59:28,120 --> 00:59:29,600 EXPECT TO SEE IS SENATE WILL 1542 00:59:29,600 --> 00:59:30,840 START MOVING APPROPRIATIONS 1543 00:59:30,840 --> 00:59:32,280 BILLS FOR VOTES FOR FLOOR VOTES 1544 00:59:32,280 --> 00:59:33,240 AND THEY ARE PROBABLY GOING TO 1545 00:59:33,240 --> 00:59:36,000 DO A SERIES OF WHAT IS CALLED 1546 00:59:36,000 --> 00:59:38,880 MINI BUS BILLS A COUPLE MAYBE 1547 00:59:38,880 --> 00:59:41,880 LESS CONTROVERSIAL BILLS 1548 00:59:41,880 --> 00:59:43,280 COMBINED TOGETHER, FREEDOM 1549 00:59:43,280 --> 00:59:45,000 CAUCUS HAS INSISTED THEY WILL 1550 00:59:45,000 --> 00:59:48,520 NOT VOTE FOR AN OMNIBUS WHICH IS 1551 00:59:48,520 --> 00:59:50,440 ALL TOGETHER. A SERIES OF MINI 1552 00:59:50,440 --> 00:59:52,560 BUSES IS LESS OBJECTIONABLE, 1553 00:59:52,560 --> 00:59:54,720 MORE TIME FOR REVIEW, IT IS LESS 1554 00:59:54,720 --> 00:59:57,920 A LIST TO GET THOSE DON DONE. TE 1555 00:59:57,920 --> 00:59:59,560 SENATE IS FAR AHEAD DOING THEIR 1556 00:59:59,560 --> 01:00:01,160 WORK, THEY MAY FINISH THEIR 1557 01:00:01,160 --> 01:00:03,520 BILLS WHAT IS KNOWN AS JAMMING 1558 01:00:03,520 --> 01:00:05,600 THE HOUSE -- THE HOUSE SNAPS THE 1559 01:00:05,600 --> 01:00:07,040 SENATE BASICALLY DOING ALL YOUR 1560 01:00:07,040 --> 01:00:08,240 WORK TOSSING TO THE OTHER SIDE 1561 01:00:08,240 --> 01:00:10,120 AND GOING HOME. THIS IS 1562 01:00:10,120 --> 01:00:11,360 SOMETHING WE SEE START TO PLAY 1563 01:00:11,360 --> 01:00:16,680 OUT AT THE END OF FISCAL YEARS. 1564 01:00:16,680 --> 01:00:19,120 I WANTED TO END ON A SOMEWHAT 1565 01:00:19,120 --> 01:00:21,800 OPTIMISTIC NOTE DESPITE THE LEAN 1566 01:00:21,800 --> 01:00:23,080 BUDGET YEAR WE ARE FACING, I 1567 01:00:23,080 --> 01:00:24,720 WANTED TO JUST I THINK SHOWN 1568 01:00:24,720 --> 01:00:28,480 THIS SLIDE TO THE BOARD BEFORE. 1569 01:00:28,480 --> 01:00:29,840 THESE ARE THE APPROPRIATIONS 1570 01:00:29,840 --> 01:00:31,400 COMMITTEES ARE HEADED BY WOMEN 1571 01:00:31,400 --> 01:00:32,360 ALL WOMEN FOR THE FIRST TIME 1572 01:00:32,360 --> 01:00:37,760 EVER. AND SHOLANDA YOUNG IS THE 1573 01:00:37,760 --> 01:00:39,640 SECOND OR THIRD OMB DIRECTOR WHO 1574 01:00:39,640 --> 01:00:41,320 IS A WOMAN. THE FIRST AFRICAN 1575 01:00:41,320 --> 01:00:42,720 AMERICAN WOMAN TO DIRECT OMB AND 1576 01:00:42,720 --> 01:00:45,280 SHE IS A FORMER HOUSE STAFF 1577 01:00:45,280 --> 01:00:46,800 PERSON WHO KNOWS MANY OF O THESE 1578 01:00:46,800 --> 01:00:49,480 PEOPLE VERY WELL. AND SO I HAVE 1579 01:00:49,480 --> 01:00:50,680 SOME CONFIDENCE AND FAITH IN 1580 01:00:50,680 --> 01:00:52,560 THESE LEADERS WHO HAVE A LONG 1581 01:00:52,560 --> 01:00:54,200 HISTORY OF WORKING IN A 1582 01:00:54,200 --> 01:00:55,720 BIPARTISAN WAY TO GET THEIR WORK 1583 01:00:55,720 --> 01:00:59,560 DONE. THAT IS MY OPTIMISTIC NOTE 1584 01:00:59,560 --> 01:01:02,680 TO CLOSE ON. SLIDE IS MY EMAIL 1585 01:01:02,680 --> 01:01:04,160 ADDRESS. GET IN TOUCH PLEASE IF 1586 01:01:04,160 --> 01:01:06,120 YOU HAVE ANY QUESTIONS. MY TEAM 1587 01:01:06,120 --> 01:01:07,720 AND I ARE HAPPY TO TALK WITH 1588 01:01:07,720 --> 01:01:08,280 BOARD MEMBERS AT ANY TIME. 1589 01:01:08,280 --> 01:01:10,160 THANK YOU. 1590 01:01:10,160 --> 01:01:12,720 >>THANKS, AS USUAL, MK AND 1591 01:01:12,720 --> 01:01:20,640 APPRECIATE THE OPTIMISTIC FINAL 1592 01:01:20,640 --> 01:01:23,880 POINT IN A -- ON TOP OF WHAT IS 1593 01:01:23,880 --> 01:01:25,880 SOMEWHAT SOBERING TO SOME 1594 01:01:25,880 --> 01:01:30,080 DEGREE. I THINK AS WE LOOK AT 1595 01:01:30,080 --> 01:01:33,640 POTENTIAL OUTCOMES OF THIS 1596 01:01:33,640 --> 01:01:35,440 PROCESS. IN THE INTEREST OF TIME 1597 01:01:35,440 --> 01:01:39,160 I THINK WE HAVE A PRESENTATION 1598 01:01:39,160 --> 01:01:42,040 ON THE BUDGET OVERVIEW FOR NCI 1599 01:01:42,040 --> 01:01:44,880 SO PERHAPS WE CAN GO THROUGH 1600 01:01:44,880 --> 01:01:46,360 THAT PRESENTATION THAT WILL BE 1601 01:01:46,360 --> 01:01:49,800 GIVEN TO US BY WHERE WESTON 1602 01:01:49,800 --> 01:01:51,640 RICKS. AND WE WILL ALSO HAVE 1603 01:01:51,640 --> 01:01:53,640 PARTICIPATION IN THE DISCUSSION 1604 01:01:53,640 --> 01:01:55,520 FROM DR. BERTAGNOLLI, LOWY, AS 1605 01:01:55,520 --> 01:01:57,640 WELL AS MK SO WHY NOT GO INTO 1606 01:01:57,640 --> 01:01:59,560 THE BUDGET OVERVIEW AND IF IF 1607 01:01:59,560 --> 01:02:01,840 THERE ARE QUESTIONS FOR MK WE 1608 01:02:01,840 --> 01:02:05,520 CAN DO THEM AFTER THIS. 1609 01:02:05,520 --> 01:02:07,360 >>GOOD AFTERNOON. I'M DIRECTOR 1610 01:02:07,360 --> 01:02:09,960 OF THE OFFICE OF BUDGET AND 1611 01:02:09,960 --> 01:02:11,680 FINANCE HERE AT NCI AND DR. 1612 01:02:11,680 --> 01:02:12,680 BERTAGNOLLI AND I WILL TALK 1613 01:02:12,680 --> 01:02:13,800 THROUGH THE BUDGET OVERVIEW 1614 01:02:13,800 --> 01:02:16,800 HERE. ONE OF THE THINGS I'M 1615 01:02:16,800 --> 01:02:18,120 HOPING WILL BE ABLE TO ANSWER 1616 01:02:18,120 --> 01:02:19,840 FOR YOU IS WHERE ARE WE AND WHAT 1617 01:02:19,840 --> 01:02:21,840 ARE WE LOOKING AT. THIS IS AN 1618 01:02:21,840 --> 01:02:26,560 IMAGE CLOSE UP IMAGE OF THE 1619 01:02:26,560 --> 01:02:28,440 QUAKING ASPEN TREE, THE LARGEST 1620 01:02:28,440 --> 01:02:30,400 ORGANISM ONE OF THE LARGEST 1621 01:02:30,400 --> 01:02:32,760 ORGANISMS ON THE PLANET THAT WE 1622 01:02:32,760 --> 01:02:34,920 LOOK AT UP CLOSE IT IS DIFFERENT 1623 01:02:34,920 --> 01:02:35,840 THAN WHAT WHEN WE LOOK AT IT 1624 01:02:35,840 --> 01:02:38,080 MAYBE FACE TO FACE. AND TO LOOK 1625 01:02:38,080 --> 01:02:40,440 AT IT AGAIN FROM THE ENVIRONMENT 1626 01:02:40,440 --> 01:02:43,960 YOU CAN SEE THE QUAKING ASPEN 1627 01:02:43,960 --> 01:02:45,160 TREE LIVES IN A SPECIFIC 1628 01:02:45,160 --> 01:02:46,560 ENVIRONMENT, CONTEXT MATTERS. 1629 01:02:46,560 --> 01:02:48,920 MY GOAL TODAY IS TO PUT NCI 1630 01:02:48,920 --> 01:02:50,800 BUDGET ACTIVITIES INTO SOME 1631 01:02:50,800 --> 01:02:54,000 CONTEXT FOR YOU AND WITH DR. 1632 01:02:54,000 --> 01:02:56,320 LILY HOPEFULLY -- LOWY WE WILL 1633 01:02:56,320 --> 01:02:57,920 HOPEFULLY ANSWER THE QUESTION 1634 01:02:57,920 --> 01:03:00,000 WHAT ARE WE AND WHAT ARE WE 1635 01:03:00,000 --> 01:03:01,160 LOOKING AT, AT THE SAME TIME 1636 01:03:01,160 --> 01:03:02,280 DESCRIBE CHALLENGES AND 1637 01:03:02,280 --> 01:03:02,880 OPPORTUNITIES WE HAVE IN FRONTS 1638 01:03:02,880 --> 01:03:06,720 OF US. THIS IS A CHART SHOWING 1639 01:03:06,720 --> 01:03:09,760 NCI BUDGET OVER THE LAST 20 1640 01:03:09,760 --> 01:03:13,160 YEARS. IT SEEMS GENERALLY CLOSE 1641 01:03:13,160 --> 01:03:15,160 UP THE LAST SEVERAL YEARS. IF I 1642 01:03:15,160 --> 01:03:19,440 PUT INTO THE CONTEXT OF 2003 1643 01:03:19,440 --> 01:03:20,360 BUYING POWER IT IS A VERY 1644 01:03:20,360 --> 01:03:22,640 DIFFERENT STORY. A NEW DIMENSION 1645 01:03:22,640 --> 01:03:25,080 OF THAT COMES INTO FOCUS. 1646 01:03:25,080 --> 01:03:26,360 DESPITE BUDGET INCREASES DURING 1647 01:03:26,360 --> 01:03:28,720 THE LAST SEVERAL YEARS, NCI 1648 01:03:28,720 --> 01:03:30,680 BUYING POWER LAGGED BEHIND OUR 1649 01:03:30,680 --> 01:03:34,640 PURCHASE POWERS TODAY. I'M SORRY 1650 01:03:34,640 --> 01:03:36,200 PURCHASE POWER OF TWO DECADES 1651 01:03:36,200 --> 01:03:38,200 AGO. FURTHERMORE NCI PORTFOLIO 1652 01:03:38,200 --> 01:03:39,720 HAS GOTTEN VASTLY MORE 1653 01:03:39,720 --> 01:03:41,520 COMPLICATED, FOR EXAMPLE WE HAVE 1654 01:03:41,520 --> 01:03:44,360 TEN MORE NCI DESIGNATED CANCER 1655 01:03:44,360 --> 01:03:46,800 CENTERS NUMEROUS NEW PROGRAMS 1656 01:03:46,800 --> 01:03:48,280 AND GRANT VEHICLES WE USE, AND 1657 01:03:48,280 --> 01:03:52,240 MANY MORE INITIATIVES WE ARE 1658 01:03:52,240 --> 01:03:53,400 SUPPORTING IN EVEN WITH THIS 1659 01:03:53,400 --> 01:03:57,000 ERODED BUYING POWER. ONE MORE 1660 01:03:57,000 --> 01:04:04,160 POINT I WANT TO MAKE TO PUT INTO 1661 01:04:04,160 --> 01:04:05,200 CONTEXT, THE SUM TOTAL OF THE 1662 01:04:05,200 --> 01:04:06,200 MISSED OPPORTUNITY HERE, RIGHT 1663 01:04:06,200 --> 01:04:09,680 NOW IF YOU LOOK AT 2013, THAT IS 1664 01:04:09,680 --> 01:04:11,760 PROBABLY THE LOW POINT, BUT OVER 1665 01:04:11,760 --> 01:04:12,960 THE LAST SEVERAL YEARS WE 1666 01:04:12,960 --> 01:04:16,320 RECEIVED BUDGET INCREASES, GONE 1667 01:04:16,320 --> 01:04:17,760 ALMOST HALFWAY BACK UP TO WHERE 1668 01:04:17,760 --> 01:04:22,680 WE ARE IN 2003. IF YOU WERE TO 1669 01:04:22,680 --> 01:04:28,480 SUM UP ACTUALLY ALL OF THESE 1670 01:04:28,480 --> 01:04:30,160 LITTLE MISSES EACH FISCAL YEAR 1671 01:04:30,160 --> 01:04:32,280 THE TOTAL SUM OF MISSED 1672 01:04:32,280 --> 01:04:35,400 OPPORTUNITIES IS REALLY CLOSER 1673 01:04:35,400 --> 01:04:39,680 TO 21 BUILD. I WON'T DWELL BUT 1674 01:04:39,680 --> 01:04:41,440 WANT TO ZOOM OUT AND PUT A 1675 01:04:41,440 --> 01:04:43,240 LITTLE CONTEXT AND SEE A LITTLE 1676 01:04:43,240 --> 01:04:46,760 BIT OF THE LANDSCAPE OF WHERE WE 1677 01:04:46,760 --> 01:04:50,280 ARE AS AN INSTITUTION BUT ALSO 1678 01:04:50,280 --> 01:04:52,520 RECOGNIZE SOME OF THE OUTSIDE 1679 01:04:52,520 --> 01:04:56,280 FORCES THAT IMPACT US. NEXT I 1680 01:04:56,280 --> 01:04:58,640 WANT TO ZOOM IN CLOSER, AND SHOW 1681 01:04:58,640 --> 01:05:01,880 YOU MORE DETAIL. AS WE APPROACH 1682 01:05:01,880 --> 01:05:03,880 THE BUDGET EVER FISCAL YEAR, YOU 1683 01:05:03,880 --> 01:05:05,680 CAN PUT MOST COSTS INTO THREE 1684 01:05:05,680 --> 01:05:07,240 MAJOR BUCKETS. SOME OF THESE 1685 01:05:07,240 --> 01:05:08,640 ARE PARALLEL TO THE THINGS YOU 1686 01:05:08,640 --> 01:05:09,960 MIGHT HAVE IN YOUR OWN 1687 01:05:09,960 --> 01:05:11,760 HOUSEHOLD, IN YOUR OWN BUSINESS 1688 01:05:11,760 --> 01:05:13,080 OR YOUR ORGANIZATION. BUT WE 1689 01:05:13,080 --> 01:05:14,600 HAVE OUTYEAR COMMITMENTS IN THE 1690 01:05:14,600 --> 01:05:17,600 FIRST PART, THOSE ARE CONTINUING 1691 01:05:17,600 --> 01:05:18,720 ACTIVITIES, CONTINUING 1692 01:05:18,720 --> 01:05:21,160 ACTIVITIES INCLUDE SOME OF THE 1693 01:05:21,160 --> 01:05:23,160 THINGS LIKE OUR CONTINUING 1694 01:05:23,160 --> 01:05:23,920 GRANTS OR CLINICAL TRIALS, 1695 01:05:23,920 --> 01:05:26,360 CANCER CENTERS, BIOREPOSITORIES, 1696 01:05:26,360 --> 01:05:27,960 ET CETERA. THEN IN THE MIDDLE 1697 01:05:27,960 --> 01:05:29,560 YOU SEE THE PAST ASSESSMENT 1698 01:05:29,560 --> 01:05:31,640 SECTION, THIS IS MORE LIKE YOUR 1699 01:05:31,640 --> 01:05:33,560 TAXES AND MORTGAGE. WE HAVE A 1700 01:05:33,560 --> 01:05:34,960 LOT OF COSTS SOME OF THEM ARE 1701 01:05:34,960 --> 01:05:38,400 UNIQUE BECAUSE WE ARE FEDERAL 1702 01:05:38,400 --> 01:05:41,240 INSTITUTIONS, WE PAY FOR PROGRAM 1703 01:05:41,240 --> 01:05:42,840 EVALUATION, WE PAY FOR A LOT OF 1704 01:05:42,840 --> 01:05:45,040 THE TECHNOLOGY WE USE FOR 1705 01:05:45,040 --> 01:05:47,080 RECORDING AND TRANSPARENCY, TYPE 1706 01:05:47,080 --> 01:05:48,480 OF SECURITY, IS A SIGNIFICANT 1707 01:05:48,480 --> 01:05:50,440 ONE THAT IS INCREASED OVER THE 1708 01:05:50,440 --> 01:05:52,040 LAST SEVERAL YEARS BECAUSE OF 1709 01:05:52,040 --> 01:05:53,360 SOME OF THE OUTSIDE CHALLENGES 1710 01:05:53,360 --> 01:05:56,240 WE HAVE IN THE FEDERAL 1711 01:05:56,240 --> 01:05:59,640 GOVERNMENT BUT ALSO THE NETWORK 1712 01:05:59,640 --> 01:06:02,480 UTILITIES ET CETERA AND WE PAID 1713 01:06:02,480 --> 01:06:03,800 CENTRALLY THROUGH NIH. THE LAST 1714 01:06:03,800 --> 01:06:05,520 ONE IS THE NEW SCIENTIFIC 1715 01:06:05,520 --> 01:06:07,960 OPPORTUNITIES AND THIS IS -- THE 1716 01:06:07,960 --> 01:06:09,320 SKY IS THE LIMIT ON THIS ONE, 1717 01:06:09,320 --> 01:06:10,800 EXAMPLE I WILL GIVE IS THE 1718 01:06:10,800 --> 01:06:12,560 CANCER MOON SHOT DATA 1719 01:06:12,560 --> 01:06:15,280 INITIATIVE, DR. BERTAGNOLLI 1720 01:06:15,280 --> 01:06:16,640 EARLIER TODAY. THERE ARE ALL 1721 01:06:16,640 --> 01:06:18,280 THESE THINGS WE NEED TO PURSUE 1722 01:06:18,280 --> 01:06:21,040 IN ORDER TO KEEP CANCER RESEARCH 1723 01:06:21,040 --> 01:06:24,840 FLOWING AND FRESH. ONE I WANTED 1724 01:06:24,840 --> 01:06:26,520 TO HIGHLIGHT JUST TO BRING A 1725 01:06:26,520 --> 01:06:27,760 LITTLE MORE PERSPECTIVE IS THE 1726 01:06:27,760 --> 01:06:29,360 OUTYEAR COMMITMENTS. I WILL TALK 1727 01:06:29,360 --> 01:06:32,320 YOU THROUGH THIS ONE MORE. IF 1728 01:06:32,320 --> 01:06:35,800 YOU WERE TO TAKE JUST THE GRANTS 1729 01:06:35,800 --> 01:06:39,160 PORTFOLIO, THAT IS ABOUT 1730 01:06:39,160 --> 01:06:41,920 $4.4 BILLION OF OUR BUDGET EVERY 1731 01:06:41,920 --> 01:06:43,160 YEAR F. YOU TAKE THAT PORTFOLIO 1732 01:06:43,160 --> 01:06:47,840 AND PACK INTO A LITTLE CUBE LIKE 1733 01:06:47,840 --> 01:06:49,480 THIS, THEN SHRINK IT DOWN WE ARE 1734 01:06:49,480 --> 01:06:52,040 MAKING AN AWARD THIS YEAR FOR 1735 01:06:52,040 --> 01:06:53,680 $4.4 BILLION. NEXT YEAR WE 1736 01:06:53,680 --> 01:06:57,160 EXPECT TO AWARD NEW GRANTS, EACH 1737 01:06:57,160 --> 01:07:01,440 OF THE FOLLOWING YEARS NEW SET 1738 01:07:01,440 --> 01:07:03,120 OF GRANTS ALL THOSE BUILD OFF 1739 01:07:03,120 --> 01:07:04,680 EACH OTHER IN A WAY THAT ALLOWS 1740 01:07:04,680 --> 01:07:07,080 US TO MOVE THINGS FORWARD. NOTE 1741 01:07:07,080 --> 01:07:08,960 THAT EACH ONE, A LITTLE BIT 1742 01:07:08,960 --> 01:07:10,320 LARGER, MAYBE IT WILL HAVE A 1743 01:07:10,320 --> 01:07:12,120 DIFFERENT SET UP INSIDE BUT EACH 1744 01:07:12,120 --> 01:07:14,840 WILL PROBABLY COST MORE JUST 1745 01:07:14,840 --> 01:07:16,040 BECAUSE THE NEW TECHNOLOGY AND 1746 01:07:16,040 --> 01:07:16,960 INFLATION AND OTHER THINGS THAT 1747 01:07:16,960 --> 01:07:20,400 ARE HAPPENING, WHILE AT THE SAME 1748 01:07:20,400 --> 01:07:22,040 TIME WE ARE SUPPORTING THE 1749 01:07:22,040 --> 01:07:23,640 OUTYEAR COSTS OF THOSE 1750 01:07:23,640 --> 01:07:26,120 COMMITMENTS WE MAKE USUALLY FOR 1751 01:07:26,120 --> 01:07:27,680 MOST GRANTS THEY ARE FIVE YEARS, 1752 01:07:27,680 --> 01:07:29,600 SOME ARE SEVEN YEARS SOME TWO 1753 01:07:29,600 --> 01:07:31,120 YEARS SO IN GENERAL FIVE YEARS. 1754 01:07:31,120 --> 01:07:34,720 THAT CREATES ENORMOUS OUTYEAR 1755 01:07:34,720 --> 01:07:39,560 COMMITMENT FOR US AS WE MOVE 1756 01:07:39,560 --> 01:07:41,440 FORWARD. ONE OF THE THINGS I 1757 01:07:41,440 --> 01:07:43,000 WANT TO BRING UP TO YOU IN IN 1758 01:07:43,000 --> 01:07:46,440 THAT SAME CONTEXT THEN QUICKLY 1759 01:07:46,440 --> 01:07:49,360 RETURN BACK TO POTENTIAL GAP IN 1760 01:07:49,360 --> 01:07:51,600 THE OUTYEARS. RETURN TO THIS 1761 01:07:51,600 --> 01:07:53,640 CHART BECAUSE YOU CAN SEE ONCE 1762 01:07:53,640 --> 01:07:56,160 AGAIN NCI AS OF TODAY HAS 13% 1763 01:07:56,160 --> 01:07:58,480 LESS BUYING POWER IN 2023 1764 01:07:58,480 --> 01:08:01,560 COMPARED TO 2003. THIS IS A 1765 01:08:01,560 --> 01:08:04,000 SIGNIFICANT GAP WHEN IT COMES TO 1766 01:08:04,000 --> 01:08:04,800 EVALUATING WHAT WE HAVE BEEN 1767 01:08:04,800 --> 01:08:08,200 ABLE TO DO FOR THE LAST TWO 1768 01:08:08,200 --> 01:08:10,240 DECADES. GIVEN THE CONVERSATION 1769 01:08:10,240 --> 01:08:12,240 MK PRESENTED TODAY THERE IS A 1770 01:08:12,240 --> 01:08:13,480 REAL POSSIBILITY OF CONTINUING 1771 01:08:13,480 --> 01:08:14,520 RESOLUTION, THERE'S SEVERAL 1772 01:08:14,520 --> 01:08:16,120 YEARS IN HER CHARTS SHE SHOW 1773 01:08:16,120 --> 01:08:19,760 THAT THE CONTINUING RESOLUTION 1774 01:08:19,760 --> 01:08:21,120 LASTED 365 DAYS. IF THAT WERE 1775 01:08:21,120 --> 01:08:23,600 THE CASE AND WE HAVE EXACTLY THE 1776 01:08:23,600 --> 01:08:27,240 SAME BUDGET WE DO TODAY YOU CAN 1777 01:08:27,240 --> 01:08:28,880 IMAGINE INFLATION DOESN'T WAIT 1778 01:08:28,880 --> 01:08:31,320 FOR ANYBODY. THE GAP WILL 1779 01:08:31,320 --> 01:08:35,280 INCREASE BASED ON NIH PROJECTED 1780 01:08:35,280 --> 01:08:37,800 BIRD PIE PERCENTAGE INCREASE, 1781 01:08:37,800 --> 01:08:41,320 THAT WOULD BE ANOTHER $276 1782 01:08:41,320 --> 01:08:43,920 MILLION OF PROJECTED INFLATION 1783 01:08:43,920 --> 01:08:46,600 WE WILL BE COMBATING HERE TO TRY 1784 01:08:46,600 --> 01:08:48,200 TO SUPPORT OUR GRANT AND 1785 01:08:48,200 --> 01:08:50,360 ACTIVITIES THAT WE KNOW WE NEED 1786 01:08:50,360 --> 01:08:51,960 TO. IN THAT CONTEXT HOPEFULLY 1787 01:08:51,960 --> 01:08:54,800 GIVE YOU A LITTLE BIT OF THE 1788 01:08:54,800 --> 01:08:57,280 LANDSCAPE NCI IS FACING OR THE 1789 01:08:57,280 --> 01:09:01,000 LANDS SCAPING WHICH NCI IS AS WE 1790 01:09:01,000 --> 01:09:04,440 FACE THE NEW BUDGET YEARS OVER 1791 01:09:04,440 --> 01:09:05,440 THE NEXT WHILE IT IS MY 1792 01:09:05,440 --> 01:09:07,560 PRIVILEGE TO TURN THE BATON OVER 1793 01:09:07,560 --> 01:09:10,120 TO DR. LOWY FOR HIM TO THEN 1794 01:09:10,120 --> 01:09:13,600 FOCUS IN A LITTLE BIT CLOSER ON 1795 01:09:13,600 --> 01:09:14,600 SOME OF THE TREES AND OTHER 1796 01:09:14,600 --> 01:09:15,560 ACTIVITIES THAT ARE PART OF OUR 1797 01:09:15,560 --> 01:09:18,720 BUDGET. 1798 01:09:18,720 --> 01:09:22,080 >>WESTON, THANKS VERY MUCH. I 1799 01:09:22,080 --> 01:09:24,360 WILL TALK A MINUTE OR SO ABOUT 1800 01:09:24,360 --> 01:09:28,880 THIS SLIDE BUT I WANT TO 1801 01:09:28,880 --> 01:09:31,360 QUESTION WITH WESTON'S THEME, 1802 01:09:31,360 --> 01:09:34,040 DISCUSS FOUR ISSUES. NUMBER ONE, 1803 01:09:34,040 --> 01:09:36,720 THE INTERCONNECTEDNESS OF THE 1804 01:09:36,720 --> 01:09:40,960 NCI BUDGET. NUMBER TWO, THE RPG 1805 01:09:40,960 --> 01:09:43,440 POOL. NUMBER THREE THAT AS 1806 01:09:43,440 --> 01:09:44,680 WESTON ALREADY POINTED OUT, WE 1807 01:09:44,680 --> 01:09:48,200 DO A LOT OF OTHER IMPORTANT 1808 01:09:48,200 --> 01:09:51,440 THINGS BEYOND THE RPG POOL. 1809 01:09:51,440 --> 01:09:54,960 NUMBER FOUR, TO TRY TO ADDRESS 1810 01:09:54,960 --> 01:09:58,360 THE POSSIBLE IMPACT OF THE 1811 01:09:58,360 --> 01:10:02,240 PROPOSED FY 24 BUDGET ON NCI 1812 01:10:02,240 --> 01:10:05,560 ACTIVITIES. SO LET'S LOOK AT 1813 01:10:05,560 --> 01:10:08,880 THIS SLIDE WHICH EMPHASIZES THE 1814 01:10:08,880 --> 01:10:10,800 INTERCONNECTEDNESS OF THE BUDGET 1815 01:10:10,800 --> 01:10:12,320 WITH THE GEARS BUT HIGHLIGHTING 1816 01:10:12,320 --> 01:10:15,560 THAT THE ULTIMATE GOAL IS TO 1817 01:10:15,560 --> 01:10:19,080 IMPROVE HEALTH OUTCOMES. WE NEED 1818 01:10:19,080 --> 01:10:21,320 MANY COMPONENTS. THIS SUMMARIZES 1819 01:10:21,320 --> 01:10:23,000 SOME OF THOSE CRITICAL 1820 01:10:23,000 --> 01:10:24,680 COMPONENTS. OF COURSE, WE NEED 1821 01:10:24,680 --> 01:10:26,880 THE RESEARCH FUNDING. BUT THEN 1822 01:10:26,880 --> 01:10:29,320 WHAT WE DO WITH IT IS TRAINING 1823 01:10:29,320 --> 01:10:31,760 AND WORK FORCE DEVELOPMENT, 1824 01:10:31,760 --> 01:10:33,680 RESOURCES FOR RESEARCHERS, THERE 1825 01:10:33,680 --> 01:10:36,800 IS OPERATING EXPENSES. THE 1826 01:10:36,800 --> 01:10:38,360 CANCER CENTER AND CLINICAL 1827 01:10:38,360 --> 01:10:41,920 TRIALS. BUT THESE AND OTHER 1828 01:10:41,920 --> 01:10:43,920 COMPONENTS ARE ALL INTERRELATED 1829 01:10:43,920 --> 01:10:46,280 FROM THE MOST BASIC RESEARCH TO 1830 01:10:46,280 --> 01:10:49,280 THE MOST APPLIED, THAT 1831 01:10:49,280 --> 01:10:50,880 ULTIMATELY LEAD TO IMPROVED 1832 01:10:50,880 --> 01:10:57,240 HEALTH OUTCOMES. I'M NOW GOING 1833 01:10:57,240 --> 01:11:01,240 TO TALK ABOUT THE RPGs AND 1834 01:11:01,240 --> 01:11:04,200 JUST TO SHOW YOU WHAT HAS 1835 01:11:04,200 --> 01:11:07,120 HAPPENED WITH THEM BUT 1836 01:11:07,120 --> 01:11:08,760 IMPORTANTLY MY LAST SLIDE IN 1837 01:11:08,760 --> 01:11:10,800 THIS SEGMENT IS GOING TO SHOW 1838 01:11:10,800 --> 01:11:14,040 YOU WHAT IS HAPPENED TO MODULAR 1839 01:11:14,040 --> 01:11:16,040 AWARDS VERSUS NON-MODULAR AWARDS 1840 01:11:16,040 --> 01:11:19,600 AND THEIR IMPACT. FIRST, 1841 01:11:19,600 --> 01:11:21,960 RESEARCH PROJECT GRANTS ARE A 1842 01:11:21,960 --> 01:11:25,640 LITTLE LESS THAN 50% OF THE 1843 01:11:25,640 --> 01:11:28,120 TOTAL NCI BUDGET BUT AS WESTON 1844 01:11:28,120 --> 01:11:30,400 POINTED OUT, OUR RESEARCH PART, 1845 01:11:30,400 --> 01:11:34,160 THE EXTRAMURAL RESEARCH IS A 1846 01:11:34,160 --> 01:11:35,720 MUCH LARGER PROPORTION THAN JUST 1847 01:11:35,720 --> 01:11:41,800 THAT. SO THIS IS A SLIDE THAT 1848 01:11:41,800 --> 01:11:45,200 TELLS YOU OVER THE LAST TEN 1849 01:11:45,200 --> 01:11:47,240 YEARS THE NUMBER OF APPLICATIONS 1850 01:11:47,240 --> 01:11:52,240 AND NUMBER OF APPLICANTS TO NCI 1851 01:11:52,240 --> 01:11:54,960 WENT UP MUCH FASTER THAN THAT OF 1852 01:11:54,960 --> 01:11:57,200 THE APPLICATIONS AND APPLICANTS 1853 01:11:57,200 --> 01:12:01,000 TO THE UTTER INSTITUTES AND 1854 01:12:01,000 --> 01:12:03,800 CENTERS OF NIH, WHICH BY ITSELF 1855 01:12:03,800 --> 01:12:05,120 EVEN IF WE SUPPORT THE SAME 1856 01:12:05,120 --> 01:12:09,040 NUMBER OF AWARDS, WOULD CHANGE 1857 01:12:09,040 --> 01:12:11,160 YOU THE PAY LINE OR THE SUCCESS 1858 01:12:11,160 --> 01:12:13,600 RATE BY MOVING IT DOWN BECAUSE 1859 01:12:13,600 --> 01:12:21,960 THE DENOMINATOR HAS GONE UP. 1860 01:12:21,960 --> 01:12:23,320 THIS SLIDE SHOWS YOU HOW OVER 1861 01:12:23,320 --> 01:12:26,640 THE LAST FEW YEARS I'M NOT LYNN 1862 01:12:26,640 --> 01:12:28,400 COLLUDING FY 23 BECAUSE WE ARE 1863 01:12:28,400 --> 01:12:29,720 STILL IN THAT BUDGET YEAR AND WE 1864 01:12:29,720 --> 01:12:33,800 DON'T HAVE THE ACCESSMENT. 1865 01:12:33,800 --> 01:12:37,840 ASSESSMENT BUT BETWEEN 2018 AND 1866 01:12:37,840 --> 01:12:41,080 '22, THE TOTAL BUDGET INCREASED 1867 01:12:41,080 --> 01:12:45,160 FROM 41% TO 44% FOR THE RPGs 1868 01:12:45,160 --> 01:12:47,600 SO THE OTHER INVESTMENTS 1869 01:12:47,600 --> 01:12:53,080 INCREASED BY LESS THAN THAT ON A 1870 01:12:53,080 --> 01:12:55,240 PERCENTAGE BASIS. YOU HEARD FROM 1871 01:12:55,240 --> 01:13:00,360 MONICA EARLIER TODAY THAT WE ARE 1872 01:13:00,360 --> 01:13:02,080 CONTINUING TO INCREASE THE SIZE 1873 01:13:02,080 --> 01:13:08,880 OF THE RPG POOL DURING FY 23. 1874 01:13:08,880 --> 01:13:13,720 THIS SLIDE SHOWS YOU A COUPLE OF 1875 01:13:13,720 --> 01:13:16,280 DIFFERENT ITEMS. FIRST IN THE 1876 01:13:16,280 --> 01:13:19,280 DARK BLUE WAS THE PAY LINE FOR 1877 01:13:19,280 --> 01:13:24,040 EXPERIENCED INVESTIGATORS 1878 01:13:24,040 --> 01:13:26,480 BETWEEN 2016 AND '22, WE WENT 1879 01:13:26,480 --> 01:13:30,880 FROM TEN DOWN TO EIGHT IN 2019 1880 01:13:30,880 --> 01:13:35,680 AND BACK UP TO 11 IN 2022 AND 1881 01:13:35,680 --> 01:13:37,480 I'M SURE THE VAST MAJORITY OF 1882 01:13:37,480 --> 01:13:41,160 YOU KNOW WE ARE AT THE 12 1883 01:13:41,160 --> 01:13:42,560 PERCENTILE THIS YEAR THANKS TO 1884 01:13:42,560 --> 01:13:48,480 THE BUDGET INCREASE FOR FY 23, 1885 01:13:48,480 --> 01:13:54,080 NOT SHOWN ON THIS SLIDE, EARLY 1886 01:13:54,080 --> 01:13:55,880 STAGE INVESTIGATORS RECEIVED AD 1887 01:13:55,880 --> 01:13:57,680 5 PERCENTAGE POINT INCREASE IN 1888 01:13:57,680 --> 01:14:00,920 TERMS OF PAY LINE. SO THAT WHEN 1889 01:14:00,920 --> 01:14:03,240 THE PAY LINE IS 12 PERCENTILE 1890 01:14:03,240 --> 01:14:05,240 THIS YEAR, FOR EXPERIENCED 1891 01:14:05,240 --> 01:14:08,840 INVESTIGATORS IS THAT IS 17TH 1892 01:14:08,840 --> 01:14:11,760 PERCENTILE FOR EARLY STAGE 1893 01:14:11,760 --> 01:14:17,120 INVESTIGATORS. SO WE -- THIS 1894 01:14:17,120 --> 01:14:19,560 YEAR DESPITE THE INCREASES WE 1895 01:14:19,560 --> 01:14:24,560 ARE NOT FUNDING THE OUTYEAR 1896 01:14:24,560 --> 01:14:27,560 COSTS, THE NON-COMPETING GRANTS, 1897 01:14:27,560 --> 01:14:31,400 AT FULLY 100%. THE REASON IS 1898 01:14:31,400 --> 01:14:33,440 THAT THE FUNDS FROM THE TURN 1899 01:14:33,440 --> 01:14:35,080 OVER COMPLETED AWARDS AND THE 1900 01:14:35,080 --> 01:14:37,400 FUNDS FROM THE APPROPRIATION 1901 01:14:37,400 --> 01:14:41,440 WERE NOT QUITE SUFFICIENT SO IN 1902 01:14:41,440 --> 01:14:44,000 THOSE SITUATIONS ALWAYS HAVE THE 1903 01:14:44,000 --> 01:14:46,120 ISSUE OF SHOULD WHICH MAKE MORE 1904 01:14:46,120 --> 01:14:48,440 AWARDS THAT IS HAVE A HIGHER PAY 1905 01:14:48,440 --> 01:14:50,720 LINE OR SHOULD WE FUND 1906 01:14:50,720 --> 01:14:53,320 NON-COMPETING GRANTS AT 100% 1907 01:14:53,320 --> 01:14:56,160 COMMITMENT. WE USUALLY AS WE DID 1908 01:14:56,160 --> 01:14:58,400 THIS YEAR PRIORITIZE FUNDING 1909 01:14:58,400 --> 01:15:01,160 MORE COMPETING AWARDS OVER 1910 01:15:01,160 --> 01:15:04,600 FUNDING THE NON-COMPETING GRANTS 1911 01:15:04,600 --> 01:15:10,960 AT FULLY 100%. THIS SLIDE SHOWS 1912 01:15:10,960 --> 01:15:15,680 YOU WHAT HAS HAPPENED OVER THE 1913 01:15:15,680 --> 01:15:18,280 LAST TEN YEARS BETWEEN THE 1914 01:15:18,280 --> 01:15:21,440 MODULAR AWARDS AND THE 1915 01:15:21,440 --> 01:15:24,520 NON-MODULAR AWARDS. FIRST THE 1916 01:15:24,520 --> 01:15:28,880 MODULAR AWARDS ARE UP TO 1917 01:15:28,880 --> 01:15:30,560 $250,000 IN DIRECT COSTS, THEY 1918 01:15:30,560 --> 01:15:33,160 ARE THE BOTTOM PART. WHAT I HOPE 1919 01:15:33,160 --> 01:15:36,200 YOU CAN APPRECIATE IS THEY HAVE 1920 01:15:36,200 --> 01:15:42,760 GONE FROM 63% OF THE AWARDS IN 1921 01:15:42,760 --> 01:15:45,800 2012 TO 17% OF THE AWARDS IN 1922 01:15:45,800 --> 01:15:51,280 2022. WE HAVE DURING THIS TIME 1923 01:15:51,280 --> 01:15:54,920 FOR MOST OF THIS TIME REDUCED 1924 01:15:54,920 --> 01:15:58,000 THE AWARD OF THE MODULAR AWARDS 1925 01:15:58,000 --> 01:15:59,960 BY 8 1/2% WHICH MEANS A MODULAR 1926 01:15:59,960 --> 01:16:03,920 AWARD IN TERMS OF DIRECT COST IS 1927 01:16:03,920 --> 01:16:07,200 ABOUT $225,000. IF YOU NOW TURN 1928 01:16:07,200 --> 01:16:10,280 YOUR ATTENTION TO THE TOP PART, 1929 01:16:10,280 --> 01:16:13,040 THESE ARE THE NON-MODULAR AWARDS 1930 01:16:13,040 --> 01:16:15,680 WHICH ARE THOSE THAT ARE MORE 1931 01:16:15,680 --> 01:16:18,360 THAN $250,000 IN DIRECT COSTS. 1932 01:16:18,360 --> 01:16:20,800 WHAT HAS HATCHED IS -- HAPPENED 1933 01:16:20,800 --> 01:16:22,440 IS THEY HAVE GONE FROM BEING 1934 01:16:22,440 --> 01:16:27,440 MINORITY OF AWARDS IN 2012, 38% 1935 01:16:27,440 --> 01:16:32,000 TO THE VAST MAJORITY, MORE THAN 1936 01:16:32,000 --> 01:16:34,160 80%, MORE THAN FOUR OUT OF FIVE 1937 01:16:34,160 --> 01:16:39,200 AWARDS IN 2022. MOST OF THESE 1938 01:16:39,200 --> 01:16:44,680 NON-MODULAR AWARDS ARE FOR 1939 01:16:44,680 --> 01:16:47,160 $499,000 WITH THE 17 PERCENT 1940 01:16:47,160 --> 01:16:49,400 DECREASED WHICH MEANS THE ACTUAL 1941 01:16:49,400 --> 01:16:55,240 DIRECT COST IS ABOUT $425,000 1942 01:16:55,240 --> 01:16:57,160 PER AWARD WHICH IS ABOUT 1943 01:16:57,160 --> 01:17:00,360 $200,000 MORE THAN THE MODULAR 1944 01:17:00,360 --> 01:17:04,120 AWARDS. THIS IS A TANGIBLE 1945 01:17:04,120 --> 01:17:05,320 REFLECTION OF WHAT WESTON HAS 1946 01:17:05,320 --> 01:17:09,640 BEEN SHOWING YOU OF THE IMPACT 1947 01:17:09,640 --> 01:17:11,160 OF INFLATION AS PEOPLE HAVE 1948 01:17:11,160 --> 01:17:13,600 VOTED WITH THEIR FEET BY GOING 1949 01:17:13,600 --> 01:17:17,920 FROM MODULAR AWARDS TO MAINLY 1950 01:17:17,920 --> 01:17:21,040 NON-MODULAR AWARDS, OVER THE 1951 01:17:21,040 --> 01:17:23,640 PAST TEN YEARS. IF WE PROJECT 1952 01:17:23,640 --> 01:17:25,400 FORWARD THE NON-MODULAR AWARDS 1953 01:17:25,400 --> 01:17:28,440 ARE ALMOST CERTAINLY GOING TO BE 1954 01:17:28,440 --> 01:17:30,520 WELL OVER 90% OF THE AWARDS IN 1955 01:17:30,520 --> 01:17:37,160 THE NEXT TWO OR THREE YEARS. I 1956 01:17:37,160 --> 01:17:38,400 NOW WANT TO TURN OUR ATTENTION 1957 01:17:38,400 --> 01:17:41,120 TO THE FACT THAT NCI FUNDS MANY 1958 01:17:41,120 --> 01:17:42,920 CRITICAL COMPONENTS OF CANCER 1959 01:17:42,920 --> 01:17:44,240 RESEARCH THROUGH MECHANISMS 1960 01:17:44,240 --> 01:17:47,320 OUTSIDE THE RPGs. THIS IS 1961 01:17:47,320 --> 01:17:49,640 JUST LISTING FOUR OF THEM. THE 1962 01:17:49,640 --> 01:17:51,640 SPORE GRANTS, CANCER CENTER 1963 01:17:51,640 --> 01:17:53,640 SUPPORT GRANTS, CANCER TRAINING 1964 01:17:53,640 --> 01:17:55,000 AND CLINICAL TRIALS NETWORKS. 1965 01:17:55,000 --> 01:17:56,640 OBVIOUSLY WE NEED TO SUPPORT 1966 01:17:56,640 --> 01:17:59,320 THESE MECHANISMS IN ADDITION TO 1967 01:17:59,320 --> 01:18:05,800 THE RPGs. THIS IS TRYING TO 1968 01:18:05,800 --> 01:18:09,800 PUT INTO CONTEXT WHAT MK HOLOHAN 1969 01:18:09,800 --> 01:18:14,360 WAS TALKING WITH YOU ABOUT WITH 1970 01:18:14,360 --> 01:18:18,520 THE BUDGET ACCORDING TO HOUSE 1971 01:18:18,520 --> 01:18:20,720 BUDGET OR THE SENATE BUDGET. I 1972 01:18:20,720 --> 01:18:24,240 THINK THE MOST IMPORTANT POINT 1973 01:18:24,240 --> 01:18:26,600 HERE, FIRST BULLET POINT IS THE 1974 01:18:26,600 --> 01:18:29,840 FLAT BUDGET MAY NOT BE FLAT. 1975 01:18:29,840 --> 01:18:31,760 THAT IS BECAUSE THE CANCER MOON 1976 01:18:31,760 --> 01:18:34,600 SHOT FUNDS WERE NEVER PART OF 1977 01:18:34,600 --> 01:18:38,440 THE NCI BASED BUDGET AND THE 1978 01:18:38,440 --> 01:18:40,520 HOUSE BUDGET FOR FY 24 DIDN'T 1979 01:18:40,520 --> 01:18:45,520 CONSIDER THE FACT THAT THE $216 1980 01:18:45,520 --> 01:18:47,720 MILLION FOR MOON SHOT WOULD GO 1981 01:18:47,720 --> 01:18:51,680 IN '23 WOULD GO DOWN TO ZERO IN 1982 01:18:51,680 --> 01:18:54,080 '24. THE SENATE MARKED BY 1983 01:18:54,080 --> 01:18:55,400 CONTRAST DID CONSIDER THIS ISSUE 1984 01:18:55,400 --> 01:19:01,240 AND DID ADD THE $216 MILLION TO 1985 01:19:01,240 --> 01:19:05,680 THE BASE BUDGET. THEN ADDED $60 1986 01:19:05,680 --> 01:19:07,680 MILLION IN ADDITION. $60 1987 01:19:07,680 --> 01:19:09,880 MILLION IS A LOT OF MONEY AND IS 1988 01:19:09,880 --> 01:19:11,960 VERY GENEROUS ON THE PART OF THE 1989 01:19:11,960 --> 01:19:16,640 SENATE. BUT IT IS LESS THAN ONE 1990 01:19:16,640 --> 01:19:22,840 PERCENT OF THE NCI FY 24 -- FY 1991 01:19:22,840 --> 01:19:25,760 23 BUDGET. IN TERMS OF OTHER 1992 01:19:25,760 --> 01:19:28,000 COSTS, THE ESTIMATE IS THAT WE 1993 01:19:28,000 --> 01:19:32,480 NEED TO ADD ABOUT $250 MILLION 1994 01:19:32,480 --> 01:19:36,240 TO THE RPG POOL IN FY 24 TO 1995 01:19:36,240 --> 01:19:37,600 MAINTAIN THE CURRENT 12 1996 01:19:37,600 --> 01:19:39,040 PERCENTILE PAY LINE FOR NEW 1997 01:19:39,040 --> 01:19:42,520 AWARDS. AND FUND NON-COMPETING 1998 01:19:42,520 --> 01:19:46,840 AWARDS AT 100%. ONENA HEADS TO 1999 01:19:46,840 --> 01:19:48,400 ADD MORE IF ONE WERE GOING TO 2000 01:19:48,400 --> 01:19:51,960 TRY TO GET TO THE 13TH 14TH AND 2001 01:19:51,960 --> 01:19:53,960 15TH PERCENTILE WHICH IS WHERE 2002 01:19:53,960 --> 01:20:01,200 WE WOULD LIKE NCI TO GO. AS 2003 01:20:01,200 --> 01:20:03,440 WESTON MENTIONED NCI INCURS 2004 01:20:03,440 --> 01:20:05,240 BETWEEN 75 AND $100 MILLION EACH 2005 01:20:05,240 --> 01:20:06,960 YEAR IN INCREASE MANDATORY 2006 01:20:06,960 --> 01:20:10,640 EXPENSES. THESE INCLUDE BUT NOT 2007 01:20:10,640 --> 01:20:13,440 LIMITED TO, PROGRAM EVALUATION, 2008 01:20:13,440 --> 01:20:16,240 CYBER SECURITY AND CENTER FOR 2009 01:20:16,240 --> 01:20:23,360 SCIENTIFIC REVIEW EXPENSES. SO 2010 01:20:23,360 --> 01:20:27,640 H IS LAST OF MY SLIDES, WHICH IS 2011 01:20:27,640 --> 01:20:32,560 TO SAY IF WE HAVE A FLAT BUDGET 2012 01:20:32,560 --> 01:20:35,320 IT SEEMS LIKELY THAT ALL PARTS 2013 01:20:35,320 --> 01:20:37,440 OF THE NCI BUDGET COULD BE 2014 01:20:37,440 --> 01:20:41,800 ADVERSELY AFFECTED AND THIS IS A 2015 01:20:41,800 --> 01:20:47,000 PARTIAL LIST. FOR THE RPG POOL I 2016 01:20:47,000 --> 01:20:49,120 HOPE IT'S CLEAR FROM WHAT I HAVE 2017 01:20:49,120 --> 01:20:50,480 BEEN SAYING THAT IT MAYBE 2018 01:20:50,480 --> 01:20:51,840 NECESSARY TO DECREASE THE PAY 2019 01:20:51,840 --> 01:20:53,480 LINE FOR NON-AWARDS AND FUND 2020 01:20:53,480 --> 01:20:56,040 NON-COMPETING AWARDS AT LOWER 2021 01:20:56,040 --> 01:21:02,240 THAN 100% IN FY 24. EVEN CANCER 2022 01:21:02,240 --> 01:21:03,160 CENTER SUPPORT GRANTS WE HAVE 2023 01:21:03,160 --> 01:21:08,520 NOT TOUCHED PREVIOUSLY, MIGHT BE 2024 01:21:08,520 --> 01:21:10,440 NECESSARY TO FORGO SOME 2025 01:21:10,440 --> 01:21:11,720 ANTICIPATED INCREASES FOR 2026 01:21:11,720 --> 01:21:13,440 COMPETING RENEWALS AND DECREASE 2027 01:21:13,440 --> 01:21:18,360 AMOUNT OF NON-COMPETING SUPPORT 2028 01:21:18,360 --> 01:21:20,480 GRANTS. CANCER TRAINING AWARDS, 2029 01:21:20,480 --> 01:21:25,080 AGAIN, WE HAVE NOT PREVIOUSLY 2030 01:21:25,080 --> 01:21:26,280 CONSIDERED DECREASING THEM BUT 2031 01:21:26,280 --> 01:21:27,720 MIGHT BE NECESSARY TO MAKE FEWER 2032 01:21:27,720 --> 01:21:31,480 NEW AWARDS. SPORE GRANTS, IT 2033 01:21:31,480 --> 01:21:35,760 MAY BE NECESSARY TO MAKE FEWER 2034 01:21:35,760 --> 01:21:37,240 NEW AWARDS AND REDUCE THE SIZE 2035 01:21:37,240 --> 01:21:40,160 OF NON-COMPETING AWARDS. THE 2036 01:21:40,160 --> 01:21:42,000 INTRAMURAL RESEARCH PROGRAM 2037 01:21:42,000 --> 01:21:44,240 WOULD BE CUT AT LEAST AS MUCH AS 2038 01:21:44,240 --> 01:21:50,520 THE EXTRAMURAL AWARDS. I DON'T 2039 01:21:50,520 --> 01:21:53,040 MEAN TO BE OVERLY DRAMATIC IN 2040 01:21:53,040 --> 01:21:55,960 SHOWING YOU THESE SEVERAL BULLET 2041 01:21:55,960 --> 01:21:56,880 POINTS BUT I THINK IT IS 2042 01:21:56,880 --> 01:21:57,960 IMPORTANT FOR US TO FACE THAT 2043 01:21:57,960 --> 01:22:01,920 THE FISCAL REALITY OF FY 24 IS 2044 01:22:01,920 --> 01:22:06,000 NOT LIKELY TO BE AS FAVORABLE AS 2045 01:22:06,000 --> 01:22:12,720 IT HAS BEEN IN THE PAS PAST. WED 2046 01:22:12,720 --> 01:22:14,280 TO THINK THROUGH SERIOUSLY HOW 2047 01:22:14,280 --> 01:22:18,600 TO PRIORITIZE WHAT WE ARE DOING, 2048 01:22:18,600 --> 01:22:21,400 AND HOW TO REALLY SUPPORT THE 2049 01:22:21,400 --> 01:22:23,280 MOST IMPORTANT CANCER RESEARCH. 2050 01:22:23,280 --> 01:22:25,240 BUT I DO WANT TO END PERHAPS 2051 01:22:25,240 --> 01:22:27,920 WITH A DIFFERENT MISTIC NOTE 2052 01:22:27,920 --> 01:22:34,920 FROM MK'S WHICH IS WE WILL HAVE 2053 01:22:34,920 --> 01:22:36,840 A SUBSTANTIAL AMOUNT OF FUNDING 2054 01:22:36,840 --> 01:22:39,520 AND CONTINUE TO MAKE THE BEST 2055 01:22:39,520 --> 01:22:43,280 PROGRESS THAT WE CAN IN OUR 2056 01:22:43,280 --> 01:22:44,360 CANCER RESEARCH. THANKS VERY 2057 01:22:44,360 --> 01:22:46,720 MUCH. MONICA, WESTON, MK AND I 2058 01:22:46,720 --> 01:22:51,240 WILL BE HAPPY TO ANSWER YOUR 2059 01:22:51,240 --> 01:22:52,080 QUESTIONS AND LISTEN TO YOUR 2060 01:22:52,080 --> 01:22:55,160 COMMENTS. 2061 01:22:55,160 --> 01:22:59,280 >>THANKS, WESTON AND DOUG. IF 2062 01:22:59,280 --> 01:23:02,160 WE CAN HAVE MONICA AND MK 2063 01:23:02,160 --> 01:23:05,520 AVAILABLE AS WELL, ARE THERE ANY 2064 01:23:05,520 --> 01:23:08,720 QUESTIONS OR COMMENTS ABOUT 2065 01:23:08,720 --> 01:23:14,440 BUDGET OVERVIEW, BUDGET PROCESS? 2066 01:23:14,440 --> 01:23:22,400 CONSEQUENCES. GO AHEAD, ANNA. 2067 01:23:22,400 --> 01:23:25,200 >>THANKS, MK. I WOULD LIKE -- 2068 01:23:25,200 --> 01:23:28,280 THANKS FOR BOTH PRESENTATIONS. 2069 01:23:28,280 --> 01:23:29,560 AS AN OVERVIEW I DON'T THINK I 2070 01:23:29,560 --> 01:23:33,880 HAVE SEEN IT DONE BETTER. SO MK, 2071 01:23:33,880 --> 01:23:39,360 ELECTION YEAR IS COMING UP. SO 2072 01:23:39,360 --> 01:23:40,440 WONDERING WHAT YOU ARE GOING TO 2073 01:23:40,440 --> 01:23:41,680 MAKE IN TERMS OF IS THAT GOING 2074 01:23:41,680 --> 01:23:47,760 TO HAVE IMPACT. PEOPLE DOP ON 2075 01:23:47,760 --> 01:23:48,640 BEHALF OF THE CANCER INSTITUTE 2076 01:23:48,640 --> 01:23:51,600 AND I'M WONDERING IF THERE 2077 01:23:51,600 --> 01:23:52,560 AREN'T OPPORTUNITIES FOR THIS 2078 01:23:52,560 --> 01:23:54,960 PARTICULAR ELECTION YEAR TO 2079 01:23:54,960 --> 01:23:56,400 MAYBE MOVE THINGS IN A DIFFERENT 2080 01:23:56,400 --> 01:23:57,400 DIRECTION LOOKING 2081 01:23:57,400 --> 01:24:01,720 OPTIMISTICALLY. 2082 01:24:01,720 --> 01:24:06,040 >>WELL, IT IS POSSIBLE WE 2083 01:24:06,040 --> 01:24:13,280 CERTAINLY HAVE CANCER CHAMPIONS. 2084 01:24:13,280 --> 01:24:14,440 WHEN THERE ARE BUDGET CAPS IN 2085 01:24:14,440 --> 01:24:18,240 PLACE, ONE THING THAT IS 2086 01:24:18,240 --> 01:24:20,920 IMPORTANT TO UNDERSTAND THEY 2087 01:24:20,920 --> 01:24:25,640 WILL NOT WHEN A BUDGET AGREEMENT 2088 01:24:25,640 --> 01:24:28,200 SAYS THIS WILL RETURN TO FY 22 2089 01:24:28,200 --> 01:24:30,120 LEVELS OR FY 23 LEVELS WE WILL 2090 01:24:30,120 --> 01:24:34,200 MAINTAIN THAT WHICH IS WHAT THE 2091 01:24:34,200 --> 01:24:38,480 FISCAL RESPONSIBILITY WOULD DO, 2092 01:24:38,480 --> 01:24:39,720 IT DOESN'T MEAN EVERY ACCOUNT 2093 01:24:39,720 --> 01:24:41,920 AND AGENCY AT THE SAME LEVEL, IT 2094 01:24:41,920 --> 01:24:46,880 MEANS THAT'S THE TOP LINE. WE 2095 01:24:46,880 --> 01:24:48,320 DID SEE IN THE HOUSE AN SENATE 2096 01:24:48,320 --> 01:24:52,520 BILLS THOUGH DIFFERENT WE 2097 01:24:52,520 --> 01:24:54,960 CERTAINLY DID SEE PICKING AND 2098 01:24:54,960 --> 01:24:59,880 CHOOSING SOME AREAS AND OTHERS 2099 01:24:59,880 --> 01:25:01,560 TARGETED FOR REDUCTIONS OR KEPT 2100 01:25:01,560 --> 01:25:04,080 FLAT OR MODEST. INCREASES SO IT 2101 01:25:04,080 --> 01:25:09,400 IS NOT ACROSS THE BOARD THING. I 2102 01:25:09,400 --> 01:25:13,520 DON'T EXPECT GRANULARITY TO BE 2103 01:25:13,520 --> 01:25:14,800 DOWN TO ONE INSTITUTE WITHIN 2104 01:25:14,800 --> 01:25:19,160 NIH. HOWEVER, WE WILL BE SEEING 2105 01:25:19,160 --> 01:25:23,400 THE PRESIDENTIAL ELECTION THAT 2106 01:25:23,400 --> 01:25:26,880 IS UPCOMING, AT PLAY CERTAINLY 2107 01:25:26,880 --> 01:25:29,520 FOR THE NEXT FISCAL YEAR, HOW 2108 01:25:29,520 --> 01:25:32,800 THIS PANS OUT WITH FY 24, THINGS 2109 01:25:32,800 --> 01:25:36,200 WILL BE UNDERWAY TO CAMPAIGNING 2110 01:25:36,200 --> 01:25:38,560 BUT I DON'T -- I THINK IT IS 2111 01:25:38,560 --> 01:25:39,800 MORE WHO IS LEFT HOLDING THE BAG 2112 01:25:39,800 --> 01:25:42,360 IF THERE IS A GOVERNMENT SHUT 2113 01:25:42,360 --> 01:25:47,960 DOWN IF WE END UP CREATING A 2114 01:25:47,960 --> 01:25:49,720 MORE DANGEROUS SITUATION IN 2115 01:25:49,720 --> 01:25:52,960 UKRAINE BECAUSE OF CHANGING 2116 01:25:52,960 --> 01:25:55,600 SUPPORT FOR THAT EFFORT. THOSE 2117 01:25:55,600 --> 01:25:57,640 TYPES OF THINGS ARE GOING TO BE 2118 01:25:57,640 --> 01:26:03,760 ISSUES. OVERALL DEBT PROBABLY 2119 01:26:03,760 --> 01:26:06,280 DECISIONS OF COVID, DECISIONS OF 2120 01:26:06,280 --> 01:26:09,640 UNSPENT MONEY ECONOMICS IS A BIG 2121 01:26:09,640 --> 01:26:11,400 PART OF IT, I THINK 2122 01:26:11,400 --> 01:26:12,880 INTERNATIONAL ISSUES WOULD BE 2123 01:26:12,880 --> 01:26:15,600 AGAIN PART OF IT, I COULD SEE AI 2124 01:26:15,600 --> 01:26:18,680 OF BEING AN ISSUE. REALLY 2125 01:26:18,680 --> 01:26:20,920 BECAUSE OF THE COMPETITIVENESS 2126 01:26:20,920 --> 01:26:22,200 IN CHINA. WE WILL HAVE TO SEE 2127 01:26:22,200 --> 01:26:24,960 HOW THAT PLAYS OUT. IT MAKES 2128 01:26:24,960 --> 01:26:26,120 EVERYTHING WORSE IN A WAY, THERE 2129 01:26:26,120 --> 01:26:28,320 MIGHT BE OPPORTUNITIES BUT THE 2130 01:26:28,320 --> 01:26:30,880 STAKES ARE DIFFERENT. AND WE 2131 01:26:30,880 --> 01:26:32,400 WILL HAVE TO SEE WHAT HAPPENS. 2132 01:26:32,400 --> 01:26:34,920 >>ONE LAST COMMENT, THE DATA 2133 01:26:34,920 --> 01:26:37,000 INITIATIVE THAT MONICA ANNOUNCED 2134 01:26:37,000 --> 01:26:39,320 TODAY I THINK IS A GAME CHANGER 2135 01:26:39,320 --> 01:26:41,640 BECAUSE THIS HAS BEEN A VERY FOR 2136 01:26:41,640 --> 01:26:44,400 ALL HEALTHCARE NOT JUST CANCER 2137 01:26:44,400 --> 01:26:46,160 WITH THE WHITE HOUSE TAKING 2138 01:26:46,160 --> 01:26:50,480 LEADERSHIP HERE I THINK THAT'S A 2139 01:26:50,480 --> 01:26:51,960 SEE CHANGE IN TERMS OF WHAT THE 2140 01:26:51,960 --> 01:26:54,480 FUTURE HOLDS, FOR ALL CANCER NOT 2141 01:26:54,480 --> 01:26:55,880 JUST CANCER BUT CANCER IS 2142 01:26:55,880 --> 01:26:57,040 LEADING THIS BUT WE DOPE KNOW 2143 01:26:57,040 --> 01:26:59,480 MUCH ABOUT IT YET BUT IT IS LONG 2144 01:26:59,480 --> 01:27:02,280 OVERDUE AND IT HAS BEEN A RAY 2145 01:27:02,280 --> 01:27:03,560 GOAL FOR THE PRESIDENT TO 2146 01:27:03,560 --> 01:27:04,880 ACTUALLY MAKE THIS HAPPEN FOR 2147 01:27:04,880 --> 01:27:08,760 MANY YEARS. I WOULDN'T BE 2148 01:27:08,760 --> 01:27:10,440 SURPRISED ELECTION YEAR TO SEE 2149 01:27:10,440 --> 01:27:12,120 PEOPLE TRY TO ONE UP SOME OF 2150 01:27:12,120 --> 01:27:13,360 THESE THINGS WHICH MIGHT BE GOOD 2151 01:27:13,360 --> 01:27:16,560 FOR US. KEEP MY FINGERS 2152 01:27:16,560 --> 01:27:16,800 CROSSED. 2153 01:27:16,800 --> 01:27:19,720 >>I SHOULD REMIND YOU THE DATA 2154 01:27:19,720 --> 01:27:22,040 CROSS HHS DATA INITIATIVE IS NOT 2155 01:27:22,040 --> 01:27:26,320 RECEIVING ANY EXTRA FUNDING. SO 2156 01:27:26,320 --> 01:27:28,960 THIS IS NOT A FUNDED THING. THIS 2157 01:27:28,960 --> 01:27:31,600 IS ALL THE AGENCIES SAYING THIS 2158 01:27:31,600 --> 01:27:34,480 IS OUR PRIORITY, WE ARE GOING TO 2159 01:27:34,480 --> 01:27:36,440 TAKE OUR EXISTING FUNDING AND 2160 01:27:36,440 --> 01:27:41,520 EXISTING PROJECTS AND ALL WORK 2161 01:27:41,520 --> 01:27:43,120 TOGETHER TO CREATE SOMETHING 2162 01:27:43,120 --> 01:27:44,880 SEAMLESS WHICH IS WONDERFUL. I'M 2163 01:27:44,880 --> 01:27:47,520 REMINDING YOU THERE IS NO 2164 01:27:47,520 --> 01:27:49,000 ADDITIONAL FUNDING WITH THAT 2165 01:27:49,000 --> 01:27:49,200 PROJECT. 2166 01:27:49,200 --> 01:27:51,800 >>I HAVE TO SAY IF YOU LOOK AT 2167 01:27:51,800 --> 01:27:52,800 THE COMMUNITIES OUT THERE, 2168 01:27:52,800 --> 01:27:54,440 ALMOST ALL OF THEM ARE VERY 2169 01:27:54,440 --> 01:27:56,800 EXCITED ABOUT THIS AND I THINK 2170 01:27:56,800 --> 01:27:57,920 THEY WILL BE ADVOCATING NEAR 2171 01:27:57,920 --> 01:27:58,840 TERM FOR FUNDING FOR THAT 2172 01:27:58,840 --> 01:28:01,160 INITIATIVE. 2173 01:28:01,160 --> 01:28:05,840 >>THANKS, ANNA. ANDREA, I SEE 2174 01:28:05,840 --> 01:28:07,960 YOUR HAND. PLEASE UNMUTE. 2175 01:28:07,960 --> 01:28:11,400 >>YES, CAN YOU HEAR ME. 2176 01:28:11,400 --> 01:28:11,920 >>YES. 2177 01:28:11,920 --> 01:28:13,840 >>I WANT TO MAKE A COMMENT 2178 01:28:13,840 --> 01:28:15,400 FIRST A BRIEF OVERVIEW, I WANT 2179 01:28:15,400 --> 01:28:16,800 TO MAKE A COMMENT ABOUT THE 2180 01:28:16,800 --> 01:28:20,880 CANCER CENTERS AND FUNDING AND I 2181 01:28:20,880 --> 01:28:24,320 WAS WONDERING WHAT SHOULD WE 2182 01:28:24,320 --> 01:28:26,000 EXPECT FROM THAT? SHOULD WE 2183 01:28:26,000 --> 01:28:29,000 EXPECT THE CANCER CENTERS WILL 2184 01:28:29,000 --> 01:28:30,760 (INAUDIBLE) FUNDING BASED ON 2185 01:28:30,760 --> 01:28:32,880 SOME METRICS OR WHAT SHOULD WE 2186 01:28:32,880 --> 01:28:38,480 EXPECT TO SEE BASED ON BUDGET? 2187 01:28:38,480 --> 01:28:41,520 >>THIS IS DOUG. I THINK IT IS 2188 01:28:41,520 --> 01:28:42,720 STILL VERY MUCH UNDER 2189 01:28:42,720 --> 01:28:47,320 DISCUSSION. BUT I THINK THAT 2190 01:28:47,320 --> 01:28:48,920 WHAT THE POINT -- MAIN POINT I 2191 01:28:48,920 --> 01:28:53,120 WAS TRYING TO MAKE I THINK, WAS 2192 01:28:53,120 --> 01:28:57,600 FIRST OVER THE LAST FEW YEARS WE 2193 01:28:57,600 --> 01:28:59,600 HAVE DONE OUR BEST TO FUND THE 2194 01:28:59,600 --> 01:29:01,440 CANCER CENTER SUPPORT GRANTS NOT 2195 01:29:01,440 --> 01:29:04,840 JUST AT THEIR CURRENT LEVEL BUT 2196 01:29:04,840 --> 01:29:06,640 EACH TIME WHEN THE CANCER 2197 01:29:06,640 --> 01:29:10,920 CENTERS HAVE COME IN FOR THEIR 2198 01:29:10,920 --> 01:29:13,000 RENEWAL TO BE ABLE TO INCREASE 2199 01:29:13,000 --> 01:29:17,200 IT AS LONG AS THEY GOT GOOD 2200 01:29:17,200 --> 01:29:22,560 SCORESS. FOR FY 24 NEITHER OF 2201 01:29:22,560 --> 01:29:25,360 THOSE MAY BE THE CASE. THAT WAS 2202 01:29:25,360 --> 01:29:27,640 ALL I WAS TALKING QUALITATIVELY 2203 01:29:27,640 --> 01:29:29,800 AND I APOLOGIZE FOR NOT GIVING 2204 01:29:29,800 --> 01:29:32,880 YOU A QUANTITATIVE ANSWER. 2205 01:29:32,880 --> 01:29:35,760 MONICA MAY WANT TO SAY MORE. 2206 01:29:35,760 --> 01:29:41,120 >>I THINK THAT WE REALLY ARE 2207 01:29:41,120 --> 01:29:45,640 TRYING TO FOCUS ON WHAT OUR 2208 01:29:45,640 --> 01:29:47,400 PRIORITIES AND HOW THE BEST 2209 01:29:47,400 --> 01:29:48,760 SUPPORT THE TOTALITY OF THE 2210 01:29:48,760 --> 01:29:50,120 COMMUNITY. THIS AS DOUG SAID 2211 01:29:50,120 --> 01:29:52,200 THIS IS ONE OF THE OPTIONS ON 2212 01:29:52,200 --> 01:29:54,560 THE TABLE.MENT THERE'S THE OLD 2213 01:29:54,560 --> 01:29:58,320 PRINCIPLE THAT IF YOU -- IF 2214 01:29:58,320 --> 01:30:01,120 EVERYBODY GETS CUT A LITTLE BIT, 2215 01:30:01,120 --> 01:30:02,840 THEN IT IS -- YOU CAN DISTRIBUTE 2216 01:30:02,840 --> 01:30:05,320 IT, IF YOU FOCUS ON ONE AREA 2217 01:30:05,320 --> 01:30:07,440 THERE IS MORE SIGNIFICANT LOSSES 2218 01:30:07,440 --> 01:30:10,320 TO THAT INDIVIDUAL ARE AREA. I T 2219 01:30:10,320 --> 01:30:12,640 SAY WE ARE CONSIDERING BOTH 2220 01:30:12,640 --> 01:30:17,200 APPROACHES AS WE GO ALONG. FOR 2221 01:30:17,200 --> 01:30:19,720 EVERYONE TO KNOW WE ARE DOING AN 2222 01:30:19,720 --> 01:30:22,360 INCREDIBLY RIGOROUS LOOK AT 2223 01:30:22,360 --> 01:30:26,760 EVERY SINGLE PROCESS WITHIN NCI, 2224 01:30:26,760 --> 01:30:28,360 LOOKING FOR CONSOLIDATION, 2225 01:30:28,360 --> 01:30:30,120 LOOKING FOR ECONOMIES OF SCALE, 2226 01:30:30,120 --> 01:30:32,440 LOOKING TO ELIMINATE 2227 01:30:32,440 --> 01:30:35,200 REDUNDANCIES AND LOOKING TO 2228 01:30:35,200 --> 01:30:36,960 GRADUATE PROJECTS THAT REALLY 2229 01:30:36,960 --> 01:30:39,760 SHOULD NO LONGER RECEIVE NCI 2230 01:30:39,760 --> 01:30:42,880 SUPPORT SO WE CAN KEEP ANY CUTS 2231 01:30:42,880 --> 01:30:44,680 WE NEED TO MAKE TO THE LOWEST 2232 01:30:44,680 --> 01:30:47,120 LEVEL POSSIBLE. FINALLY I JUST 2233 01:30:47,120 --> 01:30:48,680 HAVE TO SAY WHAT AN INCREDIBLE 2234 01:30:48,680 --> 01:30:51,480 DEAL I THINK THE CANCER CENTERS 2235 01:30:51,480 --> 01:30:53,520 ARE. I THINK -- PEOPLE HAVE 2236 01:30:53,520 --> 01:30:55,760 HEARD ME SAY THIS MANY TIMES FOR 2237 01:30:55,760 --> 01:30:57,000 ANY DOLLAR THAT GOES TO THE 2238 01:30:57,000 --> 01:30:58,760 CANCER CENTER IT IS LEVERAGED 2239 01:30:58,760 --> 01:31:01,200 MULTIPLE, MULTIPLE MULTIPLE 2240 01:31:01,200 --> 01:31:05,480 TIMES. SO WHAT AN AMAZING 2241 01:31:05,480 --> 01:31:07,320 INVESTMENT. SO MUCH VALUE RETURN 2242 01:31:07,320 --> 01:31:12,640 FOR SUCH A SMALL INVESTMENT. 2243 01:31:12,640 --> 01:31:13,400 (OVERLAPPING SPEAKERS) 2244 01:31:13,400 --> 01:31:16,840 >>I AGREE. THANK YOU. 2245 01:31:16,840 --> 01:31:20,600 >>SO WHAT IMPACT WILL HAVE HAVE 2246 01:31:20,600 --> 01:31:24,360 ON NCI FREDERICK? 2247 01:31:24,360 --> 01:31:28,720 >>NCI FREDERICK IS A SUPPORTIVE 2248 01:31:28,720 --> 01:31:29,920 INSTITUTION, FEDERALRY FUNDED 2249 01:31:29,920 --> 01:31:31,520 RESEARCH DEVELOPMENT CENTER, A 2250 01:31:31,520 --> 01:31:33,640 SUPPORTIVE INSTITUTION THAT HAS 2251 01:31:33,640 --> 01:31:35,360 MULTIPLE, MULTIPLE MULTIPLE 2252 01:31:35,360 --> 01:31:36,800 AREAS OF INTERSECTION WITHIN THE 2253 01:31:36,800 --> 01:31:41,720 NCI PROGRAMS. FOR EXAMPLE, IT 2254 01:31:41,720 --> 01:31:42,800 RUNS SOME CORE LAB RESOURCES 2255 01:31:42,800 --> 01:31:45,600 THAT ARE USED BY THE EXTRAMURAL 2256 01:31:45,600 --> 01:31:47,920 COMMUNITIES SUCH AS CRYOEM 2257 01:31:47,920 --> 01:31:48,840 FACILITY, RUNS CONTRACTING 2258 01:31:48,840 --> 01:31:50,280 SERVICES USED BY THE NATIONAL 2259 01:31:50,280 --> 01:31:52,640 CLINICAL TRIALS NETWORK. IT 2260 01:31:52,640 --> 01:31:54,320 PROVIDES CONTACTING AUTHORITY 2261 01:31:54,320 --> 01:31:56,760 FOR THAT. IT WILL -- IT IS 2262 01:31:56,760 --> 01:32:00,720 PARTICIPATING IN SOME OF OUR 2263 01:32:00,720 --> 01:32:02,200 ARPA H ACTIVITIES AS A 2264 01:32:02,200 --> 01:32:04,760 CONTRACTING ORGANIZAT ORGANIZATO 2265 01:32:04,760 --> 01:32:06,640 FREDERICK IS THERE TO SUPPORT 2266 01:32:06,640 --> 01:32:10,880 LIKE EVERYTHING WE DO AND WE GET 2267 01:32:10,880 --> 01:32:12,280 INCREDIBLE VALUE OUT OF BEING 2268 01:32:12,280 --> 01:32:18,000 ABLE TO HAVE THAT FFRDC 2269 01:32:18,000 --> 01:32:21,000 MECHANISM SO THE BOTTOM LINE IS 2270 01:32:21,000 --> 01:32:24,440 ANYTHING THAT IS EFFECTIVE AT 2271 01:32:24,440 --> 01:32:26,440 NCI IS GOING TO HAVE A COUNTER 2272 01:32:26,440 --> 01:32:29,000 PART AFFECTED AT FREDERICK. PART 2273 01:32:29,000 --> 01:32:31,240 OF WHAT WE ARE DOING TODAY IS 2274 01:32:31,240 --> 01:32:33,080 WORKING THROUGH ALL THOSE 2275 01:32:33,080 --> 01:32:35,680 COMPLEX INTERRELATIONSHIPS AS WE 2276 01:32:35,680 --> 01:32:37,720 DECIDE EXACTLY WHAT IS THE MOST 2277 01:32:37,720 --> 01:32:41,360 EFFICIENT WAY TO USE OUR MONEY. 2278 01:32:41,360 --> 01:32:45,760 >>THANKS, MONICA. YSABEL, I SEE 2279 01:32:45,760 --> 01:32:50,400 YOUR HAND UP. 2280 01:32:50,400 --> 01:33:00,960 >>HOPEFULLY (INAUDIBLE) YOU WOK 2281 01:33:09,840 --> 01:33:11,800 THIS COMPLEX -- ALL THINGS BEING 2282 01:33:11,800 --> 01:33:13,480 FAIR IN LOVE AND WAR, ARE YOU 2283 01:33:13,480 --> 01:33:17,560 LOOKING AT METRICS TO SEE WHO 2284 01:33:17,560 --> 01:33:20,320 HAVE BEEN THOSE MOST RESPONSIVE 2285 01:33:20,320 --> 01:33:22,520 TO ACHIEVING ADDRESSING 2286 01:33:22,520 --> 01:33:26,200 DISPARITIES THROUGH THEIR CANCER 2287 01:33:26,200 --> 01:33:29,040 CENTERS AND WHETHER THAT MIGHT 2288 01:33:29,040 --> 01:33:31,800 MAKE SOME DECISIONS IS ABOUT 2289 01:33:31,800 --> 01:33:33,320 WHERE IT'S FAIR TO CUT AND WHAT 2290 01:33:33,320 --> 01:33:36,320 IS FAIR TO CUT AND WHETHER OR 2291 01:33:36,320 --> 01:33:39,320 NOT THOSE PARTICULAR CENTERS 2292 01:33:39,320 --> 01:33:43,640 DOING THE WORK MIGHT GET A 2293 01:33:43,640 --> 01:33:45,640 LITTLE INCENTIVE OPPOSED TO 2294 01:33:45,640 --> 01:33:50,560 OTHERS. I JUST -- IN A TIME 2295 01:33:50,560 --> 01:33:52,040 WHERE FINALLY WE THINK 2296 01:33:52,040 --> 01:33:55,960 DISPARITIES ARING WITH ADDRES 2297 01:33:55,960 --> 01:33:57,440 ADDRESSED, -- ARE BEING 2298 01:33:57,440 --> 01:33:58,600 ADDRESSED AND STILL BEING 2299 01:33:58,600 --> 01:34:01,840 UNDERFUNDED RESEARCH IT WOULD BE 2300 01:34:01,840 --> 01:34:03,880 UNCONSCIONABLE TO STEP BACKWARDS 2301 01:34:03,880 --> 01:34:05,640 AT THE CANCER CENTERS WHERE YOU 2302 01:34:05,640 --> 01:34:08,040 SEE THEY HAVEN'T DONE ENOUGH BUT 2303 01:34:08,040 --> 01:34:12,120 NAY ARE TRYING AND THEN WE GET 2304 01:34:12,120 --> 01:34:14,080 THIS CUT THAT MIGHT FORCE 2305 01:34:14,080 --> 01:34:15,520 CHANGES AND ONCE AGAIN STEP 2306 01:34:15,520 --> 01:34:22,520 BACKS. 2307 01:34:22,520 --> 01:34:25,400 >>IS MONICA ON? 2308 01:34:25,400 --> 01:34:27,240 >>I DON'T KNOW IF SHE -- SEEMED 2309 01:34:27,240 --> 01:34:28,400 LIKE SHE WAS HAVING CONNECTION 2310 01:34:28,400 --> 01:34:33,760 ISSUES EARLIER, I WONNER IF WE 2311 01:34:33,760 --> 01:34:34,000 LOST -- 2312 01:34:34,000 --> 01:34:39,200 >>LET ME TRY TO ADDRESS YOUR 2313 01:34:39,200 --> 01:34:40,840 IMPORTANT QUESTION. THERE ARE 2314 01:34:40,840 --> 01:34:45,080 MANY FACTORS THAT CANCER CENTERS 2315 01:34:45,080 --> 01:34:49,600 ARE JUDGED BY. AND THE PEER 2316 01:34:49,600 --> 01:34:51,520 REVIEW PROCESS CERTAINLY HAS 2317 01:34:51,520 --> 01:34:54,120 BEEN LOOKING AT THE ISSUE THAT 2318 01:34:54,120 --> 01:34:57,920 YOU ARE -- THAT YOU ARE 2319 01:34:57,920 --> 01:35:02,240 DESCRIBING. THIS HAS BECOME AS 2320 01:35:02,240 --> 01:35:05,640 YOU ARE WELL AWARE, A VERY 2321 01:35:05,640 --> 01:35:07,960 IMPORTANT ISSUE IN TERMS OF 2322 01:35:07,960 --> 01:35:12,440 COMMUNITY OUTREACH, ET CETERA. 2323 01:35:12,440 --> 01:35:18,160 WHETHER THE -- WHETHER THE 2324 01:35:18,160 --> 01:35:21,880 CHANGES IN FUNDING MIGHT OCCUR 2325 01:35:21,880 --> 01:35:26,560 WITH ONLY THAT CRITERION, I 2326 01:35:26,560 --> 01:35:27,560 DOUBT, I WOULD IMAGINE IT WOULD 2327 01:35:27,560 --> 01:35:30,080 BE ONE OF NUMEROUS CRITERIA THAT 2328 01:35:30,080 --> 01:35:33,800 WOULD BE CONSIDERED. MONICA DID 2329 01:35:33,800 --> 01:35:36,680 YOU HEAR YSABEL'S QUESTION? 2330 01:35:36,680 --> 01:35:38,760 >>I DROPPED I HAD TO GET BACK 2331 01:35:38,760 --> 01:35:39,200 IN. 2332 01:35:39,200 --> 01:35:42,120 >>IF I MAY PARAPHRASE, YSABEL 2333 01:35:42,120 --> 01:35:44,360 CORRECT ME IF I'M WRONG, YSABEL 2334 01:35:44,360 --> 01:35:46,560 WAS WONDERING IN TERMS OF THE 2335 01:35:46,560 --> 01:35:49,880 CANCER CENTERS WHETHER IT MIGHT 2336 01:35:49,880 --> 01:36:00,360 BE POSSIBLE TO INTERNALLY AS 2337 01:36:11,080 --> 01:36:12,400 RESEARCH LEVEL OR EXTERNALLY AT 2338 01:36:12,400 --> 01:36:14,960 DEVELOPING THAT, INCLUDING MORE 2339 01:36:14,960 --> 01:36:16,560 COMMUNITIES OF COLOR AT THE 2340 01:36:16,560 --> 01:36:18,600 COMPREHENSIVE CANCER CENTERS FOR 2341 01:36:18,600 --> 01:36:21,120 CARE,, JUST WONDERING IF THERE 2342 01:36:21,120 --> 01:36:22,680 IS ANY METRICS OR MEASUREMENTS 2343 01:36:22,680 --> 01:36:24,400 YOU ARE LOOKING AT. 2344 01:36:24,400 --> 01:36:27,680 >>MONICA, I BASICALLY SAID IT 2345 01:36:27,680 --> 01:36:31,000 IS COMPLICATED. DIFFERENT 2346 01:36:31,000 --> 01:36:31,240 FACTORS. 2347 01:36:31,240 --> 01:36:33,560 >>I KNOW. AND OUR CENTER FOR 2348 01:36:33,560 --> 01:36:36,760 REDUCING HEALTHCARE DISPARITIES 2349 01:36:36,760 --> 01:36:38,280 LOOKS AT WORK FORCE IN GREAT 2350 01:36:38,280 --> 01:36:39,960 DETAIL AS RESPONSIBLE FOR THAT 2351 01:36:39,960 --> 01:36:42,760 AND IS INVOLVED IN MANY -- IN 2352 01:36:42,760 --> 01:36:45,560 SUPPORT MECHANISMS TO HELP. 2353 01:36:45,560 --> 01:36:47,240 THERE IS MULTIPLE MECHANISMS 2354 01:36:47,240 --> 01:36:48,840 THAT ARE BROUGHT TO BARE TO 2355 01:36:48,840 --> 01:36:53,840 SUPPORT THESE ISSUES. WE HAVE -- 2356 01:36:53,840 --> 01:36:55,760 SOME DIRECTED DIRECTLY THROUGH 2357 01:36:55,760 --> 01:36:56,760 CANCER CENTERS THEMSELVES AND 2358 01:36:56,760 --> 01:36:58,320 OTHERS ARE INDEPENDENT 2359 01:36:58,320 --> 01:37:03,760 RESEARCHER INITIATED AWARDS. 2360 01:37:03,760 --> 01:37:06,800 >>AMY. 2361 01:37:06,800 --> 01:37:09,920 >>ONE OF THE THINGS WE ARE 2362 01:37:09,920 --> 01:37:11,880 GOING THROUGH, I SUSPECT 2363 01:37:11,880 --> 01:37:12,880 EVERYBODY HAS THE SAME ISSUES 2364 01:37:12,880 --> 01:37:14,960 THAT THE CENTERS WERE IS WHERE 2365 01:37:14,960 --> 01:37:16,520 YOU GET CANCER CENTER DIRECTOR 2366 01:37:16,520 --> 01:37:18,440 WHO SPENDS TWO YEARS RAMPING UP 2367 01:37:18,440 --> 01:37:22,040 TO THE RENEWAL. THIS IS AN 2368 01:37:22,040 --> 01:37:23,960 EXTREMELY TIME CONSUMING 2369 01:37:23,960 --> 01:37:26,000 ENDEAVOR THAT INVOLVES HUNDREDS 2370 01:37:26,000 --> 01:37:27,840 OF FACULTY MEMBERS WRITING 2371 01:37:27,840 --> 01:37:30,800 REPORTS, ET CETERA. IN REALITY 2372 01:37:30,800 --> 01:37:35,880 WE ARE LOOK FOR KEY METRICS. SO 2373 01:37:35,880 --> 01:37:37,080 WHAT ABOUT STREAMLINING AND 2374 01:37:37,080 --> 01:37:39,280 GETTING AWAY FROM THE 2375 01:37:39,280 --> 01:37:40,680 DISTRACTIONS OF THESE 2376 01:37:40,680 --> 01:37:42,360 INTRA-ADVISORY BOARDS, EXTERNAL 2377 01:37:42,360 --> 01:37:44,080 ADVISORY BOARDS. WE TELL THE 2378 01:37:44,080 --> 01:37:46,840 DIRECTORS THESE ARE THE KEY 2379 01:37:46,840 --> 01:37:49,080 CRITERIA. DO YOU HAVE THIS MANY 2380 01:37:49,080 --> 01:37:50,200 COMMUNITY BASED CLINICAL TRIALS, 2381 01:37:50,200 --> 01:37:53,000 IF THAT IS A KEY CLINICAL, 2382 01:37:53,000 --> 01:37:54,680 REMEMBER WE WANT THESE CENTERS 2383 01:37:54,680 --> 01:37:57,280 BY, IT IS IN THE PRINTERER. WE 2384 01:37:57,280 --> 01:37:58,640 SEND THE STANDARDIZED FORM. 2385 01:37:58,640 --> 01:37:59,760 TRAINING GRANTS, HOW MANY, WHERE 2386 01:37:59,760 --> 01:38:01,920 ARE THEY PUBLISHED AT, HOW MANY 2387 01:38:01,920 --> 01:38:04,160 FOLKS WENT INTO ACADEMICS. T 2388 01:38:04,160 --> 01:38:07,480 WHAT IS THE NUMBER, SCORE. HOW 2389 01:38:07,480 --> 01:38:08,680 MANY PEOPLE HOW MANY CLINICAL 2390 01:38:08,680 --> 01:38:15,560 TRIALS. INTERVENTIONAL VERSUS 2391 01:38:15,560 --> 01:38:17,680 JUST SIMPLY ANALYSIS SORT OF 2392 01:38:17,680 --> 01:38:20,080 STUDIES OR RADIOGRAPHIC STUDIES 2393 01:38:20,080 --> 01:38:21,520 THEY JUST SIMPLY GIVE US THE 2394 01:38:21,520 --> 01:38:23,200 NUMBERS THERE, IS A SCORE. THAT 2395 01:38:23,200 --> 01:38:26,200 GIVES THEM THEIR BASELINE 2396 01:38:26,200 --> 01:38:28,800 FUNDING. AND IT REDUCES ALL OF 2397 01:38:28,800 --> 01:38:32,440 THE NEEDLESS WORK. BECAUSE WE 2398 01:38:32,440 --> 01:38:33,920 ARE LOOKING FOR CERTAIN THINGS 2399 01:38:33,920 --> 01:38:36,040 WHY CAN WE NOT SIMPLIFY THE 2400 01:38:36,040 --> 01:38:37,480 PROCESS ON BOTH SIDES OF THE 2401 01:38:37,480 --> 01:38:43,880 STREET. 2402 01:38:43,880 --> 01:38:45,680 >>MUTED. 2403 01:38:45,680 --> 01:38:48,800 >>I CAN START. AND SAY THAT I'M 2404 01:38:48,800 --> 01:38:50,960 ABSOLUTELY IN FAVOR OF REDUCING 2405 01:38:50,960 --> 01:38:53,240 WORK THAT BRINGS NO VALUE. 2406 01:38:53,240 --> 01:38:56,640 ABSOLUTELY. HOWEVER, IN MY 2407 01:38:56,640 --> 01:38:59,080 PREVIOUS LIFE I SERVED ON MANY 2408 01:38:59,080 --> 01:39:03,040 CANCER CENTER ADVISORY BOARDS. I 2409 01:39:03,040 --> 01:39:06,280 ALSO WAS THE RECIPIENT AT MY OWN 2410 01:39:06,280 --> 01:39:08,480 CANCER CENTER OF INTERACTION AND 2411 01:39:08,480 --> 01:39:10,360 ADVICE FROM THE VARIOUS ADVISORY 2412 01:39:10,360 --> 01:39:15,040 BOARDS AND INTERACTIONS. AND I 2413 01:39:15,040 --> 01:39:16,800 THINK THEY WERE INCREDIBLY 2414 01:39:16,800 --> 01:39:18,200 VALUABLE THEY HELPED ESTABLISH 2415 01:39:18,200 --> 01:39:19,640 RELATIONSHIPS, NETWORKING, 2416 01:39:19,640 --> 01:39:22,160 ELIMINATED SILOS, LED TO JOINT 2417 01:39:22,160 --> 01:39:23,440 PROGRAMS AND WAS IN ADDITION TO 2418 01:39:23,440 --> 01:39:26,360 HELPING A CANCER CENTER COME 2419 01:39:26,360 --> 01:39:30,880 FORWARD AND PRODUCE AN EFFECTIVE 2420 01:39:30,880 --> 01:39:32,480 LIST OF PROGRAMS BECAME SOME OF 2421 01:39:32,480 --> 01:39:34,920 THE MORE VALUABLE INTERACTIONS 2422 01:39:34,920 --> 01:39:36,120 AND RELATIONSHIPS WITH 2423 01:39:36,120 --> 01:39:38,440 COLLEAGUES I HAD IN MY -- AT 2424 01:39:38,440 --> 01:39:40,800 THAT PHASE OF MY PROFESSIONAL 2425 01:39:40,800 --> 01:39:42,440 LIFE. SO I HEAR YOU WHEN IT 2426 01:39:42,440 --> 01:39:44,000 COMES TO ACTIVITIES THAT DON'T 2427 01:39:44,000 --> 01:39:47,760 PRODUCE VALUE, I GUESS I DON'T 2428 01:39:47,760 --> 01:39:49,720 THINK THAT INTERACTIONS WITHIN A 2429 01:39:49,720 --> 01:39:53,120 CANCER CENTER OR ACROSS 2430 01:39:53,120 --> 01:39:54,280 DIFFERENT CANCER CENTERS AND 2431 01:39:54,280 --> 01:39:56,360 DIFFERENT COMMUNITIES IN FORM OF 2432 01:39:56,360 --> 01:39:58,400 ADVISORY BOARDS. I PERSONALLY 2433 01:39:58,400 --> 01:40:01,320 THINK THOSE BRING VALUE. 2434 01:40:01,320 --> 01:40:05,000 >>THAT MAY BE -- THAT IS 2435 01:40:05,000 --> 01:40:06,440 ABSOLUTELY TRUE BUT SO MUCH IS A 2436 01:40:06,440 --> 01:40:08,720 DOG AND PONY SHOW, LET'S BE 2437 01:40:08,720 --> 01:40:10,440 HONEST. EVERYBODY IS BRINGING 2438 01:40:10,440 --> 01:40:11,760 OUT THEIR HIGHLIGHTS THEY ARE 2439 01:40:11,760 --> 01:40:13,640 TRYING TO IMPRESS THE EXTERNAL 2440 01:40:13,640 --> 01:40:14,800 ADVISORY BOARD, ET CETERA AS 2441 01:40:14,800 --> 01:40:16,720 OPPOSED TO GETTING DOWN TO THE 2442 01:40:16,720 --> 01:40:18,160 BUSINESS OF WHAT IS THE AMOUNT 2443 01:40:18,160 --> 01:40:20,480 WE ARE GOING TO FUND FOR CANCER 2444 01:40:20,480 --> 01:40:22,520 CENTER BASED ON PERFORMANCE 2445 01:40:22,520 --> 01:40:24,120 ESSENTIALLY THAT IS WHAT THIS IS 2446 01:40:24,120 --> 01:40:26,240 ABOUT. SO LET'S GIVE THEM A 2447 01:40:26,240 --> 01:40:28,160 MATRIX AND SAY OKAY, IF YOU GO 2448 01:40:28,160 --> 01:40:31,040 ABOVE THIS LEVEL OF PERFORMANCE 2449 01:40:31,040 --> 01:40:32,600 THEN THIS ADDITIONAL AMOUNT. IF 2450 01:40:32,600 --> 01:40:34,400 YOU ARE ADDRESSING CATCHMENT YOU 2451 01:40:34,400 --> 01:40:37,080 GET ADDITIONAL AMOUNT HERE, 2452 01:40:37,080 --> 01:40:38,560 ENHANCING DIVERSITY IN YOUR 2453 01:40:38,560 --> 01:40:40,440 COMMUNITY, YOU GET THIS MUCH 2454 01:40:40,440 --> 01:40:41,800 ADDITIONAL AMOUNT. AS OPPOSED 2455 01:40:41,800 --> 01:40:44,840 TO, IF THEY WANT TO CONVENE 2456 01:40:44,840 --> 01:40:46,440 EXTERNAL ADVISORY BOARD TO 2457 01:40:46,440 --> 01:40:47,560 CONFORM PROGRAMS THEY CAN DO 2458 01:40:47,560 --> 01:40:49,080 THIS. I'M SAYING THAT IS TAKING 2459 01:40:49,080 --> 01:40:51,280 AN ENORMOUS AMOUNT OF EFFORT 2460 01:40:51,280 --> 01:40:52,480 AWAY FROM SCIENCE SO THAT 2461 01:40:52,480 --> 01:40:53,960 SOMEBODY CAN CREATE PRETTY 2462 01:40:53,960 --> 01:40:55,520 GRAPHS AND ALL THIS OTHER STUFF 2463 01:40:55,520 --> 01:40:57,200 FOR A LIMITED NUMBER OF PEOPLE 2464 01:40:57,200 --> 01:40:59,960 TO REVIEW AS OPPOSED TO WHEN WE 2465 01:40:59,960 --> 01:41:01,880 ARE INTERESTED IN THE KEY 2466 01:41:01,880 --> 01:41:03,160 METRICS WHICH IS ARE THEY 2467 01:41:03,160 --> 01:41:04,160 TRAINING PEOPLE THAT ARE GOING 2468 01:41:04,160 --> 01:41:07,080 INTO ACADEMIC MEDICINE OR SIZE 2469 01:41:07,080 --> 01:41:10,200 AND IF SO, WHAT IS THE NUMBER 2470 01:41:10,200 --> 01:41:11,240 FOR THIS PARTICULAR INSTITUTION. 2471 01:41:11,240 --> 01:41:13,640 HOW MANY INTERVENTIONAL CLINICAL 2472 01:41:13,640 --> 01:41:15,040 TRIALS ARE THEY RUNNING. HOW 2473 01:41:15,040 --> 01:41:16,680 MANY DIVERSIFIED PATIENTS ARE 2474 01:41:16,680 --> 01:41:18,640 THEY PUTTING ON THEIR CLINICAL 2475 01:41:18,640 --> 01:41:20,320 TRIALS? I SUSPECT WE CAN ALL 2476 01:41:20,320 --> 01:41:22,760 SORT OF AGREE ON SOME KEY 2477 01:41:22,760 --> 01:41:25,240 METRICS AS OPPOSED TO TRYING TO 2478 01:41:25,240 --> 01:41:27,840 COVER THIS ALL IN ADDITIONAL 2479 01:41:27,840 --> 01:41:29,920 DETAIL THAT MAY NOT NECESSARILY 2480 01:41:29,920 --> 01:41:31,720 BE NECESSARY FOR US MAKING THESE 2481 01:41:31,720 --> 01:41:33,400 KEY FUNDING DECISIONS FOR THESE 2482 01:41:33,400 --> 01:41:34,520 CANCER CENTERS AND IT IS 2483 01:41:34,520 --> 01:41:37,040 REDUCING THE EFFORT FOR THEM TO 2484 01:41:37,040 --> 01:41:40,800 RENEG. 2485 01:41:40,800 --> 01:41:44,280 >>INTERESTING I THINK JUST SORT 2486 01:41:44,280 --> 01:41:49,840 OF METRICS BASED APPROACH, 2487 01:41:49,840 --> 01:41:50,880 DEFINITELY SOMETHING THAT WE CAN 2488 01:41:50,880 --> 01:41:54,440 HAVE FOLLOW-UP DISCUSSION AROUND 2489 01:41:54,440 --> 01:41:55,960 FOR SURE. I GUESS WE HAVE A 2490 01:41:55,960 --> 01:41:58,160 COUPLE MORE MINUTES. LOVE TO 2491 01:41:58,160 --> 01:41:59,840 HEAR MORE ABOUT THE PRODUCTS 2492 01:41:59,840 --> 01:42:03,720 ABOUT THE ORIGINAL MOON SHOT. 2493 01:42:03,720 --> 01:42:06,280 WHEN WE DO NOW, ALL THE 2494 01:42:06,280 --> 01:42:08,120 INVESTMENT THAT WAS PUT INTO THE 2495 01:42:08,120 --> 01:42:09,760 -- AND SOME IS STILL ONGOING. IT 2496 01:42:09,760 --> 01:42:13,360 HAS BEEN AMAZING. RIGHT WHERE DO 2497 01:42:13,360 --> 01:42:18,160 WE GO WITH IT NOW? GIVEN THE 2498 01:42:18,160 --> 01:42:20,080 BUDGET SITUATION OR NOT, WHERE 2499 01:42:20,080 --> 01:42:22,280 DO WE TAKE THE PRODUCTS OF THE 2500 01:42:22,280 --> 01:42:24,840 ORIGINAL -- WHAT ARE THE 2501 01:42:24,840 --> 01:42:27,840 PRODUCTS AND HOW TO ADVANCE 2502 01:42:27,840 --> 01:42:29,880 THOSE THINGS FORWARD? I SEE A 2503 01:42:29,880 --> 01:42:31,400 SMILE ON YOUR FACE MONICA. 2504 01:42:31,400 --> 01:42:33,360 >>I WOULD LOVE TO TAKE ON THIS 2505 01:42:33,360 --> 01:42:34,600 QUESTION BUT I'M GOING TO HAND 2506 01:42:34,600 --> 01:42:38,680 OVER TO THE PERSON WHO IS REALLY 2507 01:42:38,680 --> 01:42:41,040 BEEN THE GUIDING LIGHT. WHY 2508 01:42:41,040 --> 01:42:43,160 DON'T YOU TAKE THIS ONE BECAUSE 2509 01:42:43,160 --> 01:42:45,360 I'M SURE -- YOU DESERVE THE 2510 01:42:45,360 --> 01:42:46,280 CREDIT. 2511 01:42:46,280 --> 01:42:48,800 >>I WANTED TO HEAR YOUR VOICE, 2512 01:42:48,800 --> 01:42:50,040 DANDANA. 2513 01:42:50,040 --> 01:42:52,600 >>IT IS PROBABLY WORTH HAVING A 2514 01:42:52,600 --> 01:42:57,320 MORE FORMAL PRESENTATION TO GIVE 2515 01:42:57,320 --> 01:42:58,920 AN OVERVIEW OF EVERYTHING THAT'S 2516 01:42:58,920 --> 01:43:00,720 BEEN ACCOMPLISHED, AS YOU 2517 01:43:00,720 --> 01:43:02,080 POINTED OUT IT IS GETTING 2518 01:43:02,080 --> 01:43:05,440 ENORMOUS ACROSS THE ENTIRE 2519 01:43:05,440 --> 01:43:08,440 SPECTRUM OF CANCER RESEARCH. WE 2520 01:43:08,440 --> 01:43:12,120 HAVE BEEN PLANNING OVER THE PAST 2521 01:43:12,120 --> 01:43:15,720 YEAR AND A HALF, TWO YEARS. HOW 2522 01:43:15,720 --> 01:43:21,560 DO WE MAINTAIN AND CONTINUE THE 2523 01:43:21,560 --> 01:43:23,000 SUPPORT THE REALLY IMPORTANT 2524 01:43:23,000 --> 01:43:25,440 RESEARCH STARTED UNDER THE MOON 2525 01:43:25,440 --> 01:43:26,800 SHOT? AND WE HAVE BEEN PLANNING 2526 01:43:26,800 --> 01:43:29,520 WHAT WE HAVE BEEN CALLING A SOFT 2527 01:43:29,520 --> 01:43:34,000 LANDING IF YOU WILL. NUMBER OF 2528 01:43:34,000 --> 01:43:35,560 PROGRAMS HAVE ALREADY COMPLETED 2529 01:43:35,560 --> 01:43:39,000 THE WORK THEY SET OUT TO DO. 2530 01:43:39,000 --> 01:43:42,000 OTHERS HAVE ALREADY TRANSITIONED 2531 01:43:42,000 --> 01:43:44,560 TO RPG FUNDING. SO THE NEW 2532 01:43:44,560 --> 01:43:47,240 FUNDING IS BUILDING ON WHAT WAS 2533 01:43:47,240 --> 01:43:50,560 ACCOMPLISHED BY THE MOON SHOT 2534 01:43:50,560 --> 01:43:54,400 AND THAT IS NEW PROGRAMS. THERE 2535 01:43:54,400 --> 01:43:58,000 ARE OTHER PROGRAMS THAT NEED TO 2536 01:43:58,000 --> 01:44:01,000 BE SLOWLY TRANSITIONED OVER SO 2537 01:44:01,000 --> 01:44:03,360 WE HAVE BEEN BUDGETING TO ALLOW 2538 01:44:03,360 --> 01:44:06,880 SOME OF THOSE TO CONTINUE OR A 2539 01:44:06,880 --> 01:44:10,680 YEAR OR TWO UNDER MOON SHOT 2540 01:44:10,680 --> 01:44:12,840 FUNDING, AS THE RPG FUNDING 2541 01:44:12,840 --> 01:44:14,840 PICKS UP, WE ARE TAKING INTO 2542 01:44:14,840 --> 01:44:17,720 ACCOUNT AS WE THINK ABOUT IT 2543 01:44:17,720 --> 01:44:22,640 NOW, WHAT THE POTENTIAL FLAT 2544 01:44:22,640 --> 01:44:24,120 BUDGET, THE NEW BUDGETING MIGHT 2545 01:44:24,120 --> 01:44:26,680 MEAN SO WE DO HAVE MOON SHOT 2546 01:44:26,680 --> 01:44:30,000 FUNDS STILL THAT WE SET ASIDE TO 2547 01:44:30,000 --> 01:44:31,400 BE ABLE TO CONTINUE SUPPORT SOME 2548 01:44:31,400 --> 01:44:34,680 OF THOSE CRITICAL MOON SHOT 2549 01:44:34,680 --> 01:44:36,160 PROGRAMS. WE ARE HOPING THAT WE 2550 01:44:36,160 --> 01:44:40,120 CAN GET THROUGH THE NEXT YEAR OR 2551 01:44:40,120 --> 01:44:42,480 TWO WITH CONTINUED SUPPORT FOR 2552 01:44:42,480 --> 01:44:44,680 THOSE MOON SHOT PROGRAMS TO THEN 2553 01:44:44,680 --> 01:44:49,000 BE ABLE TO GO TO THE NEXT PHASE 2554 01:44:49,000 --> 01:44:53,880 WITH APPROPRIATED FUNDS. HAPPY 2555 01:44:53,880 --> 01:44:55,720 TO GIVE YOU A PRESENTATION ON 2556 01:44:55,720 --> 01:44:56,200 THE SCIENCE. 2557 01:44:56,200 --> 01:44:58,760 >>THAT WOULD BE GREAT FOR 2558 01:44:58,760 --> 01:45:02,000 UPCOMING MEETING. NOT DETAILS ON 2559 01:45:02,000 --> 01:45:04,800 ANY SPECIFIC PROGRAM BUT MOON 2560 01:45:04,800 --> 01:45:07,880 SHOT AS A WHOLE AND OTHER PLANS, 2561 01:45:07,880 --> 01:45:09,880 ADVANCE IT FORWARD. THANKS. 2562 01:45:09,880 --> 01:45:12,320 OKAY. I THINK WE ARE ABOUT OUT 2563 01:45:12,320 --> 01:45:15,000 OF TIME FOR THIS PARTICULAR 2564 01:45:15,000 --> 01:45:17,320 COMPONENT OF THE MEETING. I 2565 01:45:17,320 --> 01:45:20,880 THINK NOW WE HAVE A BREAK, 2566 01:45:20,880 --> 01:45:22,720 15-MINUTE BREAK, WE WILL 2567 01:45:22,720 --> 01:45:25,600 RECONVENE AT 3 P.M. EASTERN 2568 01:45:25,600 --> 01:45:26,920 TIME. WE WILL HAVE A 2569 01:45:26,920 --> 01:45:27,880 PRESENTATION ON COLLABORATIVE 2570 01:45:27,880 --> 01:45:29,880 APPROACHES TO ACCELERATE BETTER 2571 01:45:29,880 --> 01:45:32,160 THERAPIES FOR PATIENTS WITH RARE 2572 01:45:32,160 --> 01:45:34,720 TUMORS. DON'T LOG OFF JUST TURN 2573 01:45:34,720 --> 01:45:36,320 OFF YOUR CAMERAS AND MICROPHONES 2574 01:45:36,320 --> 01:45:38,240 AND PLEASE LOG BACK IN PROMPTLY 2575 01:45:38,240 --> 01:45:39,160 COUPLE OF MINUTES BEFORE THE TOP 2576 01:45:39,160 --> 01:45:44,080 OF THE HOUR. 2577 01:45:44,080 --> 01:45:45,760 >>OUR NEXT PRESENTATION IS 2578 01:45:45,760 --> 01:45:47,400 COLLABORATIVE APPROACHES TO 2579 01:45:47,400 --> 01:45:49,000 ACCELERATE THERAPIES FOR 2580 01:45:49,000 --> 01:45:51,320 PATIENTS WITH RARE TUMORS GIVEN 2581 01:45:51,320 --> 01:45:53,360 BY DRS. BRING JET WIDEMANN, 2582 01:45:53,360 --> 01:45:56,720 CHIEF PEDIATRIC DOG BRANCH, 2583 01:45:56,720 --> 01:45:57,960 CENTER FOR CANCER RESEARCH AS 2584 01:45:57,960 --> 01:45:59,640 WELL AS SPECIAL ADVISOR TO THE 2585 01:45:59,640 --> 01:46:03,440 NCI DIRECTOR FOR CHILDHOOD 2586 01:46:03,440 --> 01:46:07,000 CANCERS, AND CAR LOSS REILLY, 2587 01:46:07,000 --> 01:46:08,960 PEDIATRIC ONCOLOGY BRANCH, 2588 01:46:08,960 --> 01:46:11,040 DIRECTOR NCI RARE TUMOR 2589 01:46:11,040 --> 01:46:12,040 INITIATIVE CENTER FOR CANCER 2590 01:46:12,040 --> 01:46:22,040 RESEARCH. BRIBGETTE AND CARLIN. 2591 01:46:22,040 --> 01:46:22,720 >>THANK YOU FOR -- 2592 01:46:22,720 --> 01:46:26,560 >>WE ARE SEEING THE PRESENTER 2593 01:46:26,560 --> 01:46:30,640 VIEW RIGHT NOW,. THERE YOU GO. 2594 01:46:30,640 --> 01:46:31,680 >>THANK YOU FOR THE OPPORTUNITY 2595 01:46:31,680 --> 01:46:32,880 TO PRESENT ON COLLABORATIVE 2596 01:46:32,880 --> 01:46:35,400 APPROACHES TO ACCELERATE BETTER 2597 01:46:35,400 --> 01:46:37,440 THERAPIES FOR PATIENTS WITH RARE 2598 01:46:37,440 --> 01:46:39,560 TUMORS. DR. REILLY AND I AND I 2599 01:46:39,560 --> 01:46:41,640 WILL PRESENT THIS ON BEHALF OF A 2600 01:46:41,640 --> 01:46:44,320 NUMBER OF COLLABORATIONS, 2601 01:46:44,320 --> 01:46:46,840 INTRAMURAL AND AS WELL AS 2602 01:46:46,840 --> 01:46:52,800 EXTRAMURAL I'M PROVIDING AN 2603 01:46:52,800 --> 01:46:54,120 OVERVIEW OF THE TALK HERE. I 2604 01:46:54,120 --> 01:46:57,400 WILL START WITH A DEFINITION OF 2605 01:46:57,400 --> 01:46:59,720 RARE TUMORS AND CHALLENGES 2606 01:46:59,720 --> 01:47:01,960 ASSOCIATED WITH RARE TUMORS. 2607 01:47:01,960 --> 01:47:03,880 THEN GIVE AN OVERVIEW OF 2608 01:47:03,880 --> 01:47:06,400 LANDSCAPE ANALYSIS CONDUCTED OF 2609 01:47:06,400 --> 01:47:07,840 ONGOING RARE TUMOR EFFORTS, 2610 01:47:07,840 --> 01:47:10,840 PROVIDE RESULTS ON THE CANCER 2611 01:47:10,840 --> 01:47:13,800 MOON SHOT SUPPORT MY PEDIATRIC 2612 01:47:13,800 --> 01:47:15,680 AND RARE TUMOR NETWORK WHICH 2613 01:47:15,680 --> 01:47:17,240 LINKS TO THE NCI CHILDHOOD 2614 01:47:17,240 --> 01:47:21,120 CANCER DATA INITIATIVE NATIONAL 2615 01:47:21,120 --> 01:47:23,240 RARE TUMOR WHERE WE HOPE TO 2616 01:47:23,240 --> 01:47:24,480 ESTABLISH INTERNATIONAL 2617 01:47:24,480 --> 01:47:26,040 COLLABORATION AS WELL. THEN DR. 2618 01:47:26,040 --> 01:47:28,480 REILLY WILL TAKE OVER TO PRESENT 2619 01:47:28,480 --> 01:47:32,960 ON EXCITING NEW DEVELOP PUBLIC 2620 01:47:32,960 --> 01:47:34,640 PRIVATE PARTNERSHIP TO ENABLE 2621 01:47:34,640 --> 01:47:36,360 DRUG DEVELOPMENT FOR ULTRA RARE 2622 01:47:36,360 --> 01:47:41,400 TUMORS. RARE TUMORS ARE DEFINED 2623 01:47:41,400 --> 01:47:43,520 BY INCIDENCE OF WHETHER HE SAYS 2624 01:47:43,520 --> 01:47:47,240 THAN 150 MILLION PER YEAR. 25% 2625 01:47:47,240 --> 01:47:49,480 OF ALL CANCER DIAGNOSIS ACCOUNT 2626 01:47:49,480 --> 01:47:52,680 FOR RARE TUMORS AND THE SAME 2627 01:47:52,680 --> 01:47:53,560 PERCENTAGE ACCOUNTS FOR CANCER 2628 01:47:53,560 --> 01:47:55,240 DEATH SO IT IS SUBSTANTIAL 2629 01:47:55,240 --> 01:47:58,080 BURDEN. IMPORTANTLY, ALL 2630 01:47:58,080 --> 01:48:01,200 PEDIATRIC CANCER CNS CANCER 2631 01:48:01,200 --> 01:48:02,760 SARCOMAS ARE RARE. I KNOW YOU 2632 01:48:02,760 --> 01:48:04,000 ARE AWARE OF CHALLENGES FOR 2633 01:48:04,000 --> 01:48:05,240 PATIENTS WHICH INCLUDE A LONG 2634 01:48:05,240 --> 01:48:08,680 TIME TO DIAGNOSIS, LIMITED 2635 01:48:08,680 --> 01:48:11,160 EXPERT TEE AT MANY MEDICAL 2636 01:48:11,160 --> 01:48:11,880 CENTERS FREQUENTLY LACK OF 2637 01:48:11,880 --> 01:48:14,080 STANDARD OF CARE AND LIMITED 2638 01:48:14,080 --> 01:48:17,000 SOCIAL AND ADVOCACY SUPPORT. THE 2639 01:48:17,000 --> 01:48:18,400 CHALLENGES FOR RESEARCH ARE JUST 2640 01:48:18,400 --> 01:48:20,000 AS IMPORTANT WHERE IT IS 2641 01:48:20,000 --> 01:48:21,480 DIFFICULT TO DEVELOP CLINICAL 2642 01:48:21,480 --> 01:48:23,600 TRIALS FOR RARE CANCERS, IT IS 2643 01:48:23,600 --> 01:48:24,680 HARD TO ENROLL ON THESE TRIALS. 2644 01:48:24,680 --> 01:48:27,600 WE HAVE LIMITED TOOLS AND 2645 01:48:27,600 --> 01:48:29,080 DIVERSITY OF PRE-CLINICAL 2646 01:48:29,080 --> 01:48:30,200 MODELS, THERE'S LIMITED SUPPORT 2647 01:48:30,200 --> 01:48:33,920 FROM GRANTING AGENCIES AND 2648 01:48:33,920 --> 01:48:37,320 LIMITED INTEREST AND INCENTIVE 2649 01:48:37,320 --> 01:48:39,120 FOR INDUSTRY TO COLLABORATE DR. 2650 01:48:39,120 --> 01:48:41,560 REILLY WILL ADDRESS WITH PRIVATE 2651 01:48:41,560 --> 01:48:45,560 PUBLIC PARTNERSHIP. IN 2019 WHEN 2652 01:48:45,560 --> 01:48:49,400 THE NCI CHILDHOOD KAREN DATA 2653 01:48:49,400 --> 01:48:50,840 INITIATIVE STARTED WE NOTICED 2654 01:48:50,840 --> 01:48:52,400 RARE TUMOR EFFORTS ONGOING 2655 01:48:52,400 --> 01:48:54,640 HOWEVER WE GOT THE SENSE THESE 2656 01:48:54,640 --> 01:48:56,360 EFFORTS WERE NOT ALL CONNECTED. 2657 01:48:56,360 --> 01:48:59,400 SO WE CONDUCTED INTERNET SEARCH 2658 01:48:59,400 --> 01:49:02,080 AND LITERATURE RESEARCH FOR RARE 2659 01:49:02,080 --> 01:49:03,960 TUMOR PROGRAMS AND ANYTHING THAT 2660 01:49:03,960 --> 01:49:07,280 WE COULD FIND. WE IDENTIFIED 76 2661 01:49:07,280 --> 01:49:09,720 PROGRAMS THROUGH THIS SEARCH. 2662 01:49:09,720 --> 01:49:12,240 WHICH WE WERE ABLE TO CONTACT 42 2663 01:49:12,240 --> 01:49:14,080 PROGRAMS. WE DEVELOPED A SURVEY 2664 01:49:14,080 --> 01:49:15,760 TO GET INFORMATION ABOUT THE 2665 01:49:15,760 --> 01:49:18,560 NATURE OF THESE PROGRAMS AND OF 2666 01:49:18,560 --> 01:49:20,320 THE 42 WE CONTACTED WE RECEIVED 2667 01:49:20,320 --> 01:49:23,800 23 RESPONSES. AS YOU CAN SEE, 2668 01:49:23,800 --> 01:49:30,160 THE SOURCES OF FUNDING WERE 2669 01:49:30,160 --> 01:49:31,640 PHILANTHROPY ADVOCACY AND 2670 01:49:31,640 --> 01:49:33,440 GOVERNMENT. MIDDLE COLUMN YOU 2671 01:49:33,440 --> 01:49:35,760 SEE THE DATA COLLECTED INCLUDING 2672 01:49:35,760 --> 01:49:36,880 CLINICAL DATA BIOSPECIMEN DATA 2673 01:49:36,880 --> 01:49:39,480 AND FAMILY HISTORY OF NOTE 2674 01:49:39,480 --> 01:49:41,440 THOUGH ONLY FEW PROGRAMS 2675 01:49:41,440 --> 01:49:44,000 CONDUCTED AND COMPLETED DATA 2676 01:49:44,000 --> 01:49:46,320 LONGITUDINALLY AND RATHER SMALL 2677 01:49:46,320 --> 01:49:47,360 NUMBER CONDUCTED PATIENT 2678 01:49:47,360 --> 01:49:49,000 REPORTED OUTCOMES. IN THE 2679 01:49:49,000 --> 01:49:51,760 EFFORTS. WHEN YOU LOOK AT THE 2680 01:49:51,760 --> 01:49:53,800 EFFORTS TO SHARE DATA IT IS 2681 01:49:53,800 --> 01:49:55,320 OBVIOUS NUMBER OF THE PROGRAMS 2682 01:49:55,320 --> 01:49:58,600 ARE SHARING THEIR DATA IN NIH 2683 01:49:58,600 --> 01:49:59,800 DATABASES BUT THERE WERE NUMBER 2684 01:49:59,800 --> 01:50:02,600 OF PROGRAMS SHARING DATA IN 2685 01:50:02,600 --> 01:50:05,040 OTHER DATABASES AND THEY 2686 01:50:05,040 --> 01:50:06,040 COMMENTED THAT IT IS DIFFICULT 2687 01:50:06,040 --> 01:50:07,760 TO FIND AND SHARE THE DATA AND 2688 01:50:07,760 --> 01:50:09,480 MAKE IT ACCESSIBLE WHICH IS 2689 01:50:09,480 --> 01:50:11,600 SOMETHING THE CCDI PLANS TO 2690 01:50:11,600 --> 01:50:18,400 ADDRESS. I WILL NOW OFFER YOU A 2691 01:50:18,400 --> 01:50:20,520 FAIR PEDIATRIC AND DIRECTIONAL 2692 01:50:20,520 --> 01:50:21,880 NETWORK IN SHORT MY PART WHICH 2693 01:50:21,880 --> 01:50:23,360 RECEIVES FUNDING FROM THE CANCER 2694 01:50:23,360 --> 01:50:25,760 MOON SHOT THROUGH THE PATIENT 2695 01:50:25,760 --> 01:50:27,000 ENGAGEMENT NETWORK, WHILE 2696 01:50:27,000 --> 01:50:28,360 EFFORTS WERE TO INCREASE PATIENT 2697 01:50:28,360 --> 01:50:30,160 AND FAMILY INVOLVEMENT IN RARE 2698 01:50:30,160 --> 01:50:32,280 TUMOR RESEARCH WITH THE ULTIMATE 2699 01:50:32,280 --> 01:50:33,880 GOAL TO DEVELOP NEW THERAPY FOR 2700 01:50:33,880 --> 01:50:36,800 RARE PEDIATRIC AND SOLID TUMORS 2701 01:50:36,800 --> 01:50:37,800 THROUGH INCREASE UNDERSTANDING 2702 01:50:37,800 --> 01:50:42,400 OF TUMOR BIOLOGY AND THE NATURAL 2703 01:50:42,400 --> 01:50:44,720 HISTORY. OUR GOAL WAS TO FOCUS 2704 01:50:44,720 --> 01:50:47,520 ON CHILDREN TEENS AND YOUNG 2705 01:50:47,520 --> 01:50:49,920 ADULTS WITH SOLID TUMORS, 2706 01:50:49,920 --> 01:50:51,720 HOWEVER FOR SOLID TUMORS THAT 2707 01:50:51,720 --> 01:50:53,600 OCCUR IN THESE GROUPS ALSO 2708 01:50:53,600 --> 01:50:55,640 OBSERVED IN ADULTS WE WANT TO 2709 01:50:55,640 --> 01:50:57,320 INCLUDE ADULT PATIENTS TO STUDY 2710 01:50:57,320 --> 01:51:00,960 BIOLOGY OF TUMORS ACROSS AGES. 2711 01:51:00,960 --> 01:51:04,480 OUR GOAL IS TO ENGAGE MULTIPLE 2712 01:51:04,480 --> 01:51:06,600 STAKEHOLDERS IN RESEARCH AS 2713 01:51:06,600 --> 01:51:07,840 PARTNERS, AND TO DEVELOP A 2714 01:51:07,840 --> 01:51:10,960 NATURAL HISTORY STUDY THAT WOULD 2715 01:51:10,960 --> 01:51:11,720 LONGITUDINALLY COLLECT MULTIPLE 2716 01:51:11,720 --> 01:51:13,840 DATA AS I WILL SHOW YOU LATER. 2717 01:51:13,840 --> 01:51:16,720 IN COLLABORATION WITH EXTRAMURAL 2718 01:51:16,720 --> 01:51:17,960 PARTNERS WE WILL ALSO PLANNING 2719 01:51:17,960 --> 01:51:20,080 TO HOST WORKSHOPS AND SYMPOSIA 2720 01:51:20,080 --> 01:51:22,880 ON RARE TUMORS TO DEVELOP EXPERT 2721 01:51:22,880 --> 01:51:25,440 CONSENSUS, AND TO HOST MULTI-DAY 2722 01:51:25,440 --> 01:51:29,000 CLINICS AT NIH ON RARE TUMORSS. 2723 01:51:29,000 --> 01:51:31,560 FOR THESE CONNECTS WE BRING 2724 01:51:31,560 --> 01:51:32,160 PATIENTS AND NATIONWIDE EXPERTS 2725 01:51:32,160 --> 01:51:33,800 TO THE NIH CLINICAL CENTER TO 2726 01:51:33,800 --> 01:51:38,600 STUDY RARE TUMORS JOINTLY. OUR 2727 01:51:38,600 --> 01:51:40,440 GOAL WAS TO ESTABLISH A 2728 01:51:40,440 --> 01:51:41,240 MULTI-NETWORK OF SITES TO 2729 01:51:41,240 --> 01:51:42,480 COLLABORATE AND I WILL SHOW YOU 2730 01:51:42,480 --> 01:51:44,600 IN A FEW MINUTES HOW WE 2731 01:51:44,600 --> 01:51:47,880 ACCOMPLISHED THIS FOR PEDIATRIC 2732 01:51:47,880 --> 01:51:50,280 SARCOMA AS AN EXAMPLE. THIS 2733 01:51:50,280 --> 01:51:52,480 SLIDE SHOWS SOME OF THE KEY 2734 01:51:52,480 --> 01:51:53,840 ACCOMPLISHMENTS OF MY PART. 2735 01:51:53,840 --> 01:51:55,440 FIRST WE WERE SUCCESSFUL IN 2736 01:51:55,440 --> 01:51:57,320 DEVELOPING A NATURAL HISTORY 2737 01:51:57,320 --> 01:52:00,160 STUDY WITH TUMOR SPECIFIC SUB 2738 01:52:00,160 --> 01:52:01,880 PROTOCOLS. WE WERE PREPARED 2739 01:52:01,880 --> 01:52:03,560 FROM THE GET GO FOR THE COVID 2740 01:52:03,560 --> 01:52:04,840 PANDEMIC BY ALLOWING PATIENTS TO 2741 01:52:04,840 --> 01:52:07,520 ENROLL REMOTELY OR IN PERSON AT 2742 01:52:07,520 --> 01:52:11,200 THE NIH CLINICAL CENTER. WE 2743 01:52:11,200 --> 01:52:14,560 ANALYZE TUMOR BLOOD SALIVA 2744 01:52:14,560 --> 01:52:16,240 BIOSPECIMENS, EXPANDED NIH RARE 2745 01:52:16,240 --> 01:52:20,440 TUMOR CLINICS AT THE NIH AND 2746 01:52:20,440 --> 01:52:21,400 PARTICIPATED AND CONTRIBUTED TO 2747 01:52:21,400 --> 01:52:23,000 THE INTERVENTIONAL TRIALS FOR 2748 01:52:23,000 --> 01:52:24,360 BOTH CHILDREN AND ADULTS WITH 2749 01:52:24,360 --> 01:52:27,720 RARE TUMORS FULL COLLABORATION 2750 01:52:27,720 --> 01:52:29,080 WITH THE NCI DEVELOPMENT OF 2751 01:52:29,080 --> 01:52:31,880 THERAPEUTICS CLINIC. ALSO HIGHLY 2752 01:52:31,880 --> 01:52:33,280 COMMITTED TO NOT ONLY COLLECTING 2753 01:52:33,280 --> 01:52:35,400 DATA BUT GETTING THE DATA INTO 2754 01:52:35,400 --> 01:52:36,760 SHAPE THEY CAN BE SUBMITTED TO 2755 01:52:36,760 --> 01:52:40,080 DB GAP AND SEE HERE THE DATA 2756 01:52:40,080 --> 01:52:42,600 FEELS WE HAVE FOR THE FIRST 200 2757 01:52:42,600 --> 01:52:44,880 PATIENTS AND WE HOPE TO RELEASE 2758 01:52:44,880 --> 01:52:48,720 THIS DATA PUBLICLY BY THE FOURTH 2759 01:52:48,720 --> 01:52:50,720 QUARTER OF THIS YEAR. THE NEXT 2760 01:52:50,720 --> 01:52:52,280 SLIDE GIVES AN OVERVIEW OF THE 2761 01:52:52,280 --> 01:52:54,400 NATURAL HISTORY STUDY FOR RARE 2762 01:52:54,400 --> 01:52:57,960 SOLID TUMORS. DR. MARY FRANCIS 2763 01:52:57,960 --> 01:53:00,880 (INAUDIBLE) AND DR. HEIDI 2764 01:53:00,880 --> 01:53:02,320 (INAUDIBLE) ADULT ONCOLOGISTS 2765 01:53:02,320 --> 01:53:05,040 BOTH ENSURE WE PUT IN MORE 2766 01:53:05,040 --> 01:53:06,200 PEDIATRIC PATIENTSND ADULT 2767 01:53:06,200 --> 01:53:09,080 PATIENTS. WE ARE CONDUCTING 2768 01:53:09,080 --> 01:53:11,280 STANDARDIZED LONGITUDINAL 2769 01:53:11,280 --> 01:53:12,600 EVALUATIONS WHERE PATIENTS AND 2770 01:53:12,600 --> 01:53:14,320 FAMILY COMPLETE FAMILY HISTORY, 2771 01:53:14,320 --> 01:53:15,360 MEDICAL HISTORY, PATIENT 2772 01:53:15,360 --> 01:53:18,400 REPORTED OUTCOMES, WE CONDUCT 2773 01:53:18,400 --> 01:53:19,640 EXTENSIVE OBSTRUCTION OF DATA WE 2774 01:53:19,640 --> 01:53:21,320 RECEIVE FROM THE OUTSIDE, 2775 01:53:21,320 --> 01:53:24,040 COLLECT IMAGING AND PATHOLOGY, 2776 01:53:24,040 --> 01:53:26,360 ONCE A PATIENT IS ENROLLED EVEN 2777 01:53:26,360 --> 01:53:28,560 REMOTELY OR AT THE NIH CLINICAL 2778 01:53:28,560 --> 01:53:30,680 CENTER WE REVIEW ALL DATA HAVE A 2779 01:53:30,680 --> 01:53:32,800 COMPREHENSIVE MOLECULAR TUMOR 2780 01:53:32,800 --> 01:53:34,680 BOARD, GENETIC COUNSELING, 2781 01:53:34,680 --> 01:53:36,720 PROVIDE RECOMMENDATIONS TO THE 2782 01:53:36,720 --> 01:53:38,920 PATIENTS AND CONTINUE TO FOLLOW 2783 01:53:38,920 --> 01:53:42,320 THEM LONGITUDINALLY. THIS GIVES 2784 01:53:42,320 --> 01:53:44,760 YOU A SNAP SHOT OF THE 2785 01:53:44,760 --> 01:53:45,760 ENROLLMENT ON THE NATURAL 2786 01:53:45,760 --> 01:53:48,360 HISTORY STUDIES SINCE 2019. 2787 01:53:48,360 --> 01:53:50,000 GIVEN THE TUMORS THAT WE 2788 01:53:50,000 --> 01:53:51,880 DEVELOPED THE MOST EXPERTISE AND 2789 01:53:51,880 --> 01:53:54,240 ACTUALLY THE RANGE WAS MORE 2790 01:53:54,240 --> 01:53:56,760 ADULTS AND PEDIATRIC PATIENTS, 2791 01:53:56,760 --> 01:53:59,280 WE ENROLLED PATIENTS ACROSS 46 2792 01:53:59,280 --> 01:54:02,760 STATES IN THE UNITED STATES, AND 2793 01:54:02,760 --> 01:54:03,920 WITHIN 27 COUNTRIES OUTSIDE OF 2794 01:54:03,920 --> 01:54:09,520 THE U.S. NEXT SHOWS WHAT TYPES 2795 01:54:09,520 --> 01:54:11,320 OF TUMORS WE ENROLLED MOST ON 2796 01:54:11,320 --> 01:54:14,640 AND TUMORS WERE THEY DEVELOP AND 2797 01:54:14,640 --> 01:54:19,040 CONSIDER MEANINGFUL COHORT FOR 2798 01:54:19,040 --> 01:54:20,400 CORDOMA WILD TYPE NEURAL 2799 01:54:20,400 --> 01:54:22,800 ENDOCRINE TUMORS CORTICAL 2800 01:54:22,800 --> 01:54:24,720 CARCINOMA AND MEDICAL THYROID 2801 01:54:24,720 --> 01:54:27,400 CARCINOMA. I WANT TO HIGHLIGHT 2802 01:54:27,400 --> 01:54:30,240 ADULTS USE THE SAME PROTOCOL TO 2803 01:54:30,240 --> 01:54:33,800 STUDY RARE CANCER SUCH AS 2804 01:54:33,800 --> 01:54:34,400 ADENOUS SQUAMOUS CARCINOMA OF 2805 01:54:34,400 --> 01:54:35,840 THE PANCREAS. WE HAVE A NUMBER 2806 01:54:35,840 --> 01:54:38,840 OF TUMORS WE HAVE FEWER PATIENTS 2807 01:54:38,840 --> 01:54:40,560 AND ON THE RIGHT TWO COLUMNS YOU 2808 01:54:40,560 --> 01:54:43,640 SEE TUMORS WE HAVE ONE 2809 01:54:43,640 --> 01:54:44,800 PARTICIPANT OR TWO PARTICIPANTS, 2810 01:54:44,800 --> 01:54:46,480 I THINK THIS WAS AN IMPORTANT 2811 01:54:46,480 --> 01:54:49,440 LEARNING EXPERIENCE FOR US ON MY 2812 01:54:49,440 --> 01:54:50,920 PART THEY NEED TO MAKE PROGRESS 2813 01:54:50,920 --> 01:54:52,760 IN MANY RARE TUMORS WE NEED A 2814 01:54:52,760 --> 01:54:55,000 NATIONAL POTENTIALLY 2815 01:54:55,000 --> 01:54:56,040 INTERNATIONAL COLLABORATION SO 2816 01:54:56,040 --> 01:54:59,000 ALL OF OUR N OF ONE TUMORS CAN 2817 01:54:59,000 --> 01:55:00,400 BECOME A LARGER GROUP THAT 2818 01:55:00,400 --> 01:55:03,160 BECAME MEANINGFUL STUDY. THE 2819 01:55:03,160 --> 01:55:05,520 NEXT SLIDE IS OVERVIEW OF 2820 01:55:05,520 --> 01:55:08,200 ENROLLMENT FROM 2019 TO DATE, 2821 01:55:08,200 --> 01:55:10,040 YOU CAN SEE WE STARTED WITH 2822 01:55:10,040 --> 01:55:11,600 ENROLLING MOST OF THE PATIENTS 2823 01:55:11,600 --> 01:55:14,000 AT THE NIH CLINICAL CENTER 2824 01:55:14,000 --> 01:55:15,400 DURING THE COVID PANDEMIC WE 2825 01:55:15,400 --> 01:55:17,000 SHIFTED TO REMOTE ENROLLMENT AS 2826 01:55:17,000 --> 01:55:18,600 WE WERE NOT ALLOWED TO BRING 2827 01:55:18,600 --> 01:55:20,520 PATIENTS TO THE CLINICAL CENTER 2828 01:55:20,520 --> 01:55:22,360 UNLESS WE HAD CLEAR BENEFIT BUT 2829 01:55:22,360 --> 01:55:25,520 WE COULD PROVIDE TO PATIENTS. 2830 01:55:25,520 --> 01:55:26,840 NOW THE COVID MAKE HAS COME TO 2831 01:55:26,840 --> 01:55:29,120 END OR ENDING WE STILL ENROLL 2832 01:55:29,120 --> 01:55:30,560 FAIR NUMBER OF PATIENTS REMOTELY 2833 01:55:30,560 --> 01:55:32,760 AS THIS CAN BE VERY MEANINGFUL 2834 01:55:32,760 --> 01:55:34,760 FOR PATIENTS THAT LIVE IN ORAL 2835 01:55:34,760 --> 01:55:37,880 OR REMOTE LOCATIONS. THE NEXT 2836 01:55:37,880 --> 01:55:39,360 SLIDE IS IMPORTANT AND IT SHOWS 2837 01:55:39,360 --> 01:55:43,600 OUR AGENDA, RACE AND ETHNICITY, 2838 01:55:43,600 --> 01:55:45,480 REHAD PREDOMINANTLY FEMALES 2839 01:55:45,480 --> 01:55:48,040 WHICH IN PART IS DUE TO 2840 01:55:48,040 --> 01:55:50,320 PREDOMINANCE OF TUMORS IN 2841 01:55:50,320 --> 01:55:52,280 FEMALES SUCH AS WILD TYPE 2842 01:55:52,280 --> 01:55:53,640 (INAUDIBLE) AS YOU CAN SEE WE 2843 01:55:53,640 --> 01:55:55,200 ENROLLED WHITE PATIENTS, AND WE 2844 01:55:55,200 --> 01:55:57,000 HAD FAIRLY SMALL NUMBER OF ASIAN 2845 01:55:57,000 --> 01:56:00,800 AND BLACK PATIENTS. WHAT IS ALSO 2846 01:56:00,800 --> 01:56:04,520 IMPORTANT IS THAT WE COMPARED 2847 01:56:04,520 --> 01:56:06,000 REPORTING OF RACE BASED ON 2848 01:56:06,000 --> 01:56:08,000 MEDICAL RECORD AND MEDICAL 2849 01:56:08,000 --> 01:56:09,880 RECORD AND SELF-REPORT, AS YOU 2850 01:56:09,880 --> 01:56:12,160 CAN SEE THERE WAS A DISCREPANCY 2851 01:56:12,160 --> 01:56:14,200 BETWEEN MEDICAL RECORD AND 2852 01:56:14,200 --> 01:56:16,040 SELF-REPORT AND WE FEEL STRONGLY 2853 01:56:16,040 --> 01:56:18,200 THAT SELF-REPORTING WILL BE THE 2854 01:56:18,200 --> 01:56:20,880 WAY TO MOVE FORWARD. WE ARE 2855 01:56:20,880 --> 01:56:22,320 WORKING WITH A PEER DIVERSITY 2856 01:56:22,320 --> 01:56:25,200 WORKING GROUP AND CCCR TO SEE 2857 01:56:25,200 --> 01:56:26,800 HOW WE CAN INCREASE RECRUITMENT 2858 01:56:26,800 --> 01:56:27,720 OF UNDER-REPRESENTED 2859 01:56:27,720 --> 01:56:30,680 POPULATIONS. I HAVE MENTIONED 2860 01:56:30,680 --> 01:56:32,680 WE HAVE A FOCUS ON PATIENT 2861 01:56:32,680 --> 01:56:36,960 REPORTED OUTCOMES IN PATIENTS 2862 01:56:36,960 --> 01:56:38,600 WITH USING 25 INSTRUMENTS 2863 01:56:38,600 --> 01:56:40,600 REFLECTING THE DOMAINS YOU SEE 2864 01:56:40,600 --> 01:56:43,640 HERE. OUR FIRST MANUSCRIPT DEALT 2865 01:56:43,640 --> 01:56:45,280 WITH MEDULLARY THYROID CANCER 2866 01:56:45,280 --> 01:56:46,520 WITH PATIENTS CAME FOR DECADES 2867 01:56:46,520 --> 01:56:48,280 WITH METASTATIC DISEASE AND 2868 01:56:48,280 --> 01:56:50,080 CURRENTLY ANALYZING THE PATIENT 2869 01:56:50,080 --> 01:56:53,840 REPORTED OUTCOME MEASURES AND 2870 01:56:53,840 --> 01:56:56,120 CORTICAL CARCINOMA AND 2871 01:56:56,120 --> 01:56:58,720 NEUROENDOCRINE TUMORS. THE NEXT 2872 01:56:58,720 --> 01:57:00,760 SLIDE IS AN OVERVIEW HOW WE 2873 01:57:00,760 --> 01:57:04,320 ANALYZE BIOSPECIMENS, 2874 01:57:04,320 --> 01:57:06,960 OVERWHELMINGLY WE GET PARAFFIN 2875 01:57:06,960 --> 01:57:09,080 EMBEDDED TISSUE, THIS IS 2876 01:57:09,080 --> 01:57:11,400 ANALYZED INITIALLY ACTUALLY ON 2877 01:57:11,400 --> 01:57:13,840 GENE MUTATION PANEL CALLED TSL 2878 01:57:13,840 --> 01:57:16,640 500 COLLABORATION WITH THE NCI 2879 01:57:16,640 --> 01:57:19,040 LAB OF PATHOLOGY. OVER A YEAR 2880 01:57:19,040 --> 01:57:21,680 NOW WE HAVE WHOLE EXOME 2881 01:57:21,680 --> 01:57:23,720 SEQUENCING AND RNA SEQUENCING 2882 01:57:23,720 --> 01:57:26,280 THAT IS CLIA CERTIFIED SO WE 2883 01:57:26,280 --> 01:57:29,320 HAVE EXPANDED WHAT WE CAN DO. WE 2884 01:57:29,320 --> 01:57:31,680 ARE ALSO CONDUCTING RESEARCH 2885 01:57:31,680 --> 01:57:33,800 CHARACTERIZATION FOR EXAMPLE DNA 2886 01:57:33,800 --> 01:57:36,080 METHYLATION ARRAYS AND WHOLE 2887 01:57:36,080 --> 01:57:37,960 GENOME SEQUENCING. FOR PATIENTS 2888 01:57:37,960 --> 01:57:40,680 THAT COME TO THE NIH CLINICAL 2889 01:57:40,680 --> 01:57:42,440 CENTER WE ALSO COLLECT 2890 01:57:42,440 --> 01:57:43,960 PERIPHERAL BLOOD MONONUCLEAR 2891 01:57:43,960 --> 01:57:46,600 CELLS FOR IMMUNE PHENOTYPING AND 2892 01:57:46,600 --> 01:57:48,800 CYTOKINE LEVELS. THE NEXT SLIDE 2893 01:57:48,800 --> 01:57:52,800 PROVIDES AN OVERVIEW OF THE 2894 01:57:52,800 --> 01:57:54,360 ONCOLOGY GENE PANEL. ON THE LEFT 2895 01:57:54,360 --> 01:57:56,600 TWO COLUMNS THE VARIANCE 2896 01:57:56,600 --> 01:57:58,120 IDENTIFIED MORE THAN FIVE 2897 01:57:58,120 --> 01:58:02,240 PATIENTS WITH ADRENAL CORTICAL 2898 01:58:02,240 --> 01:58:03,600 AND IDENTIFIED IN TWO PATIENTS 2899 01:58:03,600 --> 01:58:06,480 WITH MTC, YOU CAN SEE WE DID 2900 01:58:06,480 --> 01:58:08,960 IDENTIFY EXPECTED PATHOGENIC 2901 01:58:08,960 --> 01:58:10,720 MUTATIONS IN THESE TUMORS. ON 2902 01:58:10,720 --> 01:58:15,000 THE RIGHT TWO PANELS YOU SEE THE 2903 01:58:15,000 --> 01:58:16,200 ACTIONIBILITY TEARS AND PORTION 2904 01:58:16,200 --> 01:58:18,040 OF PATIENTS THAT HAVE MUTATIONS 2905 01:58:18,040 --> 01:58:24,120 VARY, FOR EXAMPLE FOR PORDOMA 2906 01:58:24,120 --> 01:58:24,840 PATIENTS WE DID NOT HAVE 2907 01:58:24,840 --> 01:58:25,960 MUTATIONS BUT MOST PATIENTS HAD 2908 01:58:25,960 --> 01:58:27,480 AT LEAST ONE PATHOGENIC 2909 01:58:27,480 --> 01:58:31,760 VARIATION. NEXT SLIDE. I 2910 01:58:31,760 --> 01:58:33,080 MENTIONED THE NIH RARE TUMOR 2911 01:58:33,080 --> 01:58:35,400 CLINICS ARE UNIQUE ASPECT OF 2912 01:58:35,400 --> 01:58:39,320 LONGITUDINAL STUDY. THESE START 2913 01:58:39,320 --> 01:58:40,840 WITH WILD TYPE CLINIC IN 2008 2914 01:58:40,840 --> 01:58:44,440 AND EXPANDED IT SINCE. WE BRING 2915 01:58:44,440 --> 01:58:45,920 10 TO 15 PATIENTS WITH A 2916 01:58:45,920 --> 01:58:47,960 SPECIFIC RARE TUMOR TO THE NIH 2917 01:58:47,960 --> 01:58:49,800 CLINICAL CENTER WE BRING 2918 01:58:49,800 --> 01:58:52,000 APPLICANTS AND CLINICIAN ACROSS 2919 01:58:52,000 --> 01:58:53,360 THE COUNTRY WITH EXPERTISE WITH 2920 01:58:53,360 --> 01:58:55,160 THESE DISEASES, PATIENTS ARE 2921 01:58:55,160 --> 01:58:56,680 EVALUATED AND MEET WITH THE 2922 01:58:56,680 --> 01:59:01,080 EXPERTS AND GET RECOMMENDATIONS. 2923 01:59:01,080 --> 01:59:03,600 IN 2019 WE HOSTED THE INAUGURAL 2924 01:59:03,600 --> 01:59:06,120 CLINIC AND SINCE CONDUCTED 2925 01:59:06,120 --> 01:59:10,440 CLINICS IN MEDULLARY CARCINOMA 2926 01:59:10,440 --> 01:59:12,600 WILL THE ADRENAL CORTICAL 2927 01:59:12,600 --> 01:59:14,160 CARCINOMA. THE NEXT SLIDE SHOWS 2928 01:59:14,160 --> 01:59:17,240 HOW THE CHORDOMA APPROACH MIGHT 2929 01:59:17,240 --> 01:59:19,040 BE PARADIGM HOW TO APPROACH VERY 2930 01:59:19,040 --> 01:59:24,880 RARE TUMOR RESEARCH, CHORDOMA 2931 01:59:24,880 --> 01:59:27,240 ARE LESS THAN 300 PATIENT AS 2932 01:59:27,240 --> 01:59:29,440 PEER PEDIATRIC CHORDOMAs ARE 2933 01:59:29,440 --> 01:59:31,440 LESS TAN 30 WITH DIFFERENT 2934 01:59:31,440 --> 01:59:32,480 BIOLOGY, MIGHT BE A CORE 2935 01:59:32,480 --> 01:59:33,640 DEFICIENCY. IT START WITH A 2936 01:59:33,640 --> 01:59:35,960 SMALL WORKING GROUP AT THE NCI 2937 01:59:35,960 --> 01:59:38,720 CCR AND DCEG, DEVELOP THE 2938 01:59:38,720 --> 01:59:40,840 NATIONAL WORKSHOP WE INVITED 2939 01:59:40,840 --> 01:59:41,960 APPLICANTS AND LEADERS IN THE 2940 01:59:41,960 --> 01:59:45,280 FIELD. WE DEVELOPED AND FORMED 2941 01:59:45,280 --> 01:59:47,600 PARTNERSHIPS WITH THE CHORDOMA 2942 01:59:47,600 --> 01:59:48,840 FOUNDATION DEVELOPED NATURAL 2943 01:59:48,840 --> 01:59:50,800 HISTORY STUDIES SUB PROTOCOL 2944 01:59:50,800 --> 01:59:53,320 SPECIFICALLY STUDY CHORDOMA HAD 2945 01:59:53,320 --> 01:59:55,840 THE CHORDOMA CLINIC AND 2946 01:59:55,840 --> 01:59:57,600 ESTABLISHED MULTI-INSTITUTIONAL 2947 01:59:57,600 --> 01:59:58,880 INTERNATIONAL TUMOR COHORT% 2948 01:59:58,880 --> 02:00:00,480 PATIENTS CAN BE REVIEWED AT ANY 2949 02:00:00,480 --> 02:00:02,200 TIME AND GET RECOMMENDATIONS. WE 2950 02:00:02,200 --> 02:00:04,760 HAVE A PEDIATRIC CHORDOMA 2951 02:00:04,760 --> 02:00:08,200 WORKING GROUP AND DR. REILLY AND 2952 02:00:08,200 --> 02:00:09,760 DR. (INAUDIBLE) FROM OREGON 2953 02:00:09,760 --> 02:00:11,680 HEALTH SCIENCE UNIVERSITY HAVE A 2954 02:00:11,680 --> 02:00:15,760 DOD GRANT TO STUDY SMART B 1 2955 02:00:15,760 --> 02:00:18,200 DEFICIENT TUMORS THE NEXT SLIDE 2956 02:00:18,200 --> 02:00:21,560 IS TRANSLATED IN A COLLABORATIVE 2957 02:00:21,560 --> 02:00:23,800 CLINICAL TRIAL IN COLLABORATION 2958 02:00:23,800 --> 02:00:26,720 WITH NCI CTEP, THE COLLABORATION 2959 02:00:26,720 --> 02:00:30,520 WITH PET CTN A MULTI-SITE 2960 02:00:30,520 --> 02:00:33,400 CLINICAL TRIAL IS DIRECTED BY -- 2961 02:00:33,400 --> 02:00:34,880 WITH THE DEVELOPMENTAL 2962 02:00:34,880 --> 02:00:37,080 THERAPEUTICS CLINIC. TWO CHECK 2963 02:00:37,080 --> 02:00:41,760 POINT INHIBITORS FOR SMARCB 1 OR 2964 02:00:41,760 --> 02:00:43,240 A 4 DEFICIENT TUMORS. PATIENTS 2965 02:00:43,240 --> 02:00:45,000 CAN EBB ROLE IN SIX COHORT, NOT 2966 02:00:45,000 --> 02:00:47,960 LIMITED BY AGE, BUT YOU CAN 2967 02:00:47,960 --> 02:00:49,920 ENROLL PATIENTS ANY AGE AND THIS 2968 02:00:49,920 --> 02:00:55,720 CLINICAL TRIAL IS ONGOING. WE 2969 02:00:55,720 --> 02:00:56,680 ALSO MADE PROGRESS IN 2970 02:00:56,680 --> 02:00:58,120 PRE-CLINICAL RESEARCH 2971 02:00:58,120 --> 02:00:59,800 ACCOMPLISHMENTS, ANY PATIENT WHO 2972 02:00:59,800 --> 02:01:01,960 HAS FILED SURGERIES AT THE NIH 2973 02:01:01,960 --> 02:01:06,480 CLINICAL CENTER, WE WILL ATTEMPT 2974 02:01:06,480 --> 02:01:08,600 TO AUTOTOPPIC DERIVED PATIENT 2975 02:01:08,600 --> 02:01:11,320 XENOGRAPHS. AN EXAMPLE HERE OF 2976 02:01:11,320 --> 02:01:13,440 ADRENAL CORTICAL CARCINOMA PDX 2977 02:01:13,440 --> 02:01:15,360 AND SINGLE CELL SEQUENCING IN 2978 02:01:15,360 --> 02:01:17,240 THESE TUMORS AND COMPARED THE 2979 02:01:17,240 --> 02:01:19,760 PRIMARY TUMOR AND THE MOUSE 2980 02:01:19,760 --> 02:01:21,760 TUMOR AS WE SEE HERE, THESE 2981 02:01:21,760 --> 02:01:23,880 TUMORS EXPRESS SIMILAR MARKERS. 2982 02:01:23,880 --> 02:01:27,560 IN COLLABORATION WITH DR. 2983 02:01:27,560 --> 02:01:28,960 (INDISCERNIBLE) WE ALSO HAVE 2984 02:01:28,960 --> 02:01:30,560 EMBARKED ON ESTABLISHING A 2985 02:01:30,560 --> 02:01:32,520 GENETICALLY ENGINEERED MOUSE 2986 02:01:32,520 --> 02:01:35,360 MODEL OF WILD TYPE. THERE ARE NO 2987 02:01:35,360 --> 02:01:37,360 PRE-CLINICAL MODELS TO STUDY 2988 02:01:37,360 --> 02:01:40,160 WILD TYPE JIST FOR THIS TUMOR 2989 02:01:40,160 --> 02:01:44,120 KNOCK OUT SBHV AND ACTIVATE BRAF 2990 02:01:44,120 --> 02:01:45,600 WHICH RESULTS IN TUMORS SIMILAR 2991 02:01:45,600 --> 02:01:48,080 TO WHAT WE SEE IN GIST AND 2992 02:01:48,080 --> 02:01:48,920 SOMEWHAT REFINEMENT WE HOPE THIS 2993 02:01:48,920 --> 02:01:52,760 WILL BE A USEFUL TOOL FOR A STEP 2994 02:01:52,760 --> 02:01:53,920 FORD FOR PRE-CLINICAL TESTING. 2995 02:01:53,920 --> 02:01:55,720 WE ARE VALIDATING THESE MODELS 2996 02:01:55,720 --> 02:01:57,520 AND WILL MAKE THEM PUBLICLY 2997 02:01:57,520 --> 02:02:03,560 AVAILABLE AS SOON AS WE CAN. 2998 02:02:03,560 --> 02:02:04,720 NEXT SLIDE OUR COMMITMENT TO 2999 02:02:04,720 --> 02:02:06,200 ENGAGEMENT AND DEE 3000 02:02:06,200 --> 02:02:07,480 ACCOMPLISHMENTS. WE HAVE 3001 02:02:07,480 --> 02:02:08,600 ESTABLISHED 29 ADVOCACY 3002 02:02:08,600 --> 02:02:10,800 PARTNERSHIPS. WE HAVE A WEBSITE 3003 02:02:10,800 --> 02:02:12,320 WITH INFORMATION AND RESOURCES 3004 02:02:12,320 --> 02:02:13,400 CENTERED ON PATIENTS AND 3005 02:02:13,400 --> 02:02:15,840 CAREGIVERS. WE HAVE AN ENGLISH 3006 02:02:15,840 --> 02:02:17,440 AND SPANISH VERSION OF THIS AND 3007 02:02:17,440 --> 02:02:20,240 HAVE APPROXIMATELY 70,000 UNIQUE 3008 02:02:20,240 --> 02:02:24,000 VISITORS PER MONTH. WE ALSO HAVE 3009 02:02:24,000 --> 02:02:24,880 PRESCRIBERS TO (INAUDIBLE) 3010 02:02:24,880 --> 02:02:26,480 LETTER AND HAVE PARTICIPANTS WHO 3011 02:02:26,480 --> 02:02:30,680 FOLLOW OUR POB AND TWITTER 3012 02:02:30,680 --> 02:02:32,280 FEEDS. I WOULD LIKE TO HIGHLIGHT 3013 02:02:32,280 --> 02:02:36,160 THE NEXT SLIDES A FEW LESSONS WE 3014 02:02:36,160 --> 02:02:38,480 LEARNED FROM MYPART. ADVOCACY 3015 02:02:38,480 --> 02:02:40,240 AND CLINICAL AND SCIENTIFIC 3016 02:02:40,240 --> 02:02:42,720 RITUAL EXPERTISE, DISEASE 3017 02:02:42,720 --> 02:02:45,400 CHAMPIONS, ARE CRITICAL FOR 3018 02:02:45,400 --> 02:02:46,600 MAKING PROGRESS. I BELIEVE 3019 02:02:46,600 --> 02:02:48,400 STRONGLY THE NIH RARE TUMOR 3020 02:02:48,400 --> 02:02:50,080 CLINICS PROVIDE INSIGHT WE COULD 3021 02:02:50,080 --> 02:02:51,840 NOT GET THROUGH EVALUATION OF 3022 02:02:51,840 --> 02:02:52,840 SINGLE PATIENTS AT DIFFERENT 3023 02:02:52,840 --> 02:02:56,280 SITES. IT IS RESOURCE AND TIME 3024 02:02:56,280 --> 02:02:58,400 INTENSIVE TO THE -- MUCH OF THE 3025 02:02:58,400 --> 02:02:59,880 MEANINGFUL COHORT. AND I BELIEVE 3026 02:02:59,880 --> 02:03:02,520 THEY HAVE TO FOCUS ON SELECTION 3027 02:03:02,520 --> 02:03:04,160 WILD TYPES TO ACCRUE SUFFICIENT 3028 02:03:04,160 --> 02:03:06,160 NUMBERS OF PATIENTS. AND FROM 3029 02:03:06,160 --> 02:03:07,960 THIS RESULT THE DESIRE TO 3030 02:03:07,960 --> 02:03:09,640 DEVELOP PARTNERSHIP WITH 3031 02:03:09,640 --> 02:03:11,960 CONSORTIA, THE COG COMMUNITY 3032 02:03:11,960 --> 02:03:13,760 HOSPITALS AND ADVOCACY AND 3033 02:03:13,760 --> 02:03:16,640 NATIONAL EXPERTS TO ACCELERATE 3034 02:03:16,640 --> 02:03:18,240 THIS PROGRESS AND WE WORK HARD 3035 02:03:18,240 --> 02:03:20,720 WITH THE NCI CCDI AND OTHERS TO 3036 02:03:20,720 --> 02:03:22,840 DEVELOP A COLLABORATIVE NATIONAL 3037 02:03:22,840 --> 02:03:24,840 STRATEGY THAT PROVIDES THE 3038 02:03:24,840 --> 02:03:27,960 INFRASTRUCTURE TO EFFICIENTLY 3039 02:03:27,960 --> 02:03:28,840 STUDY DIFFERENT TUMORS AT THE 3040 02:03:28,840 --> 02:03:30,560 SAME TIME. I'M GIVING YOU A 3041 02:03:30,560 --> 02:03:32,800 BRIEF OVERVIEW OF THIS EFFORT ON 3042 02:03:32,800 --> 02:03:36,800 THE NEXT SLIDE. WE HAVE 3043 02:03:36,800 --> 02:03:37,840 PRESENTED AND DR. -- THE 3044 02:03:37,840 --> 02:03:40,440 SCIENTIFIC DIRECTOR OF THE CCDI 3045 02:03:40,440 --> 02:03:42,400 ON THIS BIG EFFORT WHICH I WANT 3046 02:03:42,400 --> 02:03:44,600 TO EMPHASIZE IS REALLY A 3047 02:03:44,600 --> 02:03:46,760 NATIONAL EFFORT AND THE BSA 3048 02:03:46,760 --> 02:03:49,000 PROVIDED MUCH INSIGHT AND ADVICE 3049 02:03:49,000 --> 02:03:51,200 AND GUIDANCE AS TO HOW THE CCDI 3050 02:03:51,200 --> 02:03:53,000 SHOULD BE ROLLED OUT. FOR TODAY 3051 02:03:53,000 --> 02:03:56,000 I WOULD LIKE TO BRIEFLY 3052 02:03:56,000 --> 02:03:57,840 HIGHLIGHT THE MOLECULAR 3053 02:03:57,840 --> 02:03:59,360 CHARACTERIZATION INITIATIVE AND 3054 02:03:59,360 --> 02:04:03,960 THE NATIONAL RARE TUMOR 3055 02:04:03,960 --> 02:04:05,720 INITIATIVE NCI IS THE 3056 02:04:05,720 --> 02:04:07,440 PARTNERSHIP BETWEEN THE NCI AND 3057 02:04:07,440 --> 02:04:10,080 THE CHILDREN'S ONCOLOGY GROUP 3058 02:04:10,080 --> 02:04:11,440 PROJECT THE SCREENING PROTOCOL 3059 02:04:11,440 --> 02:04:16,280 OF COG. WHAT CCDI PROVIDES IN 3060 02:04:16,280 --> 02:04:17,960 LA RATION WITH COG IS STATE OF 3061 02:04:17,960 --> 02:04:18,720 THE ART MOLECULAR 3062 02:04:18,720 --> 02:04:19,960 CHARACTERIZATION TO NEWLY 3063 02:04:19,960 --> 02:04:24,720 DIAGNOSED PATIENTS WHO ENROLL IN 3064 02:04:24,720 --> 02:04:26,880 PROJECT EVERY CHILD. ROLLED OUT 3065 02:04:26,880 --> 02:04:30,760 FOR CNS TUMOR FIRST, THEN SOFT 3066 02:04:30,760 --> 02:04:32,320 TISSUE SARCOMA AND RARE CANCER. 3067 02:04:32,320 --> 02:04:33,440 THE GOAL IS NOT DOING THIS FOR 3068 02:04:33,440 --> 02:04:35,760 NEWLY DIAGNOSED BUT ALSO FOR 3069 02:04:35,760 --> 02:04:39,760 REFRACTORY TUMORS. RESULTS ARE 3070 02:04:39,760 --> 02:04:41,120 RICHER PHYSICIANS AND 3071 02:04:41,120 --> 02:04:42,840 PARTICIPANTS IN 21 DAYS. WHAT 3072 02:04:42,840 --> 02:04:44,880 THIS ALLOWS IS TO IDENTIFY NOT 3073 02:04:44,880 --> 02:04:47,320 ONLY RARE TUMORS BUT MOLECULAR 3074 02:04:47,320 --> 02:04:49,360 SUBTYPES THAT POTENTIALLY ENROLL 3075 02:04:49,360 --> 02:04:52,200 IN THE NATIONAL INITIATIVE. 3076 02:04:52,200 --> 02:04:57,080 SINCE INITIATION OF THIS EFFORT, 3077 02:04:57,080 --> 02:04:59,280 MORE THAN 3,000 PARTICIPANTS 3078 02:04:59,280 --> 02:05:01,200 HAVE BEEN ENROLLED WHICH IS 3079 02:05:01,200 --> 02:05:04,160 REALLY IMPRESSIVE. THE NEXT 3080 02:05:04,160 --> 02:05:08,360 BRIEFLY SHOWS TO YOU HOW WE 3081 02:05:08,360 --> 02:05:12,280 ENVISION TO COORDINATE THIS AND 3082 02:05:12,280 --> 02:05:14,960 PATIENTS CAN BE IDENTIFY EVERY 3083 02:05:14,960 --> 02:05:16,360 CHILD (INAUDIBLE) HOPE TO ENGAGE 3084 02:05:16,360 --> 02:05:18,480 OTHER CONSORTIA AND COMMUNITY 3085 02:05:18,480 --> 02:05:20,720 HOSPITALS TO REACH ENROLLMENT. 3086 02:05:20,720 --> 02:05:25,040 PATIENTS UNDERGO STANDARDIZED 3087 02:05:25,040 --> 02:05:26,600 CLINICAL CHARACTERIZATION THAT 3088 02:05:26,600 --> 02:05:27,560 MOLECULAR CHARACTERIZATION WILL 3089 02:05:27,560 --> 02:05:30,760 BE DONE THROUGH THE NCI. 3090 02:05:30,760 --> 02:05:32,120 RESEARCH GRADE SEQUENCE WILL BE 3091 02:05:32,120 --> 02:05:33,680 CONDUCTED IN COLLABORATION WITH 3092 02:05:33,680 --> 02:05:36,480 THE DISEASE EXPERTS. PATIENTS 3093 02:05:36,480 --> 02:05:37,720 WANTED AND FOLLOW -- MONITORED 3094 02:05:37,720 --> 02:05:40,640 AND FOLLOWED LONGITUDINALLY, ALL 3095 02:05:40,640 --> 02:05:42,520 DATA GOES INTO CCI DATA 3096 02:05:42,520 --> 02:05:44,480 ECOSYSTEM. THE NEXT SLIDE SHOWS 3097 02:05:44,480 --> 02:05:46,640 WHILE THIS IS AN NCI CCDI 3098 02:05:46,640 --> 02:05:48,920 COORDINATED EFFORT, WE HOPE THIS 3099 02:05:48,920 --> 02:05:50,120 IS INFRASTRUCTURE THAT IS 3100 02:05:50,120 --> 02:05:53,000 CONDUCTED CAN BE UTILIZED BY 3101 02:05:53,000 --> 02:05:54,720 DISEASE FROM ANY PLACE IN THE 3102 02:05:54,720 --> 02:05:56,320 U.S. AND HOPEFULLY 3103 02:05:56,320 --> 02:05:59,600 INTERNATIONALLY. SO THAT 3104 02:05:59,600 --> 02:06:01,320 PARTICIPATING EFFORTS CAN JOIN 3105 02:06:01,320 --> 02:06:03,200 THIS EFFORT AND NEW RARE TUMORS 3106 02:06:03,200 --> 02:06:04,840 CAN BE STUDIED THROUGH THIS 3107 02:06:04,840 --> 02:06:09,480 EFFORT AS WELL. THIS IS ALSO AS 3108 02:06:09,480 --> 02:06:10,680 I HAVE SHOWN ALIGNED WITH THE 3109 02:06:10,680 --> 02:06:14,280 EFFORTS OF CC DIRECT. WE HOPE 3110 02:06:14,280 --> 02:06:16,280 EVERY PATIENT WILL GOAL A 3111 02:06:16,280 --> 02:06:18,160 CORRECT TIMELY DIAGNOSIS, 3112 02:06:18,160 --> 02:06:19,480 APPROPRIATE MOLECULAR PROFILING 3113 02:06:19,480 --> 02:06:21,240 AS NEEDED, RECOMMENDATIONS TO 3114 02:06:21,240 --> 02:06:23,600 INTERNATIONAL AND NATIONAL TUMOR 3115 02:06:23,600 --> 02:06:24,960 BOARD, PATIENT NAVIGATION AND 3116 02:06:24,960 --> 02:06:27,560 PORTABLE HEALTH RECORD MAKES 3117 02:06:27,560 --> 02:06:28,200 LONGITUDINAL MONITORING AND 3118 02:06:28,200 --> 02:06:30,760 TRIAL PARTICIPATION EASIER AND 3119 02:06:30,760 --> 02:06:32,480 ULTIMATELY WHERE WE CAN GET 3120 02:06:32,480 --> 02:06:34,400 MEANINGFUL EXTERNAL CONTROLS FOR 3121 02:06:34,400 --> 02:06:36,840 SPECIFIC RARE TUMORS. THANK YOU 3122 02:06:36,840 --> 02:06:38,280 VERY MUCH. DR. REILLY WILL TAKE 3123 02:06:38,280 --> 02:06:42,960 OVER FROM HERE. 3124 02:06:42,960 --> 02:06:44,400 >>RECOGNIZING UNIQUE CHALLENGES 3125 02:06:44,400 --> 02:06:45,840 OF DRUG DEVELOPMENT FOR RARE 3126 02:06:45,840 --> 02:06:47,480 TUMORS WE PROPOSE A NEW PROGRAM 3127 02:06:47,480 --> 02:06:48,960 AIMED AT DRUG DEVELOPMENT FOR 3128 02:06:48,960 --> 02:06:51,960 RAREST OF TUMORS. WE BEGAN 3129 02:06:51,960 --> 02:06:53,080 DISCUSSION OF THE PROJECT IN 3130 02:06:53,080 --> 02:06:56,000 WINTER OF 2022, AND SHOW AS 3131 02:06:56,000 --> 02:06:58,000 MODEL THE FOUNDATION FOR NIH 3132 02:06:58,000 --> 02:06:59,520 WILL BRING TOGETHER STAKEHOLDERS 3133 02:06:59,520 --> 02:07:02,160 IN PARTNERSHIP WITH NCI NCATS 3134 02:07:02,160 --> 02:07:07,600 AND THE FDA. ON AUGUST 24 WE 3135 02:07:07,600 --> 02:07:09,680 HELD A PUBLIC STAKEHOLDER 3136 02:07:09,680 --> 02:07:10,960 MEETING FOR FEEDBACK FROM THE 3137 02:07:10,960 --> 02:07:12,200 COMMUNITY ON THE PROPOSAL. THIS 3138 02:07:12,200 --> 02:07:14,080 WAS WELL ATTENDD BY STAKEHOLDERS 3139 02:07:14,080 --> 02:07:15,840 FROM INDUSTRY, ACADEMIA, AND 3140 02:07:15,840 --> 02:07:18,560 ADVOCACY AMONG OTHERS. SO 3141 02:07:18,560 --> 02:07:21,120 THERE'S NO AGREED UPON 3142 02:07:21,120 --> 02:07:22,720 DEFINITION OF RARE TUMORS AT 3143 02:07:22,720 --> 02:07:23,520 THIS TIME HOWEVER THERE ARE 3144 02:07:23,520 --> 02:07:25,520 SOURCES OF INFORMATION TO DRAW 3145 02:07:25,520 --> 02:07:27,840 UPON. CTOS PUBLISHED A WORKING 3146 02:07:27,840 --> 02:07:31,280 GROUP REPORT IN 2021 DEFINING 3147 02:07:31,280 --> 02:07:32,760 ULTRA RARE SAW SATISFY CO-A MA 3148 02:07:32,760 --> 02:07:34,000 INCIDENCE LESS THAN ONE IN A 3149 02:07:34,000 --> 02:07:35,840 MILLION BASED ON DIFFICULTY OF 3150 02:07:35,840 --> 02:07:37,440 CONDUCTING WELL POWERED 3151 02:07:37,440 --> 02:07:40,320 PROSPECTIVE TRIALS. WORK BASED 3152 02:07:40,320 --> 02:07:41,680 IN EUROPE PROVIDES SOME OF THE 3153 02:07:41,680 --> 02:07:43,440 MOST COMPREHENSIVE INFORMATION 3154 02:07:43,440 --> 02:07:45,840 ON RARE DISEASES AND DEFINES THE 3155 02:07:45,840 --> 02:07:47,280 RAREST INCIDENCE AS LESS THAN 1 3156 02:07:47,280 --> 02:07:48,880 IN A MILLION. SO BASED ON THE 3157 02:07:48,880 --> 02:07:51,240 CURRENT U.S. POPULATION, THIS 3158 02:07:51,240 --> 02:07:53,480 WORKS OUT TO APPROXIMATELY 340 3159 02:07:53,480 --> 02:07:55,680 NEW CASES IN THE U.S. PER YEAR. 3160 02:07:55,680 --> 02:07:59,080 TO GET A BACK OF THE ENVELOPE 3161 02:07:59,080 --> 02:08:00,280 CALCULATION OF THE SCOPE OF 3162 02:08:00,280 --> 02:08:02,800 ULTRA RARE TUMORS I PROVIDE DATA 3163 02:08:02,800 --> 02:08:04,960 FROM CTOS ON THE ODE OF 200 3164 02:08:04,960 --> 02:08:07,240 ULTRA RARE TUMORS IDENTIFIED 3165 02:08:07,240 --> 02:08:09,480 WHICH AT LEAST 60 HAVE A 3166 02:08:09,480 --> 02:08:11,000 CHARACTERISTIC MOLECULAR 3167 02:08:11,000 --> 02:08:12,360 ALTERATION. SUCH ESTIMATED 3168 02:08:12,360 --> 02:08:13,960 75,000 PATIENTS IN H THE U.S. 3169 02:08:13,960 --> 02:08:15,600 ARE AFFECTED BY ULTRA RARE 3170 02:08:15,600 --> 02:08:17,480 TUMOR. BECAUSE THIS IS PRIMARILY 3171 02:08:17,480 --> 02:08:20,800 BASED ON DATA FROM THE EUROPEAN 3172 02:08:20,800 --> 02:08:22,400 GROUP MORE WORK IS NEEDED TO GET 3173 02:08:22,400 --> 02:08:24,120 ACCURATE ESTIMATE OF ULTRA RARE 3174 02:08:24,120 --> 02:08:27,120 TUMORS IN THE US. MOST OF THE 3175 02:08:27,120 --> 02:08:28,880 MOLECULAR ALTERATIONS ARE UNIQUE 3176 02:08:28,880 --> 02:08:30,480 TO SMALL NUMBER OF RARE TUMORS 3177 02:08:30,480 --> 02:08:32,080 BUT ARE ALSO FOUND IN MORE 3178 02:08:32,080 --> 02:08:35,240 COMMON CANCER. AMONG THE 3179 02:08:35,240 --> 02:08:36,560 PARTICIPANTS OF THE MY PART 3180 02:08:36,560 --> 02:08:38,720 NATIONAL HISTORY STUDY AS OF 3181 02:08:38,720 --> 02:08:42,800 SEPTEMBER 1, 43% HAVE ULTRA RARE 3182 02:08:42,800 --> 02:08:44,360 TUMOR DIAGNOSIS. THE PROPOSED 3183 02:08:44,360 --> 02:08:46,720 PARTNERSHIP RESTS ON SEVERAL 3184 02:08:46,720 --> 02:08:48,040 PRINCIPLES. FIRST DESPITE THE 3185 02:08:48,040 --> 02:08:50,200 SMALL NUMBER OF EFFECTIVE 3186 02:08:50,200 --> 02:08:51,920 PATIENTS EACH IS DESERVING 3187 02:08:51,920 --> 02:08:53,640 CURATIVE THERAPIES. SEW THOUGH 3188 02:08:53,640 --> 02:08:55,120 ULTRA RARE TUMOR DRUG 3189 02:08:55,120 --> 02:08:56,480 DEVELOPMENT MAYBE MORE DIFFICULT 3190 02:08:56,480 --> 02:08:58,040 AND COSTLY THAN FOR COMMON 3191 02:08:58,040 --> 02:08:59,840 CANCER WE OWE IT TO PATIENTS TO 3192 02:08:59,840 --> 02:09:00,440 FIND SOLUTIONS TO THE 3193 02:09:00,440 --> 02:09:03,880 CHALLENGES. MAJOR CHALLENGES AS 3194 02:09:03,880 --> 02:09:07,320 WE SEE THEM, ARE THE LACK OF 3195 02:09:07,320 --> 02:09:08,360 ECONOMIC FEASIBILITY OF 3196 02:09:08,360 --> 02:09:09,320 DEVELOPING DRUGS IN THE PRIVATE 3197 02:09:09,320 --> 02:09:13,040 SECTOR. WHICH LEADS TO DRUG 3198 02:09:13,040 --> 02:09:14,520 DEVELOPMENT WITH ADVOCACY 3199 02:09:14,520 --> 02:09:15,280 ORGANIZATIONS AN ACADEMIC 3200 02:09:15,280 --> 02:09:17,560 RESEARCHERS UNLESS THE DRUG 3201 02:09:17,560 --> 02:09:18,320 REPURPOSED FROM OTHER 3202 02:09:18,320 --> 02:09:22,560 INDICATIONS. DRUGS THAT MIGHT 3203 02:09:22,560 --> 02:09:24,600 WORK SPECIFICALLY IN ULTRA RARE 3204 02:09:24,600 --> 02:09:27,920 TUMORS ARE NOT TESTED OR DROPPED 3205 02:09:27,920 --> 02:09:29,560 DUE TO ECONOMIC INCENTIVE AND 3206 02:09:29,560 --> 02:09:31,040 TARGETS SPECIFIC TO ULTRA RARE 3207 02:09:31,040 --> 02:09:32,680 TUMORS MAY NOT BE ADEQUATELY 3208 02:09:32,680 --> 02:09:36,680 PURSUED. BECAUSE OF THE 3209 02:09:36,680 --> 02:09:37,800 DIFFICULTY DEVELOPING DRUGS IN 3210 02:09:37,800 --> 02:09:38,840 THE PRIVATE SECTOR WE BELIEVE 3211 02:09:38,840 --> 02:09:39,880 THE GOVERNMENT PLAYS AN 3212 02:09:39,880 --> 02:09:41,960 IMPORTANT ROLE IN REDUCING COSTS 3213 02:09:41,960 --> 02:09:43,480 TO INDUSTRY AND DERISKING 3214 02:09:43,480 --> 02:09:45,520 PROJECTS FOR ULTRA RARE TUMOR 3215 02:09:45,520 --> 02:09:49,440 INDICATIONS. THE AIM OF THE 3216 02:09:49,440 --> 02:09:50,800 PROPOSAL IS HARNESS STATE OF THE 3217 02:09:50,800 --> 02:09:52,160 ART TECHNOLOGIES TO TARGET WELL 3218 02:09:52,160 --> 02:09:53,920 ESTABLISHED PREVIOUSLY 3219 02:09:53,920 --> 02:09:55,440 UNDRUGGABLE BIOLOGICAL 3220 02:09:55,440 --> 02:09:57,240 VULNERABILITIES OF ULTRA RARE 3221 02:09:57,240 --> 02:09:58,400 CANCER THAT LACK COMMERCIAL 3222 02:09:58,400 --> 02:10:01,440 INCENTIVE FOR DRUG DEVELOPMENT, 3223 02:10:01,440 --> 02:10:02,840 THROUGH OPEN SCIENCE 3224 02:10:02,840 --> 02:10:03,720 MULTI-STAKEHOLDER PUBLIC PRIVATE 3225 02:10:03,720 --> 02:10:07,920 PARTNERSHIP. WE PLAN TO FOCUS ON 3226 02:10:07,920 --> 02:10:09,600 DEFINING BIOLOGY OF ULTRA RARE 3227 02:10:09,600 --> 02:10:11,800 TUMORS TO IDENTIFY POTENTIAL 3228 02:10:11,800 --> 02:10:13,480 DRUGGABLE TARGETS. COMPARING 3229 02:10:13,480 --> 02:10:14,480 DIFFERENT PLATFORMS TO TARGET 3230 02:10:14,480 --> 02:10:17,960 DRUGS TO THE TUMOR BIOLOGY. 3231 02:10:17,960 --> 02:10:19,160 DEVELOPING OPEN SCIENCE PROCESS. 3232 02:10:19,160 --> 02:10:22,920 SO ALL STAKEHOLDERS LEARN FROM 3233 02:10:22,920 --> 02:10:25,480 DECISIONS MADE AND RESOURCES 3234 02:10:25,480 --> 02:10:26,840 AVAILABLE. CHAMPION DRUG 3235 02:10:26,840 --> 02:10:28,160 DEVELOPMENT FROM CONCEPT TO 3236 02:10:28,160 --> 02:10:32,560 CLINICAL TRIAL. NIH WILL PROVIDE 3237 02:10:32,560 --> 02:10:34,120 GOVERNANCE AND OVERSIGHT FOR 3238 02:10:34,120 --> 02:10:36,400 PARTNERSHIP FACILITATING ACTIONS 3239 02:10:36,400 --> 02:10:38,160 WITH GOVERNMENT AND OTHER 3240 02:10:38,160 --> 02:10:39,760 STAKEHOLDERS. F NCI NIH WAS 3241 02:10:39,760 --> 02:10:41,000 ESTABLISHED TO FORM BRIDGES 3242 02:10:41,000 --> 02:10:46,880 BETWEEN MINI AND OTHER ENTITIES 3243 02:10:46,880 --> 02:10:48,200 -- NIH AND HELP MANY OTHER 3244 02:10:48,200 --> 02:10:51,480 FUNCTIONS NEEDED FOR SUCCESS. WE 3245 02:10:51,480 --> 02:10:53,120 ENSIX CYCLE OF DRUG DEVELOPMENT 3246 02:10:53,120 --> 02:10:54,720 REITERATED FOR ULTRA RARE 3247 02:10:54,720 --> 02:10:58,760 TUMORS. IN THE INITIAL PILOT 3248 02:10:58,760 --> 02:10:59,880 PHASE, INFRASTRUCTURE IS BUILT 3249 02:10:59,880 --> 02:11:01,480 USING ONE TO TWO ULTRA RARE 3250 02:11:01,480 --> 02:11:03,440 TUMORS WITH KNOWN AND UNDRUGGED 3251 02:11:03,440 --> 02:11:06,000 DRIVER MUTATIONS. WORKSHOP WILL 3252 02:11:06,000 --> 02:11:08,240 BE CONVENED WITH DISEASE EXPERTS 3253 02:11:08,240 --> 02:11:09,240 AND STAKEHOLDERS TO ANALYZE 3254 02:11:09,240 --> 02:11:11,240 TUMOR BIOLOGY AND IDENTIFY 3255 02:11:11,240 --> 02:11:12,200 PROMISING DRUG DEVELOPMENT 3256 02:11:12,200 --> 02:11:15,280 APPROACHES. WITH THE HELP OF F 3257 02:11:15,280 --> 02:11:16,760 NIH WE DEVELOP COLLABORATION AND 3258 02:11:16,760 --> 02:11:20,000 IP AGREEMENTS, ESTABLISH A 3259 02:11:20,000 --> 02:11:20,640 STEERING MANY I AND SCIENTIFIC 3260 02:11:20,640 --> 02:11:22,600 ADVISORY BOARD AND SET UP 3261 02:11:22,600 --> 02:11:23,520 INFRASTRUCTURE FOR OPEN NOTEBOOK 3262 02:11:23,520 --> 02:11:25,520 PLATFORM. ONCE THE TARGETING 3263 02:11:25,520 --> 02:11:28,720 APPROACHES ARE DECIDED ON, 3264 02:11:28,720 --> 02:11:29,520 RESEARCHERS FROM ACROSS 3265 02:11:29,520 --> 02:11:30,560 GOVERNMENT ACADEMIA AND INDUSTRY 3266 02:11:30,560 --> 02:11:32,680 WILL BE LEVERAGED TO DEVELOP 3267 02:11:32,680 --> 02:11:34,320 CANDIDATE DRUGS AND EARLY PHASE 3268 02:11:34,320 --> 02:11:34,960 CLINICAL TRIALS WILL BE 3269 02:11:34,960 --> 02:11:39,000 INITIATED. IMPORTANTLY 3270 02:11:39,000 --> 02:11:39,720 SUSTAINABILITY PLAN IS DEVELOPED 3271 02:11:39,720 --> 02:11:41,440 TO ENSURE SUPPLY OF DRUGS TO 3272 02:11:41,440 --> 02:11:45,200 PATIENTS LONG TERM. EITHER 3273 02:11:45,200 --> 02:11:47,240 THROUGH FOR PROFIT OR NOT FOR 3274 02:11:47,240 --> 02:11:48,640 PROFIT MECHANISM DEPENDING ON 3275 02:11:48,640 --> 02:11:49,880 CANDIDATE DRUG AND DISEASE. 3276 02:11:49,880 --> 02:11:51,800 AFTER THE INITIAL PILOT OUR GOAL 3277 02:11:51,800 --> 02:11:54,920 IS BEGIN NEW CYCLES ONE TO TWO 3278 02:11:54,920 --> 02:11:57,920 YEARS WITH ULTRA RARE TUMORS AN 3279 02:11:57,920 --> 02:12:00,080 TARGETS WITH EACH COMMUNITY. THE 3280 02:12:00,080 --> 02:12:01,080 SCIENTIFIC ADVISORY BOARD HAVE 3281 02:12:01,080 --> 02:12:02,400 FINED WITH THE APPROPRIATE 3282 02:12:02,400 --> 02:12:04,560 EXPERTS AND THE OPEN DATA 3283 02:12:04,560 --> 02:12:05,960 PLATFORM WILL ELIMINATE DECISION 3284 02:12:05,960 --> 02:12:07,160 MAKING PROCESS, PARTICULARLY 3285 02:12:07,160 --> 02:12:09,800 WITH REGARDS TO THE FDA. TO 3286 02:12:09,800 --> 02:12:11,280 PROVIDE VALUE -- ADDED VALUE TO 3287 02:12:11,280 --> 02:12:14,920 ALL RARE TUMOR DRUG DEVELOPERS. 3288 02:12:14,920 --> 02:12:17,080 SO WITHIN OUR NIH ALPHABET SOUP, 3289 02:12:17,080 --> 02:12:18,200 MANY PROGRAMS ALREADY EXIST THAT 3290 02:12:18,200 --> 02:12:20,040 CAN BE HARNESSED FOR COMPOUND 3291 02:12:20,040 --> 02:12:22,280 IDENTIFICATION AND OPTIMIZATION. 3292 02:12:22,280 --> 02:12:23,680 PRE-CLINICAL TESTING, 3293 02:12:23,680 --> 02:12:24,280 UNDERSTANDING THE NATURAL 3294 02:12:24,280 --> 02:12:26,880 HISTORY AND MOLECULAR DRIVERS. 3295 02:12:26,880 --> 02:12:29,680 AS DR. WIDEMANN PRESENTED, FIRST 3296 02:12:29,680 --> 02:12:31,960 IN HUMAN TRIALS AND COOPERATIVE 3297 02:12:31,960 --> 02:12:34,200 TRIAL NETWORKS. SO THROUGH OUR 3298 02:12:34,200 --> 02:12:35,200 DISCUSSIONS WITH MANY 3299 02:12:35,200 --> 02:12:36,640 STAKEHOLDERS OVER THE PAST YEAR, 3300 02:12:36,640 --> 02:12:39,960 WE HAVE CLARIFIED THE FOLLOWING. 3301 02:12:39,960 --> 02:12:41,960 THE PARTNERSHIP WILL FOCUS ON 3302 02:12:41,960 --> 02:12:45,000 ULTRA RARE TUMORS WITHIN 3303 02:12:45,000 --> 02:12:46,000 ADEQUATE THERAPIES, WELL 3304 02:12:46,000 --> 02:12:47,040 ESTABLISHED UNDRUGGABLE 3305 02:12:47,040 --> 02:12:48,200 MOLECULAR TARGETS CHARACTERISTIC 3306 02:12:48,200 --> 02:12:50,080 OF THE TUMOR. COLLABORATION AND 3307 02:12:50,080 --> 02:12:51,840 IP AGREEMENTS TO PROMOTE DRUG 3308 02:12:51,840 --> 02:12:53,400 DEVELOPMENT, REGULATORY 3309 02:12:53,400 --> 02:12:54,320 APPROVAL, AND SUSTAIN DRUG 3310 02:12:54,320 --> 02:12:57,040 SUPPLY FOR PATIENTS. A 3311 02:12:57,040 --> 02:12:57,880 TRANSPARENT OPEN SCIENCE 3312 02:12:57,880 --> 02:13:00,160 PARADIGM THAT WORKS ACROSS 3313 02:13:00,160 --> 02:13:00,840 GOVERNMENT ACADEMIA AND 3314 02:13:00,840 --> 02:13:02,280 INDUSTRY. AND BRINGING TOGETHER 3315 02:13:02,280 --> 02:13:04,120 CHAMPIONS FOR THE ULTRA RARE 3316 02:13:04,120 --> 02:13:07,400 TUMOR, BIOLOGICAL MECHANISMS AND 3317 02:13:07,400 --> 02:13:09,120 TARGETING TECHNOLOGY. THE 3318 02:13:09,120 --> 02:13:10,440 PARTNERSHIP IS NOT INTENDED TO 3319 02:13:10,440 --> 02:13:11,800 COMPETE WITH OTHER DRUG 3320 02:13:11,800 --> 02:13:13,120 DEVELOPMENT PROGRAMS FOR ULTRA 3321 02:13:13,120 --> 02:13:15,200 RARE OR RARE TUMORS. OR TO 3322 02:13:15,200 --> 02:13:18,520 FOCUS ON TUMOR AGNOSTIC 3323 02:13:18,520 --> 02:13:20,760 THERAPIES, IMMUNOTHERAPY, THESE 3324 02:13:20,760 --> 02:13:22,800 MAYBE MORE ABLE TO BE DEVELOPED 3325 02:13:22,800 --> 02:13:26,560 COMMERCIALLY. WE DON'T PLAN TO 3326 02:13:26,560 --> 02:13:28,920 FOCUS ON ULTRA RARE TUMORS 3327 02:13:28,920 --> 02:13:29,880 CHARACTERISTIC BIOLOGY HAS NOT 3328 02:13:29,880 --> 02:13:35,560 BEEN IDENTIFIED. AS PART OF 3329 02:13:35,560 --> 02:13:36,880 FEEDBACK WE IDENTIFIED THEMES 3330 02:13:36,880 --> 02:13:39,440 FOR ELEMENTS OF SUCCESS. SUCCESS 3331 02:13:39,440 --> 02:13:41,720 WILL LIKELY REQUIRE STRONG 3332 02:13:41,720 --> 02:13:42,440 EFFECTIVE GOVERNANCE TO KEEP 3333 02:13:42,440 --> 02:13:44,200 PROJECTS MOVING FORWARD QUICKLY 3334 02:13:44,200 --> 02:13:45,920 FOCUSING ON A SMALL NUMBER OF 3335 02:13:45,920 --> 02:13:47,880 NEW TUMORS EACH YEAR WHILE 3336 02:13:47,880 --> 02:13:48,520 DEVELOPING INFRASTRUCTURE TO 3337 02:13:48,520 --> 02:13:49,960 MOVE THROUGH THEM QUICKLY TO 3338 02:13:49,960 --> 02:13:51,560 ADDRESS AS MANY ULTRA RARE 3339 02:13:51,560 --> 02:13:53,400 TUMORS AS POSSIBLE. DEVELOPING 3340 02:13:53,400 --> 02:13:55,360 TEAMS OF CHAMPIONSNA MAY TURN 3341 02:13:55,360 --> 02:13:57,400 OVER WITH EACH NEW ULTRA RARE 3342 02:13:57,400 --> 02:13:58,640 TUMOR: AND ESTABLISHING 3343 02:13:58,640 --> 02:14:00,400 COLLABORATION AND IP AGREEMENTS 3344 02:14:00,400 --> 02:14:02,720 THAT WILL REQUIRE MINIMUM 3345 02:14:02,720 --> 02:14:04,560 RENEGOTIATION AT EACH ITERATION 3346 02:14:04,560 --> 02:14:05,800 AND PRESERVE COMMERCIALIZATION 3347 02:14:05,800 --> 02:14:08,000 STRATEGIES AS WELL AS GOVERNMENT 3348 02:14:08,000 --> 02:14:10,480 MARCHING RIGHT OF THE PRIVATE 3349 02:14:10,480 --> 02:14:11,440 COMMERCIALIZATION SOLUTION IS 3350 02:14:11,440 --> 02:14:13,280 NOT ECONOMICALLY FEASIBLE. OPEN 3351 02:14:13,280 --> 02:14:15,080 NOTEBOOK STRATEGIES THAT WILL 3352 02:14:15,080 --> 02:14:17,400 BENEFIT ALL RESEARCHERS WHILE 3353 02:14:17,400 --> 02:14:19,160 PRESERVING TRADE SECRETS AND IP 3354 02:14:19,160 --> 02:14:21,520 TO ALLOW INDUSTRY AND ACADEMIC 3355 02:14:21,520 --> 02:14:22,800 INSTITUTIONS WITH LICENSING 3356 02:14:22,800 --> 02:14:24,400 INTEREST TO PARTICIPATE. 3357 02:14:24,400 --> 02:14:25,480 HARNESSING EXISTING GOVERNMENT 3358 02:14:25,480 --> 02:14:27,400 AND PRIVATE SECTOR RESOURCES TO 3359 02:14:27,400 --> 02:14:29,480 MOVE THROUGH THE STEPS OF DRUG 3360 02:14:29,480 --> 02:14:31,240 DEVELOPMENT AND DEVELOPING 3361 02:14:31,240 --> 02:14:32,840 INCENTIVES FOR INDUSTRY 3362 02:14:32,840 --> 02:14:36,240 PARTICIPATE INCLUDING USE FROM 3363 02:14:36,240 --> 02:14:37,440 THE FDA. WE NEED TO. 3364 02:14:37,440 --> 02:14:39,120 COUP WITH INNOVATIVE STRATEGIES 3365 02:14:39,120 --> 02:14:41,160 TO CREATE SAFER ENVIRONMENTS FOR 3366 02:14:41,160 --> 02:14:42,600 INDUSTRY TO SHARE COMPOUNDS AND 3367 02:14:42,600 --> 02:14:44,280 HIGH RISK PROJECTS FOR ULTRA 3368 02:14:44,280 --> 02:14:46,200 RARE TUMORS WITHOUT JEOPARDIZING 3369 02:14:46,200 --> 02:14:48,560 THE MAIN INDICATIONS. AND WE 3370 02:14:48,560 --> 02:14:50,240 NEED TO DEVELOP SUSTAINABILITY 3371 02:14:50,240 --> 02:14:51,760 STRATEGIES MAKING DRUGS 3372 02:14:51,760 --> 02:14:53,160 AVAILABLE TO PATIENTS WITH RARE 3373 02:14:53,160 --> 02:15:00,360 TUMORS LONG TERM. IN ADDITION TO 3374 02:15:00,360 --> 02:15:02,280 TO CUSSING ON ULTRA RARE TUMORS 3375 02:15:02,280 --> 02:15:04,600 WITH LIMITED NEED WELL DEFINED 3376 02:15:04,600 --> 02:15:06,640 MOLECULAR DRIVERS PRIORITIZATION 3377 02:15:06,640 --> 02:15:08,560 IS WELL CHARACTERIZED 3378 02:15:08,560 --> 02:15:10,120 EXPERIMENTAL MODEL SYSTEMS FOR 3379 02:15:10,120 --> 02:15:12,240 CLINICAL TESTING, COMMITTED AT 3380 02:15:12,240 --> 02:15:13,480 SLOW KATES ACT AS LIAISONS TO 3381 02:15:13,480 --> 02:15:15,360 THE PATIENT COMMUNITY. CLINICIAN 3382 02:15:15,360 --> 02:15:18,160 CHAMPIONS WILLING TO LEADS EARLY 3383 02:15:18,160 --> 02:15:18,720 PHASE CLINICAL TRIALS AND 3384 02:15:18,720 --> 02:15:20,320 COMMITTED RESEARCHERS WITH 3385 02:15:20,320 --> 02:15:21,760 EXPERTISE IN BIOLOGICAL TARGETS 3386 02:15:21,760 --> 02:15:23,880 WITH INNOVATIVE TECHNOLOGICAL 3387 02:15:23,880 --> 02:15:25,680 APPROACHES WILLING TO COMMIT TO 3388 02:15:25,680 --> 02:15:34,680 RAPID DRUG OPTIMIZATION. DRUG 3389 02:15:34,680 --> 02:15:36,240 DEVELOPMENT APPROACHES TO 3390 02:15:36,240 --> 02:15:37,680 IDENTIFY TREATMENT ASPECT OF 3391 02:15:37,680 --> 02:15:39,520 PROPOSAL CAN BENEFIT ALL CANCER 3392 02:15:39,520 --> 02:15:41,400 PATIENTS. RARE TUMOR 3393 02:15:41,400 --> 02:15:43,280 RESEARCHERS MUST COLLABORATE TO 3394 02:15:43,280 --> 02:15:44,680 BE SUCCESSFUL THIS MAY DERIVE 3395 02:15:44,680 --> 02:15:46,320 CREATIVE SOLUTIONS TO IP AND 3396 02:15:46,320 --> 02:15:47,040 COLLABORATION BARRIERS THAT 3397 02:15:47,040 --> 02:15:50,720 COULD BE ADOPTED MORE BROADLY. 3398 02:15:50,720 --> 02:15:52,560 THE STUDY OF RARE TUMORS 3399 02:15:52,560 --> 02:15:54,080 INFORMED HALLMARK FEATURES OF 3400 02:15:54,080 --> 02:15:55,200 CANCER AND DRUG DEVELOPMENT FOR 3401 02:15:55,200 --> 02:15:57,840 ULTRA RARE TUMORS AND THIS MAY 3402 02:15:57,840 --> 02:15:58,920 YIELD INSIGHTS FOR CANCER 3403 02:15:58,920 --> 02:16:03,920 TREATMENT. AS COMMON CANCER 3404 02:16:03,920 --> 02:16:04,960 BECOME DEFINED BINARY ROW 3405 02:16:04,960 --> 02:16:06,840 SUBTYPES THE PATHWAYS TO DRUG 3406 02:16:06,840 --> 02:16:08,000 DEVELOPMENT AND REGULATIVE 3407 02:16:08,000 --> 02:16:10,240 APPROVAL IN RARE TUMORS MAY 3408 02:16:10,240 --> 02:16:14,480 BECOME BROADLY APPLICABLE. WE 3409 02:16:14,480 --> 02:16:15,720 BELIEVE THIS PROPOSAL CAN 3410 02:16:15,720 --> 02:16:17,840 ADDRESS UNMET NEED IN ULTRA RARE 3411 02:16:17,840 --> 02:16:19,400 TUMORS WHILE DEVELOPING 3412 02:16:19,400 --> 02:16:20,520 PARADIGMS AND INCENTIVES FOR 3413 02:16:20,520 --> 02:16:24,840 DRUG DEVELOPMENT. IN SUMMARY AS 3414 02:16:24,840 --> 02:16:27,520 DR. WIDEMANN PRESENTED THE MY 3415 02:16:27,520 --> 02:16:29,360 PART NETWORK FOR RARE TUMOR 3416 02:16:29,360 --> 02:16:30,840 RESEARCH IS SUBSTANTIAL PROGRESS 3417 02:16:30,840 --> 02:16:33,320 FOR ENGAGE REGULAR SEARCHERS AND 3418 02:16:33,320 --> 02:16:35,400 ADVOCACY GROUPS TO STUDY RARE 3419 02:16:35,400 --> 02:16:37,000 TUMORS, MY PARTNERSHIP IS A 3420 02:16:37,000 --> 02:16:38,600 STRONG FOUNDATION AND FOR 3421 02:16:38,600 --> 02:16:41,160 COLLECTION AND ANALYSIS OF RARE 3422 02:16:41,160 --> 02:16:42,480 TUMORS FROM THE NIH CLINICAL 3423 02:16:42,480 --> 02:16:43,600 CENTER. WE DEVELOPED 3424 02:16:43,600 --> 02:16:45,680 COLLABORATIVE PEDIATRIC ADULT 3425 02:16:45,680 --> 02:16:46,480 INTERVENTION TRIALS AND CONTINUE 3426 02:16:46,480 --> 02:16:48,680 TO LOOK FOR COLLABORATION 3427 02:16:48,680 --> 02:16:49,920 OPPORTUNITIES. FOR EXAMPLE BENCH 3428 02:16:49,920 --> 02:16:52,080 TO BEDSIDE AND UO 1 3429 02:16:52,080 --> 02:16:54,040 OPPORTUNITIES WITH EXTRAMURAL 3430 02:16:54,040 --> 02:16:56,160 RESEARCHERS. MY PART IS PLAYING 3431 02:16:56,160 --> 02:16:59,520 A KEY ROLE ESTABLISHING NATIONAL 3432 02:16:59,520 --> 02:17:01,320 PROGRAM FOR RARE TUMOR RESEARCH 3433 02:17:01,320 --> 02:17:03,360 IN COLLABORATION WITH CCDI AND 3434 02:17:03,360 --> 02:17:06,720 FDA. WE WOULD LIKE THE THANK 3435 02:17:06,720 --> 02:17:08,160 THE MEMBERS OF MY PART TEAM PAST 3436 02:17:08,160 --> 02:17:09,280 ANT PRESENT AS WELL AS OUR 3437 02:17:09,280 --> 02:17:11,720 PARTNERS IN THE INTRAMURAL 3438 02:17:11,720 --> 02:17:14,440 RESEARCH PROGRAM INSTITUTE. WE 3439 02:17:14,440 --> 02:17:16,040 APPRECIATE THE COLLEAGUES FOR 3440 02:17:16,040 --> 02:17:17,600 COLLABORATIONS ADVICE AND 3441 02:17:17,600 --> 02:17:19,360 HELPFUL DISCUSSIONS, IN 3442 02:17:19,360 --> 02:17:20,280 PARTICULAR THESE INDIVIDUALS 3443 02:17:20,280 --> 02:17:23,280 DEVELOPING PLANS FOR THE CCDI 3444 02:17:23,280 --> 02:17:25,400 NATIONAL COHORT STUDY, AND THE 3445 02:17:25,400 --> 02:17:26,960 PUBLIC PRIVATE PARTNERSHIP. MOST 3446 02:17:26,960 --> 02:17:28,480 IMPORTANTLY WE WANT TO THANK 3447 02:17:28,480 --> 02:17:29,920 ADVOCACY PARTNERS AND PATIENTS 3448 02:17:29,920 --> 02:17:31,360 WITH CAREGIVERS AND FAMILY 3449 02:17:31,360 --> 02:17:32,840 MEMBERS WHO CONTRIBUTED TO THE 3450 02:17:32,840 --> 02:17:37,520 MY PART STUDY. WITH THAT WE CAN 3451 02:17:37,520 --> 02:17:43,800 TAKE QUESTIONS. 3452 02:17:43,800 --> 02:17:47,080 >>THANK YOU SO MUCH, DOCTORS 3453 02:17:47,080 --> 02:17:52,200 REILLY AND WIDEMANN. WE CAN OPEN 3454 02:17:52,200 --> 02:17:57,280 THE FLOOR FOR QUESTIONS. 3455 02:17:57,280 --> 02:17:59,080 RICHARD, IF YOU HAVE A QUESTION 3456 02:17:59,080 --> 02:18:01,520 PLEASE USE THE TOOL AT BOTTOM 3457 02:18:01,520 --> 02:18:03,640 THAT WAY I CAN -- GO AHEAD 3458 02:18:03,640 --> 02:18:03,880 RICHARD. 3459 02:18:03,880 --> 02:18:07,040 >>THANK YOU. THE ONLY QUESTION 3460 02:18:07,040 --> 02:18:08,520 I HAVE IS WHETHER THERE'S 3461 02:18:08,520 --> 02:18:11,920 CONSIDERATION FOR IMPROVING OR 3462 02:18:11,920 --> 02:18:12,760 MITIGATING THE LIABILITY 3463 02:18:12,760 --> 02:18:16,080 INSURANCE ISSUES WITH CREATING 3464 02:18:16,080 --> 02:18:22,080 NEW MEDICATIONS FOR RARE TUMORS 3465 02:18:22,080 --> 02:18:24,120 >>I THINK THIS IS SOMETHING 3466 02:18:24,120 --> 02:18:27,960 CERTAINLY BROUGHT UP MANY TIMES. 3467 02:18:27,960 --> 02:18:29,680 I DON'T KNOW NCI IS NECESSARILY 3468 02:18:29,680 --> 02:18:31,480 IN THE POSITION TO SOLVE THE 3469 02:18:31,480 --> 02:18:32,680 PROBLEM BUT I THINK DEFINITELY 3470 02:18:32,680 --> 02:18:35,360 WE NEED TO LOOK FOR CREATIVE 3471 02:18:35,360 --> 02:18:36,680 SOLUTIONS. LOOKS LIKE MONICA 3472 02:18:36,680 --> 02:18:37,520 MIGHT HAVE A RESPONSE TO THAT 3473 02:18:37,520 --> 02:18:41,200 TOO. 3474 02:18:41,200 --> 02:18:44,000 >>MONICA, DID YOU HAVE A 3475 02:18:44,000 --> 02:18:44,720 COMMENT OR ADDITIONAL QUESTION? 3476 02:18:44,720 --> 02:18:48,480 >>NO, THANK YOU. I WANTED TO 3477 02:18:48,480 --> 02:18:51,040 SAY FIRST THANK YOU BRIDGETTE 3478 02:18:51,040 --> 02:18:52,160 AND CAROLYN FOR PRESENTING THIS. 3479 02:18:52,160 --> 02:18:54,280 I WANTED TO LET EVERYONE KNOW 3480 02:18:54,280 --> 02:18:57,720 THIS IS ONE EXAMPLE, WHEN YOU 3481 02:18:57,720 --> 02:18:59,640 LOOK AT THE PUBLIC INVESTMENT IN 3482 02:18:59,640 --> 02:19:02,720 THE NCI INTRAMURAL PROGRAM, WE 3483 02:19:02,720 --> 02:19:04,040 WANTED TO SHOW THIS BECAUSE IT 3484 02:19:04,040 --> 02:19:07,040 IS ONE OF MANY EXAMPLES OF WHERE 3485 02:19:07,040 --> 02:19:08,840 OUR GOAL FOR THE INTRAMURAL 3486 02:19:08,840 --> 02:19:12,680 PROGRAM IS TO DO THINGS THAT 3487 02:19:12,680 --> 02:19:14,080 AUGMENT THAT CAN'T BE DONE IN 3488 02:19:14,080 --> 02:19:16,440 THE EXTRAMURAL COMMUNITY THAT 3489 02:19:16,440 --> 02:19:20,840 BRING VALUE TO EVERYBODY, THAT 3490 02:19:20,840 --> 02:19:22,240 DON'T FORM A POINT OF 3491 02:19:22,240 --> 02:19:23,800 COMPETITION WITH THE EXTRAMURAL 3492 02:19:23,800 --> 02:19:26,960 COMMUNITY BUT RATHER A SYNERGY. 3493 02:19:26,960 --> 02:19:29,600 SOMETHING WE CAN UNIQUELY OFFER. 3494 02:19:29,600 --> 02:19:32,520 I THINK THE CLINICAL CENTER IS A 3495 02:19:32,520 --> 02:19:34,800 TREMENDOUS RESOURCE AND SO THIS 3496 02:19:34,800 --> 02:19:37,280 IS JUST ONE OF MANY EXAMPLES WE 3497 02:19:37,280 --> 02:19:39,400 CAN GIVE YOU OF OUR APPROACH TO 3498 02:19:39,400 --> 02:19:41,000 THE INTRAMURAL PROGRAM AND HOW 3499 02:19:41,000 --> 02:19:43,920 IT CAN REALLY BE COMPLIMENTARY 3500 02:19:43,920 --> 02:19:45,120 TO WHEREVER ELSE WE PUT OUR 3501 02:19:45,120 --> 02:19:52,600 FUNDING. 3502 02:19:52,600 --> 02:19:54,600 >>GREAT. 3503 02:19:54,600 --> 02:19:56,640 >>I GUESS I DO HAVE A QUESTION 3504 02:19:56,640 --> 02:19:58,600 IN TERMS OF IF WE LOOK AT RARE 3505 02:19:58,600 --> 02:20:00,560 CANCER, IS THERE A SPECTRUM OF 3506 02:20:00,560 --> 02:20:04,760 THOSE THAT TEND TO PRESENT 3507 02:20:04,760 --> 02:20:06,680 AGGRESSIVELY AND HAVE MUCH 3508 02:20:06,680 --> 02:20:08,480 HIGHER MORTALITY RATES VERSUS 3509 02:20:08,480 --> 02:20:10,800 THOSE THAT ARE -- CAN BE A BIT 3510 02:20:10,800 --> 02:20:13,560 MORE MANAGEABLE IF DIAGNOSED 3511 02:20:13,560 --> 02:20:17,640 EARLY -- AND SO HOW ARE YOU 3512 02:20:17,640 --> 02:20:21,960 PRIORITIZING YOUR AREAS OF FOCUS 3513 02:20:21,960 --> 02:20:22,360 AND INTEREST? 3514 02:20:22,360 --> 02:20:24,600 >>I THINK THERE IS -- THAT IS 3515 02:20:24,600 --> 02:20:26,160 AN EXCELLENT QUESTION. ONE OF 3516 02:20:26,160 --> 02:20:28,320 THE LIMITATIONS THAT WE HAVE FOR 3517 02:20:28,320 --> 02:20:30,000 PATIENTS TO COME UP TO THE NIH 3518 02:20:30,000 --> 02:20:32,480 CLINICAL CENTER LONGITUDINALLY, 3519 02:20:32,480 --> 02:20:34,280 THE AGGRESSIVE CANCERS WHERE WE 3520 02:20:34,280 --> 02:20:36,560 DON'T HAVE ANYTHING TO OFFER AS 3521 02:20:36,560 --> 02:20:38,680 RELATES TO TREATMENT, WILL BE 3522 02:20:38,680 --> 02:20:41,040 DIFFICULT. AND I THINK THIS IS 3523 02:20:41,040 --> 02:20:43,000 ONE OF THE PRIME EXAMPLES WHERE 3524 02:20:43,000 --> 02:20:44,760 IT WOULD BE WONDERFUL TO 3525 02:20:44,760 --> 02:20:46,120 COLLABORATE WITH MEMORY OR WITH 3526 02:20:46,120 --> 02:20:48,720 A SITE THAT TREATS AGGRESSIVE 3527 02:20:48,720 --> 02:20:49,840 CANCER OR BOSTON CHILDREN'S 3528 02:20:49,840 --> 02:20:51,160 WHERE WE KNOW THAT IS THE 3529 02:20:51,160 --> 02:20:53,800 SURGICAL EXPERTISE OR OTHER 3530 02:20:53,800 --> 02:20:56,160 EXPERTISE WHERE THE SAME DATA 3531 02:20:56,160 --> 02:20:57,520 ELEMENTS, CLINICAL DATA ELEMENTS 3532 02:20:57,520 --> 02:21:00,160 WE USE THE INFRASTRUCTURE CAN BE 3533 02:21:00,160 --> 02:21:03,400 USED BUT EXPERTISE COMES FROM 3534 02:21:03,400 --> 02:21:05,440 THE DISEASE (INAUDIBLE) AT THIS 3535 02:21:05,440 --> 02:21:07,560 SPECIFIC SITE. ONCE WE HAVE A 3536 02:21:07,560 --> 02:21:09,280 CLINICAL TRIAL INTERVENTIONAL 3537 02:21:09,280 --> 02:21:10,840 TRIAL THEN IT CHANGES. THEN WE 3538 02:21:10,840 --> 02:21:12,440 CAN GET PATIENTS TO COME TO THE 3539 02:21:12,440 --> 02:21:14,800 NIH CLINICAL CENTER AND OTHER 3540 02:21:14,800 --> 02:21:16,680 SITES. BUT TO REALLY MAKE 3541 02:21:16,680 --> 02:21:19,040 PROGRESS ON THE VERY AGGRESSIVE 3542 02:21:19,040 --> 02:21:20,120 CANCERS WE NEED THE 3543 02:21:20,120 --> 02:21:21,480 COLLABORATION WITH THE 3544 02:21:21,480 --> 02:21:24,160 EXTRAMURAL PARTNERS AND WE HOPE 3545 02:21:24,160 --> 02:21:25,400 THIS INFRASTRUCTURE THAT WILL BE 3546 02:21:25,400 --> 02:21:27,600 CREATED THROUGH THE CCDI CAN BE 3547 02:21:27,600 --> 02:21:31,240 UTILIZED AND FACILITATE ENABLE 3548 02:21:31,240 --> 02:21:32,360 THE RESEARCH DIFFICULT TO DO 3549 02:21:32,360 --> 02:21:36,240 OTHERWISE. AT EXTRAMURAL SITES. 3550 02:21:36,240 --> 02:21:36,400 T 3551 02:21:36,400 --> 02:21:39,840 >>ONE THING I WANT TO ADD, YOU 3552 02:21:39,840 --> 02:21:41,840 TALKING ABOUT EARLY DETECTION 3553 02:21:41,840 --> 02:21:44,640 AND PREVENTION TO MAKE THESE 3554 02:21:44,640 --> 02:21:47,440 THINGS EASIER TO WORK WITH. FROM 3555 02:21:47,440 --> 02:21:49,080 SO MANY RARE TUMORS THERE IS NOT 3556 02:21:49,080 --> 02:21:51,040 THE KNOWLEDGE BASE THERE. AND 3557 02:21:51,040 --> 02:21:53,480 THERE ISN'T THE FAMILIARITY IN 3558 02:21:53,480 --> 02:21:55,720 THE COMMUNITY. SO WHAT WE FIND 3559 02:21:55,720 --> 02:21:57,640 IS THAT THE DIAGNOSTIC ODYSSEYS 3560 02:21:57,640 --> 02:21:59,440 FOR THESE PATIENTS IS VERY LONG 3561 02:21:59,440 --> 02:22:02,160 AND USUALLY DIAGNOSED LATE AND 3562 02:22:02,160 --> 02:22:04,040 USUALLY DIAGNOSED MUCH HIGHER 3563 02:22:04,040 --> 02:22:04,960 LEVEL AGGRESSIVENESS THAN 3564 02:22:04,960 --> 02:22:07,360 NECESSARY. SO I THINK THAT IS 3565 02:22:07,360 --> 02:22:09,280 ONE OUR GOALS IS TO BE 3566 02:22:09,280 --> 02:22:13,800 DISSEMINATING THE INFORMATION SO 3567 02:22:13,800 --> 02:22:15,960 THAT THIS BECOMES MORE 3568 02:22:15,960 --> 02:22:17,360 RECOGNIZED PAPPED TUMORS CAN BE 3569 02:22:17,360 --> 02:22:18,400 CAUGHT EARLIER AND WE CAN FOCUS 3570 02:22:18,400 --> 02:22:19,960 ON THE ONES THAT ARE MUCH MORE 3571 02:22:19,960 --> 02:22:23,920 AGGRESSIVE. 3572 02:22:23,920 --> 02:22:26,640 >>ANOTHER FASCINATING ASPECT I 3573 02:22:26,640 --> 02:22:28,560 THINK OF SOME OF THESE PEDIATRIC 3574 02:22:28,560 --> 02:22:31,440 AND AYA CANCERS IS YOU DO HAVE 3575 02:22:31,440 --> 02:22:32,880 THOSE THAT ARE DRIVEN BY FOR 3576 02:22:32,880 --> 02:22:34,920 INSTANCE BETA CATENIN, THINGS 3577 02:22:34,920 --> 02:22:40,240 MORE ONCOGENIC, VERSUS SORT OF 3578 02:22:40,240 --> 02:22:41,560 ALTERATIONS THAT PROCURE 3579 02:22:41,560 --> 02:22:44,200 PROCESSES THAT ARE MORE 3580 02:22:44,200 --> 02:22:47,920 DEVELOPMENT AND DIFFERENTIATION. 3581 02:22:47,920 --> 02:22:50,840 SO HOW ARE YOU STRATIFYING THE 3582 02:22:50,840 --> 02:22:53,640 WHOLE CONCEPT OF PRIORITIZATION, 3583 02:22:53,640 --> 02:22:56,080 RIGHT? BECAUSE THE BIOLOGICAL 3584 02:22:56,080 --> 02:23:01,280 PROCESS IS THAT DRIVER CANCER 3585 02:23:01,280 --> 02:23:02,400 DIFFERENT WHICH DRIVES 3586 02:23:02,400 --> 02:23:03,640 APPROACHES TO TREATMENT THAT CAN 3587 02:23:03,640 --> 02:23:03,960 BE DIFFERENT. 3588 02:23:03,960 --> 02:23:08,480 >>THAT IS ABSOLUTELY RIGH RIGHO 3589 02:23:08,480 --> 02:23:09,960 YOU WANT TO RESPOND TO THAT 3590 02:23:09,960 --> 02:23:10,360 FIRST? 3591 02:23:10,360 --> 02:23:12,560 >>IT IS THE PRIORITIZATION 3592 02:23:12,560 --> 02:23:14,800 COULD BE WHERE THE GREATEST 3593 02:23:14,800 --> 02:23:17,000 UNMET NEED. BUT WHICH I THINK 3594 02:23:17,000 --> 02:23:20,200 WOULD BE STILL FAIR TO DO. I 3595 02:23:20,200 --> 02:23:22,240 FEEL FOR SUCCESS IF WE KNOW OF 3596 02:23:22,240 --> 02:23:23,640 DISEASE CHAMPIONS WE KNOW OF 3597 02:23:23,640 --> 02:23:25,320 PEOPLE WHO ARE ALREADY INVESTED 3598 02:23:25,320 --> 02:23:27,000 BUT WE HAVE NOT HAD THE ABILITY 3599 02:23:27,000 --> 02:23:29,040 TO RECRUIT MEANINGFUL COHORT, 3600 02:23:29,040 --> 02:23:32,400 THAT IS WHERE I WOULD GO. FOUR 3601 02:23:32,400 --> 02:23:35,280 AREAS WE BEGIN TO UNDERSTAND THE 3602 02:23:35,280 --> 02:23:37,520 BIOLOGY AND MIGHT BE CLOSE, I 3603 02:23:37,520 --> 02:23:39,720 WOULD ALSO GO, I THINK IT IS A 3604 02:23:39,720 --> 02:23:43,960 GREAT QUESTION HOW WE 3605 02:23:43,960 --> 02:23:46,520 PRIORITIZE, IN MY MIND HAVING 3606 02:23:46,520 --> 02:23:48,440 SOMETHING TRUTHFULLY COMMITTED 3607 02:23:48,440 --> 02:23:51,640 AND GOING ALL THE WAY FOR EVERY 3608 02:23:51,640 --> 02:23:54,200 PATIENT TO ALLOW US TO HOPEFULLY 3609 02:23:54,200 --> 02:23:57,120 THE GREATEST PROGRESS. 3610 02:23:57,120 --> 02:23:58,640 >>COLLEAGUES THAT WE ARE 3611 02:23:58,640 --> 02:23:59,920 WORKING ON WITH THIS ARE MOST 3612 02:23:59,920 --> 02:24:02,640 INTERESTED IN THE IDEA THAT 3613 02:24:02,640 --> 02:24:04,160 THERE -- THAT PEOPLE DON'T KNOW 3614 02:24:04,160 --> 02:24:06,720 ABOUT EACH OTHER. THERE MAYBE 3615 02:24:06,720 --> 02:24:07,960 TECHNOLOGIES THAT COULD BE 3616 02:24:07,960 --> 02:24:12,160 APPLIED TO SOME OF THESE FUSIONS 3617 02:24:12,160 --> 02:24:15,560 WHERE WE KNOW THAT IT IS 3618 02:24:15,560 --> 02:24:18,480 IMPORTANT TUMOR BUT IT HASN'T 3619 02:24:18,480 --> 02:24:21,040 HAD THE RIGHT TECHNOLOGY APPLIED 3620 02:24:21,040 --> 02:24:24,280 TO IT. SO THAT'S ONE OF THE 3621 02:24:24,280 --> 02:24:25,880 GOALS OF THIS PUBLIC PRIVATE 3622 02:24:25,880 --> 02:24:28,640 PARTNERSHIP IS TO REALLY BE ABLE 3623 02:24:28,640 --> 02:24:30,080 TO TRY AND APPLY NEW 3624 02:24:30,080 --> 02:24:31,440 TECHNOLOGIES. 3625 02:24:31,440 --> 02:24:33,800 >>GREAT. I THINK I SAW 3626 02:24:33,800 --> 02:24:35,280 HOWARD'S HAND FIRST, THEN ANN 3627 02:24:35,280 --> 02:24:42,520 BARKER. HOWARD. 3628 02:24:42,520 --> 02:24:44,520 >>THANK YOU, VERY MUCH FOR 3629 02:24:44,520 --> 02:24:47,200 DOING THIS. AND THE EFFORTS. 3630 02:24:47,200 --> 02:24:52,160 COMING FROM INDUSTRY, I HAVE 3631 02:24:52,160 --> 02:24:55,200 SEEN THE -- A LOT OF 3632 02:24:55,200 --> 02:24:56,240 MISPERCEPTIONS THAT SEEM THE 3633 02:24:56,240 --> 02:24:58,800 LEAD TO BARRIERS TO DECISION 3634 02:24:58,800 --> 02:25:01,200 MAKING WORKING ON UN-- ON RARE 3635 02:25:01,200 --> 02:25:04,240 TUMORS. SOME OF THEM HAVE TO DO 3636 02:25:04,240 --> 02:25:07,480 WITH HISTORIC BARRIERS TO -- FOR 3637 02:25:07,480 --> 02:25:10,480 IP, ET CETERA. COULD YOU SHARE 3638 02:25:10,480 --> 02:25:14,800 YOUR THOUGHTS ON THIS AND YOU 3639 02:25:14,800 --> 02:25:20,200 SEE WAYS THAT YOUR 3640 02:25:20,200 --> 02:25:21,600 COLLABORATIONS, ARE WITHIN ON 3641 02:25:21,600 --> 02:25:24,320 THE LEGAL SIDE, ALL THESE SIDES, 3642 02:25:24,320 --> 02:25:26,760 ARE GOING TO HELP MITIGATE 3643 02:25:26,760 --> 02:25:29,560 THESE, AND HELP ADVANCE INDUSTRY 3644 02:25:29,560 --> 02:25:32,000 SPONSORS TO SEEK OUTS MORE 3645 02:25:32,000 --> 02:25:33,120 COLLABORATIONS WITH YOU ALONG 3646 02:25:33,120 --> 02:25:35,480 THE LINES OF WHAT WE HEARD ABOUT 3647 02:25:35,480 --> 02:25:40,080 FOR THE SOFT TISSUE SARCOMA 3648 02:25:40,080 --> 02:25:40,680 WORK? 3649 02:25:40,680 --> 02:25:42,400 >>YEAH, ONE OF THE HOPES IS THE 3650 02:25:42,400 --> 02:25:46,480 OPEN NOTEBOOK PROCESS WOULD 3651 02:25:46,480 --> 02:25:48,480 DISPEL SOME OF THE PRE-CONCEIVED 3652 02:25:48,480 --> 02:25:50,520 NOTIONS, THAT WE DON'T WANT 3653 02:25:50,520 --> 02:25:52,400 INDUSTRY DECIDING NOT TO 3654 02:25:52,400 --> 02:25:53,720 PARTICIPATE BECAUSE THEY ASSUME 3655 02:25:53,720 --> 02:25:57,080 THAT THE FDA WILL SHUT DOWN THE 3656 02:25:57,080 --> 02:25:59,680 IDEAS UP FRONT. SO THE IDEA IS 3657 02:25:59,680 --> 02:26:02,480 THAT THERE WILL BE THIS RECORD 3658 02:26:02,480 --> 02:26:04,400 OF HOW THE FDA MADE ITS DECISION 3659 02:26:04,400 --> 02:26:07,200 MAKING PROCESSES THAT CAN THEN 3660 02:26:07,200 --> 02:26:09,120 REFER BACK TO AND REALLY PEOPLE 3661 02:26:09,120 --> 02:26:14,040 CAN SEE A WAY FORWARD. TOWARDS 3662 02:26:14,040 --> 02:26:17,280 DOING THESE KINDS OF THINGS. WE 3663 02:26:17,280 --> 02:26:18,440 ACKNOWLEDGE THERE WILL BE CASES 3664 02:26:18,440 --> 02:26:22,400 WHERE THERE IS NO FINANCIAL 3665 02:26:22,400 --> 02:26:23,840 INCENTIVE FOR INDUSTRY. THERE 3666 02:26:23,840 --> 02:26:25,640 WON'T BE ENOUGH PATIENTS AND IT 3667 02:26:25,640 --> 02:26:28,520 JUST WON'T WORK. THAT'S WHERE 3668 02:26:28,520 --> 02:26:29,640 THE GOVERNMENT I THINK NEEDS TO 3669 02:26:29,640 --> 02:26:36,040 STEP IN. BECAUSE IF WE CAN CURE 3670 02:26:36,040 --> 02:26:37,600 EVERYONE WITH THE SAME 3671 02:26:37,600 --> 02:26:38,600 IMMUNOTHERAPY WE DON'T NEED THIS 3672 02:26:38,600 --> 02:26:42,320 PROGRAM. SO I THINK REALLY THE 3673 02:26:42,320 --> 02:26:45,280 IDEA IS TO TRY AND FOCUS ON 3674 02:26:45,280 --> 02:26:46,680 THINGS WHERE IT WON'T HAPPEN ON 3675 02:26:46,680 --> 02:26:52,880 ITS OWN. AGREE, A HUGE PART OF 3676 02:26:52,880 --> 02:26:55,840 THIS PROGRAM WILL BE GETTING THE 3677 02:26:55,840 --> 02:26:59,160 IP RIGHTS, RIGHT UP FRONT. SO I 3678 02:26:59,160 --> 02:27:00,520 THINK THAT THAT WILL BE A BIG 3679 02:27:00,520 --> 02:27:02,880 PART OF IT. IS TO GET CREATIVE 3680 02:27:02,880 --> 02:27:05,320 ON IT. 3681 02:27:05,320 --> 02:27:09,000 >>RIGHT P. 3682 02:27:09,000 --> 02:27:11,600 >>QUICK COMMENT. DRUG DISCOVERY 3683 02:27:11,600 --> 02:27:13,880 AT THE NCI GOES BACK TO THE 3684 02:27:13,880 --> 02:27:15,120 1970s AND WE WERE FIRST IN 3685 02:27:15,120 --> 02:27:17,640 CLASS IN TERMS OF EVEN FIGURING 3686 02:27:17,640 --> 02:27:20,120 OUT WHO MAKES THOSE DRUGS AND WE 3687 02:27:20,120 --> 02:27:23,080 LEARNED A LOT, WE STILL HAVE A 3688 02:27:23,080 --> 02:27:24,560 VERY POWERFUL I THINK MAYBE THE 3689 02:27:24,560 --> 02:27:27,000 MOST POWERFUL DRUG DISCOVERY 3690 02:27:27,000 --> 02:27:28,120 DEVELOPMENT ACTIVITIES OF ANY OF 3691 02:27:28,120 --> 02:27:30,040 THE INSTITUTES OR ANYWHERE ELSE 3692 02:27:30,040 --> 02:27:31,520 ACTUALLY. SO I'M BONDING ARE HOW 3693 02:27:31,520 --> 02:27:34,360 MUCH OF THAT KNOWLEDGE CAN YOU 3694 02:27:34,360 --> 02:27:37,760 LEVERAGE? WHEN YOU GET -- THE 3695 02:27:37,760 --> 02:27:39,280 DISCOVERIES WILL LEAD TO 3696 02:27:39,280 --> 02:27:40,400 DISCOVERIES, THAT IS GREAT BUT 3697 02:27:40,400 --> 02:27:42,520 AFTER THAT ALL BECOMES HOW YOU 3698 02:27:42,520 --> 02:27:44,600 DEVELOP THIS TARGET HOW YOU 3699 02:27:44,600 --> 02:27:47,800 DEVELOP THIS. I LOVE THE IDEA OF 3700 02:27:47,800 --> 02:27:52,360 INDUSTRY BEING ENGAGED. I'M NOT 3701 02:27:52,360 --> 02:27:54,240 REALLY OPTIMISTIC YET THAT I 3702 02:27:54,240 --> 02:27:55,680 WILL PICK HEM UP AN RUN WITH 3703 02:27:55,680 --> 02:27:58,360 THEM. I WORK IN GBN A LOT AND 3704 02:27:58,360 --> 02:28:00,080 THAT IS WHAT THEY TELL YOU, THEY 3705 02:28:00,080 --> 02:28:01,320 DON'T WANT -- THEY WANT TO HELP 3706 02:28:01,320 --> 02:28:05,520 YOU BUT NOT WITH WARE DRUG. SO 3707 02:28:05,520 --> 02:28:06,720 HOW MUCH CAN YOU LOVE WHAT WE 3708 02:28:06,720 --> 02:28:08,960 ALREADY KNOW HOW TO DO AND THEN 3709 02:28:08,960 --> 02:28:10,360 WHAT SPECIFICALLY ARE YOU GOING 3710 02:28:10,360 --> 02:28:12,240 TO DO TO ENTICE THE INDUSTRY 3711 02:28:12,240 --> 02:28:13,400 INTO THIS SPACE? I WOULD LOVE TO 3712 02:28:13,400 --> 02:28:19,560 SEE IT. WE FOUGHT THIS BATTLE 3713 02:28:19,560 --> 02:28:20,600 FOR A LONG TIME. 3714 02:28:20,600 --> 02:28:22,840 >>I ABSOLUTELY AGREE WITH YOU. 3715 02:28:22,840 --> 02:28:26,840 THERE ARE MANY PROGRAMS AT OUR 3716 02:28:26,840 --> 02:28:28,640 STAKEHOLDER MEETING WE HEARD 3717 02:28:28,640 --> 02:28:31,160 FROM SOME PEOPLE INVOLVED IN 3718 02:28:31,160 --> 02:28:33,040 CHEMICAL BIOLOGY OPTIMIZATION, 3719 02:28:33,040 --> 02:28:34,320 THERE'S THE NEXT PROGRAM. WE 3720 02:28:34,320 --> 02:28:35,120 HEARD FROM SOMEONE ELSE ABOUT 3721 02:28:35,120 --> 02:28:39,720 THAT. I THINK ALL OF THESE WE 3722 02:28:39,720 --> 02:28:41,080 NEED TO TAKE ADVANTAGE OF THE 3723 02:28:41,080 --> 02:28:45,920 EXPERIENCE DEVELOPED THERE. AND 3724 02:28:45,920 --> 02:28:47,520 IN TERMS OF ENTICING INDUSTRY, I 3725 02:28:47,520 --> 02:28:49,040 THINK IT IS STILL AN OPEN 3726 02:28:49,040 --> 02:28:51,160 QUESTION. IT MAY BE THE KIND OF 3727 02:28:51,160 --> 02:28:54,760 THING WHERE WE NEED TO RELY ON 3728 02:28:54,760 --> 02:29:00,640 THIRD IN CLASS DRUGS BEING PUT 3729 02:29:00,640 --> 02:29:02,400 FORWARD OR ALLOWING THINGS TO GO 3730 02:29:02,400 --> 02:29:03,640 INTO CHILDREN WHERE THEY HAVEN'T 3731 02:29:03,640 --> 02:29:05,720 BEEN IN CHILDREN BEFORE. WE ARE 3732 02:29:05,720 --> 02:29:09,120 GOING TO NEED TO BE CREATIVE IN 3733 02:29:09,120 --> 02:29:10,960 TERMS OF THESE THINGS. I THINK 3734 02:29:10,960 --> 02:29:14,160 IT IS FRUSTRATING WHEN YOU THINK 3735 02:29:14,160 --> 02:29:16,160 OF SOMETHING LIKE SOME OF THESE 3736 02:29:16,160 --> 02:29:21,560 FUSIONS IDENTIFIED FOR DECADES 3737 02:29:21,560 --> 02:29:24,640 AND DECADES. IS THERE'S BEEN NO 3738 02:29:24,640 --> 02:29:26,160 SUCCESSFUL APPROACHES YET SO ONE 3739 02:29:26,160 --> 02:29:27,640 OF THE THINGS WE HOPE IS THAT 3740 02:29:27,640 --> 02:29:32,040 THERE ARE GOING TO BE TECHNOLOGY 3741 02:29:32,040 --> 02:29:34,680 FIRMS THAT MAYBE AREN'T IN THE 3742 02:29:34,680 --> 02:29:35,880 ONCOLOGY SPACE THAT WILL BE 3743 02:29:35,880 --> 02:29:37,360 INTERESTED IN TESTING OUT SOME 3744 02:29:37,360 --> 02:29:41,560 OF THE TECHNOLOGIES. THAN 3745 02:29:41,560 --> 02:29:44,720 THROUGH PARTNERSHIP, BEING ABLE 3746 02:29:44,720 --> 02:29:47,880 TO USE RESOURCES AND NCATS AND 3747 02:29:47,880 --> 02:29:49,680 NCI TO REALLY REDUCE THEIR COST 3748 02:29:49,680 --> 02:29:53,760 OF DRUG DEVELOPMENT. HOPEFULLY 3749 02:29:53,760 --> 02:29:56,640 COME UP WITH WAYS TO PROVIDE 3750 02:29:56,640 --> 02:29:58,200 DRUG LONG TERM TO PATIENTS 3751 02:29:58,200 --> 02:29:59,840 BECAUSE THAT IS THE BIG 3752 02:29:59,840 --> 02:30:01,520 QUESTION, WE HAD SOME PEOPLE AT 3753 02:30:01,520 --> 02:30:03,280 THE STAKEHOLDER MEETING DESCRIBE 3754 02:30:03,280 --> 02:30:05,960 DRUGS BUT GOTTEN APPROVED FOR 3755 02:30:05,960 --> 02:30:09,480 ULTRA RARE CANCERS AND THEN WERE 3756 02:30:09,480 --> 02:30:10,280 DROPPED BY INDUSTRY BECAUSE 3757 02:30:10,280 --> 02:30:13,240 THERE WASN'T A MARKET. THAT IS 3758 02:30:13,240 --> 02:30:15,640 PARTS OF THIS IS FIGURE OUT THE 3759 02:30:15,640 --> 02:30:16,520 GOVERNMENT STAKE THAT STUFF BACK 3760 02:30:16,520 --> 02:30:18,640 AND MAKE SURE IT STAYS AVAILABLE 3761 02:30:18,640 --> 02:30:19,680 FOR THE PATIENTS. 3762 02:30:19,680 --> 02:30:22,680 >>WE HAD TO DO A LOT, KATHLEEN, 3763 02:30:22,680 --> 02:30:26,320 TO GET YOU -- PEDIATRICS ON THE 3764 02:30:26,320 --> 02:30:30,360 AGENDA, INDUSTRY AT ALL ALL. ANW 3765 02:30:30,360 --> 02:30:31,600 THIS NEXT PHASE, IT IS 3766 02:30:31,600 --> 02:30:33,080 INTERESTING O TO SEE HOW THIS 3767 02:30:33,080 --> 02:30:34,360 GOES. I COME BACK WITH A COMMENT 3768 02:30:34,360 --> 02:30:37,720 ON IP, IF YOU PROTECT IT 3769 02:30:37,720 --> 02:30:38,840 CAREFULLY THAT INDUSTRY WILL 3770 02:30:38,840 --> 02:30:42,200 CERTAINLY ENTERTAIN THE IDEA. 3771 02:30:42,200 --> 02:30:44,280 BUT MAYBE CERTAIN COMPANIES THAT 3772 02:30:44,280 --> 02:30:45,880 BECOME SPECIALISTS IN THIS AREA. 3773 02:30:45,880 --> 02:30:47,280 AND FOR RARE TUMORS I CAN SEE 3774 02:30:47,280 --> 02:30:50,080 THAT IN THE FUTURE. 3775 02:30:50,080 --> 02:30:53,240 >>I TALKED TO SOMEONE FROM AN 3776 02:30:53,240 --> 02:30:57,320 ASTRA ZENECA SPIN OFF INTERESTED 3777 02:30:57,320 --> 02:30:58,560 IN THIS KIND OF THING. TALKING 3778 02:30:58,560 --> 02:31:00,760 TO PEOPLE ABOUT THE NUTS AND 3779 02:31:00,760 --> 02:31:03,680 BOLTS OF LICENSING. I THINK THAT 3780 02:31:03,680 --> 02:31:09,120 THERE IS A LOT OF FEAR THAT 3781 02:31:09,120 --> 02:31:13,800 BRINGING SOMETHING -- BRINGING 3782 02:31:13,800 --> 02:31:15,440 SOMETHING FORWARD THAT IS 3783 02:31:15,440 --> 02:31:18,480 ALREADY GOOD IN A COMMON 3784 02:31:18,480 --> 02:31:20,280 APPLICATION, THERE CAN ONLY BE 3785 02:31:20,280 --> 02:31:21,720 NEGATIVE REPERCUSSIONS OF 3786 02:31:21,720 --> 02:31:26,360 TESTING IT IN SOMETHING ELSE. 3787 02:31:26,360 --> 02:31:27,720 THAT IS WHAT WE HAVE TO COME UP 3788 02:31:27,720 --> 02:31:29,720 WITH SOLUTIONS FOR. 3789 02:31:29,720 --> 02:31:34,560 >>AGAIN, A LOT OF THE WORK IS 3790 02:31:34,560 --> 02:31:36,200 DONE. , TARGETS THAT ARE COMMON 3791 02:31:36,200 --> 02:31:38,520 IN ADULT CANCERS. AND THE 3792 02:31:38,520 --> 02:31:40,080 PROCESSES ARE JUST A BIT 3793 02:31:40,080 --> 02:31:44,400 DIFFERENT. THERE'S OVERLAP OF 3794 02:31:44,400 --> 02:31:46,080 COURSE. BUT WE HAVE TO CONSIDER 3795 02:31:46,080 --> 02:31:50,560 NEW APPROACHES. ANTIBODY BASED 3796 02:31:50,560 --> 02:31:52,800 APPROACHES AND MAYBE CELL BASED 3797 02:31:52,800 --> 02:31:55,760 THERAPY APPROACHES GO BEYOND THE 3798 02:31:55,760 --> 02:31:58,240 STANDARD SMALL MOLECULE DRUG 3799 02:31:58,240 --> 02:32:00,320 DEVELOPMENT THAT WE TEND TO 3800 02:32:00,320 --> 02:32:02,120 ALWAYS WANT TO FALL BACK TO. 3801 02:32:02,120 --> 02:32:05,720 >>THERE'S BEEN A LOT OF 3802 02:32:05,720 --> 02:32:08,080 ENTHUSIASM WITHIN OUR DISCUSSION 3803 02:32:08,080 --> 02:32:10,680 GROUPS FOR ANTISENSE AND PROTAX 3804 02:32:10,680 --> 02:32:14,760 AND THINGS LIKE THIS. AND FOR 3805 02:32:14,760 --> 02:32:16,520 THE FUSION PROTEINS AND 3806 02:32:16,520 --> 02:32:18,640 PEDIATRICS THOSE AREN'T GOING TO 3807 02:32:18,640 --> 02:32:22,800 BE APPLICABLE. BUT THEY MAY BE 3808 02:32:22,800 --> 02:32:24,280 INCREDIBLY EFFECTI EFFECTIVE. IU 3809 02:32:24,280 --> 02:32:29,080 THINK IN TERMS OF PRODUCTIVE 3810 02:32:29,080 --> 02:32:31,360 YEARS OF INDIVIDUALS, THAT YOU 3811 02:32:31,360 --> 02:32:33,040 ARE TREATING, I THINK FROM A 3812 02:32:33,040 --> 02:32:34,440 SOCIETAL POINT OF VIEW IT IS A 3813 02:32:34,440 --> 02:32:39,600 GREAT INVESTMENT. 3814 02:32:39,600 --> 02:32:42,840 >>INCREDIBLE ADVANCES IN CRYOEM 3815 02:32:42,840 --> 02:32:44,200 WILL HELP WITH STRUCTURAL 3816 02:32:44,200 --> 02:32:45,800 BIOLOGY AND REALLY 3817 02:32:45,800 --> 02:32:48,520 UNDERSTANDING, IF SOME OF THESE 3818 02:32:48,520 --> 02:32:49,760 ARE DRUGGABLE TARGETS. 3819 02:32:49,760 --> 02:32:51,720 WONDERFUL WORK. I AGREE WITH 3820 02:32:51,720 --> 02:32:53,080 MONICA, THIS IS WHEN WE THINK 3821 02:32:53,080 --> 02:32:56,240 ABOUT THE INTRAMURAL PROGRAM, WE 3822 02:32:56,240 --> 02:32:58,560 CAN BE DONE THERE, THAT CAN'T BE 3823 02:32:58,560 --> 02:32:59,720 DONE ANYWHERE ELSE THAT'S THE 3824 02:32:59,720 --> 02:33:02,160 WORK THIS IS, THANK YOU SO MUCH 3825 02:33:02,160 --> 02:33:07,120 FOR ALL THESE EFFORTS. 3826 02:33:07,120 --> 02:33:11,800 >>I THINK WE NOW WILL CONSIDER 3827 02:33:11,800 --> 02:33:15,680 ONGOING BUSINESS. SO PRIOR TO 3828 02:33:15,680 --> 02:33:16,720 ADJOURNING THE OPEN SESSION ARE 3829 02:33:16,720 --> 02:33:21,040 THERE OTHER ISSUES THAT ANY OF 3830 02:33:21,040 --> 02:33:23,880 THE MEMBERS OR NCI PARTNERS 3831 02:33:23,880 --> 02:33:25,200 WOULD LIKE TO CONSIDER 3832 02:33:25,200 --> 02:33:35,720 ADDRESSING? I THINK WITH ALL THE 3833 02:33:40,720 --> 02:33:42,240 BUDGET, IT WAS GREAT TO ENDS ON 3834 02:33:42,240 --> 02:33:48,680 THAT TALK. RIGHT? ALL OF THE 3835 02:33:48,680 --> 02:33:51,600 SORT OF THE BUDGETARY CONCERNS 3836 02:33:51,600 --> 02:33:55,960 AND DISCUSSIONS. I THINK MANY OF 3837 02:33:55,960 --> 02:33:57,920 US DEFINITELY WANT TO PROTECT 3838 02:33:57,920 --> 02:34:00,320 OUR TRAINEES AT OUR EARLY STAGE 3839 02:34:00,320 --> 02:34:02,000 INVESTIGATORS. I THINK CERTAINLY 3840 02:34:02,000 --> 02:34:03,600 BACK TO THAT IN FUTURE MEETINGS 3841 02:34:03,600 --> 02:34:08,080 WOULD BE AWESOME. I THINK AS 3842 02:34:08,080 --> 02:34:09,480 MENTIONED EARLIER WOULD BE GREAT 3843 02:34:09,480 --> 02:34:11,640 TO HEAR MORE ABOUT THE PAST, THE 3844 02:34:11,640 --> 02:34:14,520 PRESENT, THE FUTURE FOR THE 3845 02:34:14,520 --> 02:34:17,280 CANCER MOON SHOT. HOW WE SHORE 3846 02:34:17,280 --> 02:34:19,640 THAT UP AND MAKE SURE THAT ALL 3847 02:34:19,640 --> 02:34:21,760 OF THE INVESTMENT THAT WAS PUT 3848 02:34:21,760 --> 02:34:25,960 INTO IT CONTINUES TO BE 3849 02:34:25,960 --> 02:34:30,800 LEVERAGED. ANY ADDITIONAL 3850 02:34:30,800 --> 02:34:31,440 QUESTIONS AND COMMENTS FROM THE 3851 02:34:31,440 --> 02:34:41,840 BOARD? OKAY. PAULETTE. 3852 02:34:42,120 --> 02:34:44,120 >>SUGGESTIONS FOR FUTURE AGENDA 3853 02:34:44,120 --> 02:34:49,480 ATEAMITEM? 3854 02:34:49,480 --> 02:34:50,320 >>I MENTIONED THE TWO, WOULD 3855 02:34:50,320 --> 02:34:52,760 LOVE TO HEAR FROM OTHERS. 3856 02:34:52,760 --> 02:34:55,320 >>HOWARD, DID I SEE YOUR HAND? 3857 02:34:55,320 --> 02:35:03,080 >>YES. BIOMARKERS. THE 3858 02:35:03,080 --> 02:35:05,640 BIOMARKER CONSORTIUM NCI 3859 02:35:05,640 --> 02:35:08,080 SUPPORTS IN COLLABORATION WITH 3860 02:35:08,080 --> 02:35:11,280 INDUSTRY AND CMAX, WE HAVE HAD 3861 02:35:11,280 --> 02:35:13,240 REVIEWS OF THIS IN PAST YEARS 3862 02:35:13,240 --> 02:35:16,200 BUT THERE IS A LOT OF WORK AND 3863 02:35:16,200 --> 02:35:19,960 FAILURES IN MY VIEW. 3864 02:35:19,960 --> 02:35:21,080 INTERVENTIONS DRIVEN BY SOME OF 3865 02:35:21,080 --> 02:35:23,720 THOSE BIOMARKERS. AND I THINK IT 3866 02:35:23,720 --> 02:35:25,760 WOULD BE GREAT TO HEAR WHERE 3867 02:35:25,760 --> 02:35:31,600 SOME OF THOUGHT LEADERS ON THAT 3868 02:35:31,600 --> 02:35:33,360 SEE THE BARRIERS AND HOW WE ARE 3869 02:35:33,360 --> 02:35:34,440 GOING TO ADDRESS THAT GOING 3870 02:35:34,440 --> 02:35:37,200 FORWARDFORWARD. IN TERMS OF IMG 3871 02:35:37,200 --> 02:35:40,560 THE PUBLIC HEALTH USING 3872 02:35:40,560 --> 02:35:42,200 IMMUNO-ONCOLOGY PRODUCTS WHICH 3873 02:35:42,200 --> 02:35:44,920 WERE REALLY SOME OF THE GOALS 3874 02:35:44,920 --> 02:35:47,720 WHEN I SAY BIOMARKERS I MEAN 3875 02:35:47,720 --> 02:35:50,400 ESPECIALLY COMPANION DIAGNOSTICS 3876 02:35:50,400 --> 02:35:54,280 TO BETTER DESIGN NEW TRIALS, 3877 02:35:54,280 --> 02:35:58,240 SUCCESSFUL NEW TRIALS. 3878 02:35:58,240 --> 02:36:01,280 >>YOU SAID BIOMARKERS C MAX. 3879 02:36:01,280 --> 02:36:03,200 OKAY. 3880 02:36:03,200 --> 02:36:05,440 >>CMAC INSTITUTIONS THAT ARE 3881 02:36:05,440 --> 02:36:08,000 PART OF THE MOON SHOT THAT WERE 3882 02:36:08,000 --> 02:36:11,240 FUNDED BY THE MOON SHOT 3883 02:36:11,240 --> 02:36:13,040 CONSORTIUM TO VALIDATE 3884 02:36:13,040 --> 02:36:17,280 IMMUNO-ONCOLOGY BIOMARKERS. 3885 02:36:17,280 --> 02:36:20,880 >>ARE THERE OTHER SUGGESTIONS 3886 02:36:20,880 --> 02:36:25,280 FOR FUTURE AGENDA ITEMS? 3887 02:36:25,280 --> 02:36:28,720 >>I WOULD LOVE TO HEAR MORE 3888 02:36:28,720 --> 02:36:34,080 ABOUT FUTURE OF NCOR IN TERMS OF 3889 02:36:34,080 --> 02:36:36,400 THE STRATEGY GOING FORWARD, 3890 02:36:36,400 --> 02:36:39,720 INTEGRATION CANCER CENTERS AND 3891 02:36:39,720 --> 02:36:41,720 BE GET TO HEAR A LITTLE BIT 3892 02:36:41,720 --> 02:36:45,120 MORE, NOT ABOUT THE PREVIOUS BUT 3893 02:36:45,120 --> 02:36:46,880 WHAT IS MCOR THINKING ABOUT IN 3894 02:36:46,880 --> 02:36:53,560 TERMS OF THE FUTURE. SUCH AN 3895 02:36:53,560 --> 02:36:57,400 IMPORTANT COMPONENT OF THE NCI. 3896 02:36:57,400 --> 02:36:57,920 >>OKAY. 3897 02:36:57,920 --> 02:36:59,400 >>KAREN. 3898 02:36:59,400 --> 02:37:01,960 >>THANK YOU SO MUCH. THANK YOU 3899 02:37:01,960 --> 02:37:03,400 FOR ALL THE PRESENTATIONS. I 3900 02:37:03,400 --> 02:37:06,200 WOULD LIKE TO HEAR MORE ABOUT 3901 02:37:06,200 --> 02:37:07,480 THE MULTI-CANCER DETECTION. I 3902 02:37:07,480 --> 02:37:09,080 THINK THAT THAT IS AN AREA THAT 3903 02:37:09,080 --> 02:37:11,640 WE NEED TO BE ON THE FOREFRONT 3904 02:37:11,640 --> 02:37:13,400 ON. IT IS AN EXPENSIVE PROPOSAL 3905 02:37:13,400 --> 02:37:16,160 IN MANY, MANY WAYS AND WE ARE 3906 02:37:16,160 --> 02:37:17,640 JUST TALK ABOUT BUDGET CUTS, 3907 02:37:17,640 --> 02:37:19,640 VERY NICE TO HEAR MORE ABOUT 3908 02:37:19,640 --> 02:37:22,240 WHAT THE NCI IS DOING AROUND 3909 02:37:22,240 --> 02:37:25,160 THIS AREA, SPECIFICALLY, I KNOW 3910 02:37:25,160 --> 02:37:27,960 THERE ARE LARGE CONSORTIA, THERE 3911 02:37:27,960 --> 02:37:30,240 ARE WORK FROM NCDs BUT HELPFUL 3912 02:37:30,240 --> 02:37:31,360 TO UNDERSTAND THE RESEARCH 3913 02:37:31,360 --> 02:37:41,920 LANDSCAPE IN THIS SPACE. OTHER? 3914 02:37:45,360 --> 02:37:48,560 OKAY. WE HAVE THREE FUTURE 3915 02:37:48,560 --> 02:37:49,040 AGENDA ITEMS PROPOSED. 3916 02:37:49,040 --> 02:37:50,680 >>I HAVE THE TWO OTHERS LISTED 3917 02:37:50,680 --> 02:37:52,840 FOR YOU, PAULETTE TOO. THERE'S 3918 02:37:52,840 --> 02:37:55,640 TWO MORE THAT DR. CARPTEN 3919 02:37:55,640 --> 02:37:57,480 PRESENTED, I CAN GET THEM TO YOU 3920 02:37:57,480 --> 02:37:57,880 AFTERWARD. 3921 02:37:57,880 --> 02:37:59,600 >>OKAY. THANK YOU. 3922 02:37:59,600 --> 02:38:06,480 >>GREAT. WITH THAT, WE WILL 3923 02:38:06,480 --> 02:38:09,160 ADJOURN THE OPEN SESSION. SO 3924 02:38:09,160 --> 02:38:13,840 THERE WILL BE ROUGHLY 15 MINUTE 3925 02:38:13,840 --> 02:38:16,080 BREAK OR ACTUALLY A BIT MORE 3926 02:38:16,080 --> 02:38:18,320 THAN 15 MINUTES. WE WILL -- WE 3927 02:38:18,320 --> 02:38:21,480 NEED EVERYONE TO COME BACK TO 3928 02:38:21,480 --> 02:38:25,720 START THE CLOSED SESSION AT 4:15 3929 02:38:25,720 --> 02:38:29,680 EASTERN. OKAY? 3930 02:38:29,680 --> 02:38:32,400 >>HAVE THEM RETURN AT 4:10 AND 3931 02:38:32,400 --> 02:38:35,280 THAT WAY WE WILL HAVE THEM ALL 3932 02:38:35,280 --> 02:38:36,080 IN ACCOUNTED FOR. 3933 02:38:36,080 --> 02:38:37,120 >>E WHERE. YES. 3934 02:38:37,120 --> 02:38:41,120 >>10 AFTER. EVERYONE TAKE A 3935 02:38:41,120 --> 02:38:45,160 SHORT BREAK. AND I THINK YOU 3936 02:38:45,160 --> 02:38:47,480 WILL LOG OFF TO THIS AND WILL IS 3937 02:38:47,480 --> 02:38:48,880 A SEPARATE LINK IN THE EMAIL 3938 02:38:48,880 --> 02:38:55,880 THAT WAS PROVIDED FR. 4:10 EASTN 3939 02:38:55,880 --> 02:38:57,840 TIME WE WILL RECONVENE. 3940 02:38:57,840 --> 02:39:08,080 >>THANK YOU.